Sentence	entity_1	entity_2	entity_3	entity_4	json	split
Although the bcr - abl translocation has been shown to be the causative genetic aberration in chronic myeloid leukemia ( CML), there is mounting evidence that the deregulation of other genes, such as the transcription factor interferon regulatory factor 4 ( IRF - 4), is also implicated in the pathogenesis of CML.	bcr,13,16,Protein	abl,19,22,Protein	interferon regulatory factor 4,225,255,Protein	IRF - 4,258,265,Protein	"[{""token"": ""bcr"", ""start_span"": 13, ""end_span"": 16, ""type"": ""Protein""}, {""token"": ""abl"", ""start_span"": 19, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""interferon regulatory factor 4"", ""start_span"": 225, ""end_span"": 255, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 258, ""end_span"": 265, ""type"": ""Protein""}]"	train
The primary antibodies were goat anti - IRF - 4 / ICSAT ( M - 17) ( Santa Cruz Biotechnology, Santa Cruz, CA) and mouse anti - beta - actin ( AC - 74) ( Sigma).	IRF - 4,40,47,Protein	ICSAT,50,55,Protein	M - 17,58,64,Protein	beta - actin,127,139,Protein	"[{""token"": ""IRF - 4"", ""start_span"": 40, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""ICSAT"", ""start_span"": 50, ""end_span"": 55, ""type"": ""Protein""}, {""token"": ""M - 17"", ""start_span"": 58, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""beta - actin"", ""start_span"": 127, ""end_span"": 139, ""type"": ""Protein""}]"	train
In general, the methylational status ranged from one cell line with a nearly non - methylated IRF - 4 promoter ( SD - 1, IRF - 4 - positive) to a completely methylated IRF - 4 promoter in CML - T1 ( IRF - 4 - negative).	IRF - 4,94,101,Protein	IRF - 4,121,128,Protein	IRF - 4,168,175,Protein	IRF - 4,199,206,Protein	"[{""token"": ""IRF - 4"", ""start_span"": 94, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 121, ""end_span"": 128, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 168, ""end_span"": 175, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 199, ""end_span"": 206, ""type"": ""Protein""}]"	train
It has been shown that NFkappaB elements play an important role in IRF - 4 induction as IRF - 4 expression depends on binding of the transactivator c - Rel to these elements in the IRF - 4 promoter ( 31, 37).	IRF - 4,67,74,Protein	IRF - 4,88,95,Protein	c - Rel,148,155,Protein	IRF - 4,181,188,Protein	"[{""token"": ""IRF - 4"", ""start_span"": 67, ""end_span"": 74, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 88, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""c - Rel"", ""start_span"": 148, ""end_span"": 155, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 181, ""end_span"": 188, ""type"": ""Protein""}]"	train
But in contrast to IRF - 4, the loss of this IRF could not be reverted in ICSBP - negative cell lines ( EM - 2, CML - T1, K - 562 and LAMA - 84) by treatment with AzadC ( Figure 6) and AzadC has no effect on ICSBP levels in ICSBP - positive U - 937 cells ( Figure 6).	IRF - 4,19,26,Protein	ICSBP,74,79,Protein	ICSBP,208,213,Protein	ICSBP,224,229,Protein	"[{""token"": ""IRF - 4"", ""start_span"": 19, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""ICSBP"", ""start_span"": 74, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""ICSBP"", ""start_span"": 208, ""end_span"": 213, ""type"": ""Protein""}, {""token"": ""ICSBP"", ""start_span"": 224, ""end_span"": 229, ""type"": ""Protein""}]"	train
IRF - 4, similar to many other classical tumor suppressor genes p15INK4b, p16INK4a or p53, may thus be a subject of alterations in the promoter methylation status leading to expression changes, which might contribute to the initiation and / or progression of cancer.	IRF - 4,0,7,Protein	p15INK4b,64,72,Protein	p16INK4a,74,82,Protein	p53,86,89,Protein	"[{""token"": ""IRF - 4"", ""start_span"": 0, ""end_span"": 7, ""type"": ""Protein""}, {""token"": ""p15INK4b"", ""start_span"": 64, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""p16INK4a"", ""start_span"": 74, ""end_span"": 82, ""type"": ""Protein""}, {""token"": ""p53"", ""start_span"": 86, ""end_span"": 89, ""type"": ""Protein""}]"	train
In multiple myeloma ( MM) a translocation on chromosome 14q was reported to lead to a fusion gene of immunoglobulin heavy - chain ( IgH) and IRF - 4 resulting in a subsequent overexpression of IRF - 4 ( 48, 49).	immunoglobulin heavy - chain,101,129,Protein	IgH,132,135,Protein	IRF - 4,141,148,Protein	IRF - 4,193,200,Protein	"[{""token"": ""immunoglobulin heavy - chain"", ""start_span"": 101, ""end_span"": 129, ""type"": ""Protein""}, {""token"": ""IgH"", ""start_span"": 132, ""end_span"": 135, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 141, ""end_span"": 148, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 193, ""end_span"": 200, ""type"": ""Protein""}]"	train
Down - regulation of IRF - 4 may promote leukemogenesis in myeloid cell context ( 3), which was recently confirmed in IRF - 4 - / - ICSBP - / - double knock - out mice ( 53), while IRF - 4 up - regulation may induce a growth advantage in lymphomas or MM ( 48).	IRF - 4,21,28,Protein	IRF - 4,118,125,Protein	ICSBP,132,137,Protein	IRF - 4,181,188,Protein	"[{""token"": ""IRF - 4"", ""start_span"": 21, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 118, ""end_span"": 125, ""type"": ""Protein""}, {""token"": ""ICSBP"", ""start_span"": 132, ""end_span"": 137, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 181, ""end_span"": 188, ""type"": ""Protein""}]"	train
Taken together, our data suggest that IRF - 4 promoter methylation regulates IRF - 4 expression, and that aberrant expression of IRF - 4 in certain types of leukemia may be a consequence of IRF - 4 promoter hypermethylation.	IRF - 4,38,45,Protein	IRF - 4,77,84,Protein	IRF - 4,129,136,Protein	IRF - 4,190,197,Protein	"[{""token"": ""IRF - 4"", ""start_span"": 38, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 77, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 129, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 190, ""end_span"": 197, ""type"": ""Protein""}]"	train
Finally, comparison of the percent Foxp3 + CD4 + CD25 + T cells to the HTLV - I proviral load in HTLV - I - infected asymptomatic carriers and patients with HTLV - I - associated myelopathy / tropical spastic paraparesis suggested that high Foxp3 expression is associated with low proviral load and absence of disease.	Foxp3,35,40,Protein	CD4,43,46,Protein	CD25,49,53,Protein	Foxp3,241,246,Protein	"[{""token"": ""Foxp3"", ""start_span"": 35, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 43, ""end_span"": 46, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 49, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 241, ""end_span"": 246, ""type"": ""Protein""}]"	train
To define the requirements of Foxp3 with respect to inhibition of NF - kappaB - dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain ( Figure 2A) [ 16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [ 4, 11, 14, 17].	Foxp3,30,35,Protein	Foxp3,129,134,Protein	Foxp3,207,212,Protein	Foxp3,235,240,Protein	"[{""token"": ""Foxp3"", ""start_span"": 30, ""end_span"": 35, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 129, ""end_span"": 134, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 207, ""end_span"": 212, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 235, ""end_span"": 240, ""type"": ""Protein""}]"	train
Western blot analysis of NF - kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF - kappaB activation at the level of p65 protein expression ( Figure 2E).	p65,37,40,Protein	Foxp3,70,75,Protein	deltaFKH,80,88,Protein	p65,143,146,Protein	"[{""token"": ""p65"", ""start_span"": 37, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 70, ""end_span"": 75, ""type"": ""Protein""}, {""token"": ""deltaFKH"", ""start_span"": 80, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 143, ""end_span"": 146, ""type"": ""Protein""}]"	train
Since Foxp3 is expressed almost exclusively within CD4 + CD25 + T cells, a major viral reservoir for HTLV - I [ 33], it was important to determine whether there was an association between Foxp3 and HTLV - I replication in infected patients.	Foxp3,6,11,Protein	CD4,51,54,Protein	CD25,57,61,Protein	Foxp3,188,193,Protein	"[{""token"": ""Foxp3"", ""start_span"": 6, ""end_span"": 11, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 51, ""end_span"": 54, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 57, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 188, ""end_span"": 193, ""type"": ""Protein""}]"	train
However, Foxp3 failed to markedly affect transcriptional activation of Gal4 - BD - c - Jun ( c - Jun has also been demonstrated to bind to the HTLV - I LTR) and Gal4 - BD - Tax ( see Figure 5).	Foxp3,9,14,Protein	Gal4 - BD - c - Jun,71,90,Protein	c - Jun,93,100,Protein	Gal4 - BD - Tax,161,176,Protein	"[{""token"": ""Foxp3"", ""start_span"": 9, ""end_span"": 14, ""type"": ""Protein""}, {""token"": ""Gal4 - BD - c - Jun"", ""start_span"": 71, ""end_span"": 90, ""type"": ""Protein""}, {""token"": ""c - Jun"", ""start_span"": 93, ""end_span"": 100, ""type"": ""Protein""}, {""token"": ""Gal4 - BD - Tax"", ""start_span"": 161, ""end_span"": 176, ""type"": ""Protein""}]"	train
Therefore, our data suggest that Foxp3 may interfere with CREB signaling at an upstream event, such as phosphorylation of CREB or recruitment / function of coactivator proteins CREB - binding protein ( CBP) / p300.	Foxp3,33,38,Protein	CREB - binding protein,177,199,Protein	CBP,202,205,Protein	p300,209,213,Protein	"[{""token"": ""Foxp3"", ""start_span"": 33, ""end_span"": 38, ""type"": ""Protein""}, {""token"": ""CREB - binding protein"", ""start_span"": 177, ""end_span"": 199, ""type"": ""Protein""}, {""token"": ""CBP"", ""start_span"": 202, ""end_span"": 205, ""type"": ""Protein""}, {""token"": ""p300"", ""start_span"": 209, ""end_span"": 213, ""type"": ""Protein""}]"	train
The functional interaction between Foxp3 and CREB did not affect the DNA - binding activity of CREB - 1, but did show a modest decrease in activating transcription factor 2 ( ATF - 2) DNA - binding activity in the presence of forskolin as determined by transcription factor ELISA ( Figure 7B).	Foxp3,35,40,Protein	CREB - 1,95,103,Protein	activating transcription factor 2,139,172,Protein	ATF - 2,175,182,Protein	"[{""token"": ""Foxp3"", ""start_span"": 35, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""CREB - 1"", ""start_span"": 95, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""activating transcription factor 2"", ""start_span"": 139, ""end_span"": 172, ""type"": ""Protein""}, {""token"": ""ATF - 2"", ""start_span"": 175, ""end_span"": 182, ""type"": ""Protein""}]"	train
Foxp3, again, repressed basal levels of Gal4 - BD - CREB - 1 activation by more than 2 - fold, while effectively neutralizing Gal4 - BD - CREB - 1 activation in the presence of p300.	Foxp3,0,5,Protein	Gal4 - BD - CREB - 1,40,60,Protein	Gal4 - BD - CREB - 1,126,146,Protein	p300,177,181,Protein	"[{""token"": ""Foxp3"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""Gal4 - BD - CREB - 1"", ""start_span"": 40, ""end_span"": 60, ""type"": ""Protein""}, {""token"": ""Gal4 - BD - CREB - 1"", ""start_span"": 126, ""end_span"": 146, ""type"": ""Protein""}, {""token"": ""p300"", ""start_span"": 177, ""end_span"": 181, ""type"": ""Protein""}]"	train
However, when we attempted to determine whether Foxp3 could physically interact with the coactivator protein p300, we found that p300 immunoprecipitated Foxp3 when both proteins were overexpressed in HEK 293T cells ( Figure 7D).	Foxp3,48,53,Protein	p300,109,113,Protein	p300,129,133,Protein	Foxp3,153,158,Protein	"[{""token"": ""Foxp3"", ""start_span"": 48, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""p300"", ""start_span"": 109, ""end_span"": 113, ""type"": ""Protein""}, {""token"": ""p300"", ""start_span"": 129, ""end_span"": 133, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 153, ""end_span"": 158, ""type"": ""Protein""}]"	train
However, Tax - mediated transactivation of the HTLV - I LTR was inhibited by overexpression of both full - length Foxp3 as well as deltaFKH in both HEK 293T cells and CD4 + T cells.	Tax,9,12,Protein	Foxp3,114,119,Protein	deltaFKH,131,139,Protein	CD4,167,170,Protein	"[{""token"": ""Tax"", ""start_span"": 9, ""end_span"": 12, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 114, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""deltaFKH"", ""start_span"": 131, ""end_span"": 139, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 167, ""end_span"": 170, ""type"": ""Protein""}]"	train
We demonstrated that Foxp3 did not directly affect the functioning of Tax, but rather Foxp3 targeted the transcription factors required for Tax transactivation ( i. e., NF - kappaB and a then - unknown cellular factor, which we identified in this study as CREB).	Foxp3,21,26,Protein	Tax,70,73,Protein	Foxp3,86,91,Protein	Tax,140,143,Protein	"[{""token"": ""Foxp3"", ""start_span"": 21, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""Tax"", ""start_span"": 70, ""end_span"": 73, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 86, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""Tax"", ""start_span"": 140, ""end_span"": 143, ""type"": ""Protein""}]"	train
Importantly, we demonstrated that HTLV - I - infected individuals with the highest levels of Foxp3 protein expression within the CD4 + CD25 + T cells population exhibited lower proviral loads than did individuals with the lowest levels of Foxp3 protein expression.	Foxp3,93,98,Protein	CD4,129,132,Protein	CD25,135,139,Protein	Foxp3,239,244,Protein	"[{""token"": ""Foxp3"", ""start_span"": 93, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 129, ""end_span"": 132, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 135, ""end_span"": 139, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 239, ""end_span"": 244, ""type"": ""Protein""}]"	train
With respect to HTLV - I LTR activity, while full - length Foxp3 inhibited both basal and Tax - dependent transcription by ~ 50%, deltaFKH appeared less effective in suppressing basal activation ( ~ 25% inhibition) compared to Tax - dependent activation ( ~ 50% inhibition).	Foxp3,59,64,Protein	Tax,90,93,Protein	deltaFKH,130,138,Protein	Tax,227,230,Protein	"[{""token"": ""Foxp3"", ""start_span"": 59, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""Tax"", ""start_span"": 90, ""end_span"": 93, ""type"": ""Protein""}, {""token"": ""deltaFKH"", ""start_span"": 130, ""end_span"": 138, ""type"": ""Protein""}, {""token"": ""Tax"", ""start_span"": 227, ""end_span"": 230, ""type"": ""Protein""}]"	train
NF - kappaB p65 and CREB - 1 were detected using rabbit anti - human polyclonal ( p65) or monoclonal antibody ( CREB - 1; 48H2) ( Cell Signaling Technology).	p65,12,15,Protein	CREB - 1,20,28,Protein	p65,82,85,Protein	CREB - 1,112,120,Protein	"[{""token"": ""p65"", ""start_span"": 12, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""CREB - 1"", ""start_span"": 20, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 82, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""CREB - 1"", ""start_span"": 112, ""end_span"": 120, ""type"": ""Protein""}]"	train
Cells were washed twice and stained for surface CD4 expression with PE - labeled anti - CD4 ( BD) and CD25 expression with FITC - labeled anti - CD25 ( BD).	CD4,48,51,Protein	CD4,88,91,Protein	CD25,102,106,Protein	CD25,145,149,Protein	"[{""token"": ""CD4"", ""start_span"": 48, ""end_span"": 51, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 88, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 102, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 145, ""end_span"": 149, ""type"": ""Protein""}]"	train
In B lymphocytes, LMP1 mimics CD40 signaling, and both LMP1 and CD40 are essential for EBV - mediated B cell transformation [ 9 - 11].	LMP1,18,22,Protein	CD40,30,34,Protein	LMP1,55,59,Protein	CD40,64,68,Protein	"[{""token"": ""LMP1"", ""start_span"": 18, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 30, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 55, ""end_span"": 59, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 64, ""end_span"": 68, ""type"": ""Protein""}]"	train
LMP1 and CD40 interact with the same tumor necrosis factor receptor - associated factors ( TRAFs) leading to activation of NFkappaB, c - Jun N terminal kinase ( JNK), and p38 MAPK signaling pathways [ 12 - 16].	LMP1,0,4,Protein	CD40,9,13,Protein	tumor necrosis factor,37,58,Protein	c - Jun,133,140,Protein	"[{""token"": ""LMP1"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 9, ""end_span"": 13, ""type"": ""Protein""}, {""token"": ""tumor necrosis factor"", ""start_span"": 37, ""end_span"": 58, ""type"": ""Protein""}, {""token"": ""c - Jun"", ""start_span"": 133, ""end_span"": 140, ""type"": ""Protein""}]"	train
In contrast, both LMP1 - positive and - negative lymphoma cells were independent of IL4 co - stimulation for survival and proliferation in vitro with a complete absence of activated Stat6, the IL4 target.	LMP1,18,22,Protein	IL4,84,87,Protein	Stat6,182,187,Protein	IL4,193,196,Protein	"[{""token"": ""LMP1"", ""start_span"": 18, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""IL4"", ""start_span"": 84, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""Stat6"", ""start_span"": 182, ""end_span"": 187, ""type"": ""Protein""}, {""token"": ""IL4"", ""start_span"": 193, ""end_span"": 196, ""type"": ""Protein""}]"	train
Activated Stat6 ( pStat6), a target of the IL4 receptor pathway, was detected in the wild - type and LMP1 transgenic lymphocytes ( Figure 4B).	Stat6,10,15,Protein	pStat6,18,24,Protein	IL4 receptor,43,55,Protein	LMP1,101,105,Protein	"[{""token"": ""Stat6"", ""start_span"": 10, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""pStat6"", ""start_span"": 18, ""end_span"": 24, ""type"": ""Protein""}, {""token"": ""IL4 receptor"", ""start_span"": 43, ""end_span"": 55, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 101, ""end_span"": 105, ""type"": ""Protein""}]"	train
Transcription of IL10, IL15, and IFNgamma were reproducibly detected in LMP1 transgenic lymphocytes and lymphoma cells and was higher than in the B cell lymphoma cell lines 967 and K46mu ( Figure 5A).	IL10,17,21,Protein	IL15,23,27,Protein	IFNgamma,33,41,Protein	LMP1,72,76,Protein	"[{""token"": ""IL10"", ""start_span"": 17, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""IL15"", ""start_span"": 23, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 33, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 72, ""end_span"": 76, ""type"": ""Protein""}]"	train
Immunoblot analysis indicated that LMP1 transgenic lymphocytes and wild - type and LMP1 transgenic lymphoma cells had corresponding increased levels of phosphorylated alpha and beta isoforms of activated Stat3, a target of the IL10 receptor ( Figure 5B).	LMP1,35,39,Protein	LMP1,83,87,Protein	Stat3,204,209,Protein	IL10,227,231,Protein	"[{""token"": ""LMP1"", ""start_span"": 35, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 83, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""Stat3"", ""start_span"": 204, ""end_span"": 209, ""type"": ""Protein""}, {""token"": ""IL10"", ""start_span"": 227, ""end_span"": 231, ""type"": ""Protein""}]"	train
The constitutive activation of pStat3 and abundant nuclear Stat3 suggests that Stat3 signaling contributes to LMP1 - mediated lymphoma development.	pStat3,31,37,Protein	Stat3,59,64,Protein	Stat3,79,84,Protein	LMP1,110,114,Protein	"[{""token"": ""pStat3"", ""start_span"": 31, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""Stat3"", ""start_span"": 59, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""Stat3"", ""start_span"": 79, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 110, ""end_span"": 114, ""type"": ""Protein""}]"	train
To determine if Akt signaling is activated in LMP1 transgenic mice, pAkt and several of its targets were assessed by immunoblotting of splenic CD19 + MACS - purified B cells.	Akt,16,19,Protein	LMP1,46,50,Protein	pAkt,68,72,Protein	CD19,143,147,Protein	"[{""token"": ""Akt"", ""start_span"": 16, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 46, ""end_span"": 50, ""type"": ""Protein""}, {""token"": ""pAkt"", ""start_span"": 68, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""CD19"", ""start_span"": 143, ""end_span"": 147, ""type"": ""Protein""}]"	train
LMP1 transgenic B cells had increased levels of pAkt compared to wild - type lymphocytes; however, progression to lymphoma in both LMP1 - positive and - negative lymphoma cells did not further increase pAkt levels.	LMP1,0,4,Protein	pAkt,48,52,Protein	LMP1,131,135,Protein	pAkt,202,206,Protein	"[{""token"": ""LMP1"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""pAkt"", ""start_span"": 48, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 131, ""end_span"": 135, ""type"": ""Protein""}, {""token"": ""pAkt"", ""start_span"": 202, ""end_span"": 206, ""type"": ""Protein""}]"	train
The Akt target glycogen synthase kinase 3 ( GSK3) is inactivated by phosphorylation; however, increased phosphorylated GSK3 was not detected in the transgenic lymphocytes and was almost absent in the lymphoma samples ( Figure 6A).	Akt,4,7,Protein	glycogen synthase kinase 3,15,41,Protein	GSK3,44,48,Protein	GSK3,119,123,Protein	"[{""token"": ""Akt"", ""start_span"": 4, ""end_span"": 7, ""type"": ""Protein""}, {""token"": ""glycogen synthase kinase 3"", ""start_span"": 15, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""GSK3"", ""start_span"": 44, ""end_span"": 48, ""type"": ""Protein""}, {""token"": ""GSK3"", ""start_span"": 119, ""end_span"": 123, ""type"": ""Protein""}]"	train
Activated p - mTOR was not increased in LMP1 transgenic lymphocytes or lymphoma cells, indicating that this pathway is not affected by LMP1 - induced Akt activation and does not contribute to lymphoma development ( Figure 6B).	p - mTOR,10,18,Protein	LMP1,40,44,Protein	LMP1,135,139,Protein	Akt,150,153,Protein	"[{""token"": ""p - mTOR"", ""start_span"": 10, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 40, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 135, ""end_span"": 139, ""type"": ""Protein""}, {""token"": ""Akt"", ""start_span"": 150, ""end_span"": 153, ""type"": ""Protein""}]"	train
LMP1 - transformed rodent fibroblasts have decreased expression of p27, upregulation of Cdk2, and subsequent phosphorylation and inactivation of the tumor suppressor gene Rb [ 45].	LMP1,0,4,Protein	p27,67,70,Protein	Cdk2,88,92,Protein	Rb,171,173,Protein	"[{""token"": ""LMP1"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""p27"", ""start_span"": 67, ""end_span"": 70, ""type"": ""Protein""}, {""token"": ""Cdk2"", ""start_span"": 88, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""Rb"", ""start_span"": 171, ""end_span"": 173, ""type"": ""Protein""}]"	train
LMP1 transgenic B cells had enhanced levels of pRb with concomitant stabilization of total Rb levels and Cdk2 compared to wild - type B lymphocytes ( Figure 6C).	LMP1,0,4,Protein	pRb,47,50,Protein	Rb,91,93,Protein	Cdk2,105,109,Protein	"[{""token"": ""LMP1"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""pRb"", ""start_span"": 47, ""end_span"": 50, ""type"": ""Protein""}, {""token"": ""Rb"", ""start_span"": 91, ""end_span"": 93, ""type"": ""Protein""}, {""token"": ""Cdk2"", ""start_span"": 105, ""end_span"": 109, ""type"": ""Protein""}]"	train
Progression to lymphoma in both wild - type and LMP1 transgenic lymphoma cells led to increased levels of Rb, correspondingly high levels of Cdk2, and decreased levels of p27 ( Figure 6C).	LMP1,48,52,Protein	Rb,106,108,Protein	Cdk2,141,145,Protein	p27,171,174,Protein	"[{""token"": ""LMP1"", ""start_span"": 48, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""Rb"", ""start_span"": 106, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""Cdk2"", ""start_span"": 141, ""end_span"": 145, ""type"": ""Protein""}, {""token"": ""p27"", ""start_span"": 171, ""end_span"": 174, ""type"": ""Protein""}]"	train
These data indicate that the Rb pathway is deregulated in LMP1 transgenic lymphocytes and that lymphoma cells are distinguished by loss of FoxO1 and decreased p27.	Rb,29,31,Protein	LMP1,58,62,Protein	FoxO1,139,144,Protein	p27,159,162,Protein	"[{""token"": ""Rb"", ""start_span"": 29, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 58, ""end_span"": 62, ""type"": ""Protein""}, {""token"": ""FoxO1"", ""start_span"": 139, ""end_span"": 144, ""type"": ""Protein""}, {""token"": ""p27"", ""start_span"": 159, ""end_span"": 162, ""type"": ""Protein""}]"	train
A second reported inhibitor of Stat3, AG490, had no effect on growth ( Figure 7), but activation of Akt, Stat3, or levels of IkappaBalpha were also not affected ( Figure 8).	Stat3,31,36,Protein	Akt,100,103,Protein	Stat3,105,110,Protein	IkappaBalpha,125,137,Protein	"[{""token"": ""Stat3"", ""start_span"": 31, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""Akt"", ""start_span"": 100, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""Stat3"", ""start_span"": 105, ""end_span"": 110, ""type"": ""Protein""}, {""token"": ""IkappaBalpha"", ""start_span"": 125, ""end_span"": 137, ""type"": ""Protein""}]"	train
These findings suggest that inhibition of Stat3 can induce cell death in LMP1 transgenic lymphocytes and lymphoma cells, but Stat3 inhibition also has considerable crossover effects on Akt and NFkappaB signaling.	Stat3,42,47,Protein	LMP1,73,77,Protein	Stat3,125,130,Protein	Akt,185,188,Protein	"[{""token"": ""Stat3"", ""start_span"": 42, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 73, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""Stat3"", ""start_span"": 125, ""end_span"": 130, ""type"": ""Protein""}, {""token"": ""Akt"", ""start_span"": 185, ""end_span"": 188, ""type"": ""Protein""}]"	train
LMP1 has also been shown to activate JNK and p38 MAPK pathways [ 13, 48], and LMP1 transgenic lymphocytes were mildly susceptible to growth inhibition by SB202190, an inhibitor of p38 MAPK, but not U0126, an inhibitor of MEK1 / 2 activity.	LMP1,0,4,Protein	LMP1,78,82,Protein	MEK1,221,225,Protein	2,228,229,Protein	"[{""token"": ""LMP1"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 78, ""end_span"": 82, ""type"": ""Protein""}, {""token"": ""MEK1"", ""start_span"": 221, ""end_span"": 225, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 228, ""end_span"": 229, ""type"": ""Protein""}]"	train
The lymphomas were marked by the upregulation of IL10, constitutive activation of Stat3 signaling, and a requirement for activation of Akt, NFkappaB, and Stat3 pathways ( Figures 5 and 7).	IL10,49,53,Protein	Stat3,82,87,Protein	Akt,135,138,Protein	Stat3,154,159,Protein	"[{""token"": ""IL10"", ""start_span"": 49, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""Stat3"", ""start_span"": 82, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""Akt"", ""start_span"": 135, ""end_span"": 138, ""type"": ""Protein""}, {""token"": ""Stat3"", ""start_span"": 154, ""end_span"": 159, ""type"": ""Protein""}]"	train
This suggests that although Stat3 is constitutively activated in the lymphoma cells, the induction of IL10 may further enhance Stat3 activation or may contribute to other IL10 - responsive signaling pathways.	Stat3,28,33,Protein	IL10,102,106,Protein	Stat3,127,132,Protein	IL10,171,175,Protein	"[{""token"": ""Stat3"", ""start_span"": 28, ""end_span"": 33, ""type"": ""Protein""}, {""token"": ""IL10"", ""start_span"": 102, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""Stat3"", ""start_span"": 127, ""end_span"": 132, ""type"": ""Protein""}, {""token"": ""IL10"", ""start_span"": 171, ""end_span"": 175, ""type"": ""Protein""}]"	train
NFkappaB and PI3K signaling are crucial for CD40 - induced proliferation, and mice deficient for cRel or the p85 regulatory subunit of PI3K are unresponsive to mitogenic stimuli, including CD40 ligation [ 66 - 68].	CD40,44,48,Protein	cRel,97,101,Protein	p85,109,112,Protein	CD40,189,193,Protein	"[{""token"": ""CD40"", ""start_span"": 44, ""end_span"": 48, ""type"": ""Protein""}, {""token"": ""cRel"", ""start_span"": 97, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""p85"", ""start_span"": 109, ""end_span"": 112, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 189, ""end_span"": 193, ""type"": ""Protein""}]"	train
Our observations suggest that similar to CD40 - induced proliferation, LMP1 induces proliferation through PI3K - mediated activation of Akt and activation of NFkappaB components such as cRel.	CD40,41,45,Protein	LMP1,71,75,Protein	Akt,136,139,Protein	cRel,186,190,Protein	"[{""token"": ""CD40"", ""start_span"": 41, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 71, ""end_span"": 75, ""type"": ""Protein""}, {""token"": ""Akt"", ""start_span"": 136, ""end_span"": 139, ""type"": ""Protein""}, {""token"": ""cRel"", ""start_span"": 186, ""end_span"": 190, ""type"": ""Protein""}]"	train
APC - conjugated rat IgG2akappa anti - mouse CD19 ( clone 6D5), PE - conjugated mouse IgG2akappa anti - LMP1 ( clone S12), un - conjugated mouse IgG2a anti - Rb ( clone 2), and anti - Cdk2 ( clone 55) were purchased from BD Bioscience.	CD19,45,49,Protein	LMP1,104,108,Protein	Rb,158,160,Protein	Cdk2,184,188,Protein	"[{""token"": ""CD19"", ""start_span"": 45, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 104, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""Rb"", ""start_span"": 158, ""end_span"": 160, ""type"": ""Protein""}, {""token"": ""Cdk2"", ""start_span"": 184, ""end_span"": 188, ""type"": ""Protein""}]"	train
( B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in ( B) purified B cells ( CD19 +) at the time of harvest or in ( C) whole splenocytes cultured with or without IL4.	LMP1,41,45,Protein	pStat6,76,82,Protein	CD19,110,114,Protein	IL4,195,198,Protein	"[{""token"": ""LMP1"", ""start_span"": 41, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""pStat6"", ""start_span"": 76, ""end_span"": 82, ""type"": ""Protein""}, {""token"": ""CD19"", ""start_span"": 110, ""end_span"": 114, ""type"": ""Protein""}, {""token"": ""IL4"", ""start_span"": 195, ""end_span"": 198, ""type"": ""Protein""}]"	train
( C) Immunoblot analysis for cell cycle proteins regulating the Rb pathway, probing for activated pRb, and total levels of Cdk2 and the Cdk inhibitor p27.	Rb,64,66,Protein	pRb,98,101,Protein	Cdk2,123,127,Protein	p27,150,153,Protein	"[{""token"": ""Rb"", ""start_span"": 64, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""pRb"", ""start_span"": 98, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""Cdk2"", ""start_span"": 123, ""end_span"": 127, ""type"": ""Protein""}, {""token"": ""p27"", ""start_span"": 150, ""end_span"": 153, ""type"": ""Protein""}]"	train
Naive CD8 + T cells differentiate into effector CTLs with the ability to lyse antigen - bearing target cells by exocytosis of lytic granules containing perforin and granzymes, and to produce inflammatory cytokines such as IFN - gamma and TNF upon restimulation through the TCR ( 1, 2).	CD8,6,9,Protein	perforin,152,160,Protein	IFN - gamma,222,233,Protein	TNF,238,241,Protein	"[{""token"": ""CD8"", ""start_span"": 6, ""end_span"": 9, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 152, ""end_span"": 160, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 222, ""end_span"": 233, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 238, ""end_span"": 241, ""type"": ""Protein""}]"	train
In this study, we have used in vitro systems such as those developed to study CD4 + T cell differentiation to define the molecular basis of effector CTL differentiation ( 5, 6). The T - box transcription factors Eomesodermin ( Eomes) and T - bet are needed for important aspects of effector and memory CTL differentiation ( 7).	CD4,78,81,Protein	Eomesodermin,212,224,Protein	Eomes,227,232,Protein	T - bet,238,245,Protein	"[{""token"": ""CD4"", ""start_span"": 78, ""end_span"": 81, ""type"": ""Protein""}, {""token"": ""Eomesodermin"", ""start_span"": 212, ""end_span"": 224, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 227, ""end_span"": 232, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 238, ""end_span"": 245, ""type"": ""Protein""}]"	train
Runx3 and perforin mRNA are expressed by double - positive ( DP) thymocytes and CD8 + single - positive ( SP) thymocytes but not in CD4 + SP cells ( 14).	Runx3,0,5,Protein	perforin,10,18,Protein	CD8,80,83,Protein	CD4,132,135,Protein	"[{""token"": ""Runx3"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 10, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 80, ""end_span"": 83, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 132, ""end_span"": 135, ""type"": ""Protein""}]"	train
Although Runx3 is not expressed in naive CD4 + T cells, its expression is up - regulated during Th1 cell differentiation, and Runx3 influences Th1 cell differentiation and function through direct regulation of theIl4andIfngcytokine genes ( 15, 16).	Runx3,9,14,Protein	CD4,41,44,Protein	Runx3,126,131,Protein	theIl4andIfngcytokine,210,231,Protein	"[{""token"": ""Runx3"", ""start_span"": 9, ""end_span"": 14, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 41, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 126, ""end_span"": 131, ""type"": ""Protein""}, {""token"": ""theIl4andIfngcytokine"", ""start_span"": 210, ""end_span"": 231, ""type"": ""Protein""}]"	train
T - bet mRNA expression slightly preceded the expression of GzmB mRNA; similarly, Eomes mRNA and protein were expressed ~ 1 d ahead of the reexpression of perforin mRNA and protein, respectively ( Fig. 1, B and D).	T - bet,0,7,Protein	GzmB,60,64,Protein	Eomes,82,87,Protein	perforin,155,163,Protein	"[{""token"": ""T - bet"", ""start_span"": 0, ""end_span"": 7, ""type"": ""Protein""}, {""token"": ""GzmB"", ""start_span"": 60, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 82, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 155, ""end_span"": 163, ""type"": ""Protein""}]"	train
T - bet is required early for IFN - gamma production, and our data suggested that Eomes might not function during this early period but rather might contribute later to the control of perforin expression.	T - bet,0,7,Protein	IFN - gamma,30,41,Protein	Eomes,82,87,Protein	perforin,184,192,Protein	"[{""token"": ""T - bet"", ""start_span"": 0, ""end_span"": 7, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 30, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 82, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 184, ""end_span"": 192, ""type"": ""Protein""}]"	train
As expected, Eo - VP16 also rescued the early defect in IFN - gamma production observed in T - bet - deficient CD8 + T cells ( Fig. 2 D).	Eo - VP16,13,22,Protein	IFN - gamma,56,67,Protein	T - bet,91,98,Protein	CD8,111,114,Protein	"[{""token"": ""Eo - VP16"", ""start_span"": 13, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 56, ""end_span"": 67, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 91, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 111, ""end_span"": 114, ""type"": ""Protein""}]"	train
We isolated CD8 + T cells from Runx3 - / - ( KO) mice of the outbred ICR background and their WT Runx3 + / + littermates by positive selection with anti - CD8 magnetic beads ( Figs. S1 and S2, available at http: / / www. jem. org / cgi / content / full / jem. 20081242 / DC1).	CD8,12,15,Protein	Runx3,31,36,Protein	Runx3,97,102,Protein	CD8,155,158,Protein	"[{""token"": ""CD8"", ""start_span"": 12, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 31, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 97, ""end_span"": 102, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 155, ""end_span"": 158, ""type"": ""Protein""}]"	train
Notably, Eo - VP16 did not up - regulate perforin expression when expressed in Runx3 - / - cells, even though it restored the capacity to induce IFN - gamma expression upon TCR restimulation ( Fig. 4, A and B).	Eo - VP16,9,18,Protein	perforin,41,49,Protein	Runx3,79,84,Protein	IFN - gamma,145,156,Protein	"[{""token"": ""Eo - VP16"", ""start_span"": 9, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 41, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 79, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 145, ""end_span"": 156, ""type"": ""Protein""}]"	train
As expected from their defect in perforin and granzyme B expression, Runx3 - / - CD8 + T cells showed defective cytolytic activity in a mixed lymphocyte reaction ( 12).	perforin,33,41,Protein	granzyme B,46,56,Protein	Runx3,69,74,Protein	CD8,81,84,Protein	"[{""token"": ""perforin"", ""start_span"": 33, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""granzyme B"", ""start_span"": 46, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 69, ""end_span"": 74, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 81, ""end_span"": 84, ""type"": ""Protein""}]"	train
Surprisingly, Runx3 contributed to the optimal expression of TNF, IL - 2, and IFN - gamma at day 4 ( Fig. S2).	Runx3,14,19,Protein	TNF,61,64,Protein	IL - 2,66,72,Protein	IFN - gamma,78,89,Protein	"[{""token"": ""Runx3"", ""start_span"": 14, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 61, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 66, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 78, ""end_span"": 89, ""type"": ""Protein""}]"	train
Eomes, which is induced late and functions downstream of Runx3, may substitute for T - bet in promoting the acute expression of IFN - gamma in restimulated CTLs ( 8).	Eomes,0,5,Protein	Runx3,57,62,Protein	T - bet,83,90,Protein	IFN - gamma,128,139,Protein	"[{""token"": ""Eomes"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 57, ""end_span"": 62, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 83, ""end_span"": 90, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 128, ""end_span"": 139, ""type"": ""Protein""}]"	train
Surprisingly, however, Eomes and T - bet appeared nonredundant in their ability to induce two other markers of CTL function, Prf1 and Gzmb ( Fig. 4 C).	Eomes,23,28,Protein	T - bet,33,40,Protein	Prf1,125,129,Protein	Gzmb,134,138,Protein	"[{""token"": ""Eomes"", ""start_span"": 23, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 33, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""Prf1"", ""start_span"": 125, ""end_span"": 129, ""type"": ""Protein""}, {""token"": ""Gzmb"", ""start_span"": 134, ""end_span"": 138, ""type"": ""Protein""}]"	train
Collectively, our data are consistent with a transcriptional network in which preexisting Runx3 cooperates with the induced T - box factors T - bet and Eomes and IL - 2Rbeta signals ( unpublished data) to orchestrate CTL differentiation ( Fig. 4 C).	Runx3,90,95,Protein	T - bet,140,147,Protein	Eomes,152,157,Protein	IL - 2Rbeta,162,173,Protein	"[{""token"": ""Runx3"", ""start_span"": 90, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 140, ""end_span"": 147, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 152, ""end_span"": 157, ""type"": ""Protein""}, {""token"": ""IL - 2Rbeta"", ""start_span"": 162, ""end_span"": 173, ""type"": ""Protein""}]"	train
As expected from their ability to up - regulate CD25, Runx3 - / - CD8 + T cells responded to IL - 2 supplementation after day 2 and efficiently expanded until day 6 of the culture period, albeit at slower rates compared with WT cells ( Fig. S1).	CD25,48,52,Protein	Runx3,54,59,Protein	CD8,66,69,Protein	IL - 2,93,99,Protein	"[{""token"": ""CD25"", ""start_span"": 48, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 54, ""end_span"": 59, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 66, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 93, ""end_span"": 99, ""type"": ""Protein""}]"	train
Although a fraction of the KO DP cells silenced CD4 expression after activation, the ratio of SP / DP cells in each enriched population remained constant thereafter, and we did not observe any major differences between these two populations throughout the culture period, indicating that in terms of effector CTL differentiation and under our culture conditions, Runx3 - / - CD8 + T cells that also coexpress CD4 are indistinguishable from those that do not.	CD4,48,51,Protein	Runx3,363,368,Protein	CD8,375,378,Protein	CD4,409,412,Protein	"[{""token"": ""CD4"", ""start_span"": 48, ""end_span"": 51, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 363, ""end_span"": 368, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 375, ""end_span"": 378, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 409, ""end_span"": 412, ""type"": ""Protein""}]"	train
( A) IFN - gamma expression by WT ( Tbx21 + / +) and T - bet - deficient ( Tbx21 - / -) T cells.	IFN - gamma,5,16,Protein	Tbx21,36,41,Protein	T - bet,53,60,Protein	Tbx21,75,80,Protein	"[{""token"": ""IFN - gamma"", ""start_span"": 5, ""end_span"": 16, ""type"": ""Protein""}, {""token"": ""Tbx21"", ""start_span"": 36, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 53, ""end_span"": 60, ""type"": ""Protein""}, {""token"": ""Tbx21"", ""start_span"": 75, ""end_span"": 80, ""type"": ""Protein""}]"	train
( C) Granzyme B and IFN - gamma expression by Tbx21 + / + and Tbx21 - / - T cells analyzed in restimulated cells that had been cultured for 5 d.	Granzyme B,5,15,Protein	IFN - gamma,20,31,Protein	Tbx21,46,51,Protein	Tbx21,62,67,Protein	"[{""token"": ""Granzyme B"", ""start_span"": 5, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 20, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""Tbx21"", ""start_span"": 46, ""end_span"": 51, ""type"": ""Protein""}, {""token"": ""Tbx21"", ""start_span"": 62, ""end_span"": 67, ""type"": ""Protein""}]"	train
( B) Northern blot analysis of Prf1 mRNA expression in Runx3 + / + versus Runx3 - / - CD8 + T cells differentiated for 6 d.	Prf1,31,35,Protein	Runx3,55,60,Protein	Runx3,74,79,Protein	CD8,86,89,Protein	"[{""token"": ""Prf1"", ""start_span"": 31, ""end_span"": 35, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 55, ""end_span"": 60, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 74, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 86, ""end_span"": 89, ""type"": ""Protein""}]"	train
Interleukin - 10 Production by Th1 Cells Requires Interleukin - 12 - Induced STAT4 Transcription Factor and ERK MAP Kinase Activation by High Antigen Dose	Interleukin - 10,0,16,Protein	Interleukin - 12,50,66,Protein	STAT4,77,82,Protein	ERK,108,111,Protein	"[{""token"": ""Interleukin - 10"", ""start_span"": 0, ""end_span"": 16, ""type"": ""Protein""}, {""token"": ""Interleukin - 12"", ""start_span"": 50, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""STAT4"", ""start_span"": 77, ""end_span"": 82, ""type"": ""Protein""}, {""token"": ""ERK"", ""start_span"": 108, ""end_span"": 111, ""type"": ""Protein""}]"	train
The development of Th17 cells requires IL - 6, TGF - beta, and the STAT3 - dependent expression of the transcription factor RORgammat ( Ivanov et al., 2007; Stockinger and Veldhoen, 2007).	IL - 6,39,45,Protein	TGF - beta,47,57,Protein	STAT3,67,72,Protein	RORgammat,124,133,Protein	"[{""token"": ""IL - 6"", ""start_span"": 39, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 47, ""end_span"": 57, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 67, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""RORgammat"", ""start_span"": 124, ""end_span"": 133, ""type"": ""Protein""}]"	train
Thus, the development of IL - 10 - producing Th1 cells only depended on the presence of IL - 12 together with high antigen dose and not on other soluble factors such as IL - 2 or TGF - beta or on the presence of other T cell types.	IL - 10,25,32,Protein	IL - 12,88,95,Protein	IL - 2,169,175,Protein	TGF - beta,179,189,Protein	"[{""token"": ""IL - 10"", ""start_span"": 25, ""end_span"": 32, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 88, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 169, ""end_span"": 175, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 179, ""end_span"": 189, ""type"": ""Protein""}]"	train
Naive CD4 + D011. 10 T cells deficient in STAT4 ( Ouyang et al., 1998) were cultured in the presence of IL - 12 and OVA.	CD4,6,9,Protein	STAT4,42,47,Protein	IL - 12,104,111,Protein	OVA,116,119,Protein	"[{""token"": ""CD4"", ""start_span"": 6, ""end_span"": 9, ""type"": ""Protein""}, {""token"": ""STAT4"", ""start_span"": 42, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 104, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""OVA"", ""start_span"": 116, ""end_span"": 119, ""type"": ""Protein""}]"	train
The absence of STAT6 did not impair the differentiation of IL - 10 - producing Th1 cells in the presence of IL - 12 and OVA ( Figure 2A).	STAT6,15,20,Protein	IL - 10,59,66,Protein	IL - 12,108,115,Protein	OVA,120,123,Protein	"[{""token"": ""STAT6"", ""start_span"": 15, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 59, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 108, ""end_span"": 115, ""type"": ""Protein""}, {""token"": ""OVA"", ""start_span"": 120, ""end_span"": 123, ""type"": ""Protein""}]"	train
As expected, lack of STAT6 abrogated both IL - 4 and IL - 10 production by T cells developed with IL - 4 or with low antigen dose ( Figures 2B and 2C).	STAT6,21,26,Protein	IL - 4,42,48,Protein	IL - 10,53,60,Protein	IL - 4,98,104,Protein	"[{""token"": ""STAT6"", ""start_span"": 21, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 42, ""end_span"": 48, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 53, ""end_span"": 60, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 98, ""end_span"": 104, ""type"": ""Protein""}]"	train
As observed in the absence of STAT6 ( Figure 2A), IL - 4 deficiency had no effect on the development of Th1 cells producing IL - 10 ( Figure 2E), but compromised the development of Th2 cells producing IL - 10 ( Figure 2F).	STAT6,30,35,Protein	IL - 4,50,56,Protein	IL - 10,124,131,Protein	IL - 10,201,208,Protein	"[{""token"": ""STAT6"", ""start_span"": 30, ""end_span"": 35, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 50, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 124, ""end_span"": 131, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 201, ""end_span"": 208, ""type"": ""Protein""}]"	train
Thus, our data suggested that IL - 10 production by Th1 or Th2 cells was dependent on the specific signaling pathways required for their differentiation, given that STAT4 is required for the induction of IL - 10 production by Th1 cells and STAT6 for Th2 cells.	IL - 10,30,37,Protein	STAT4,165,170,Protein	IL - 10,204,211,Protein	STAT6,240,245,Protein	"[{""token"": ""IL - 10"", ""start_span"": 30, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""STAT4"", ""start_span"": 165, ""end_span"": 170, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 204, ""end_span"": 211, ""type"": ""Protein""}, {""token"": ""STAT6"", ""start_span"": 240, ""end_span"": 245, ""type"": ""Protein""}]"	train
This in vivo immunization induced IL - 10 and IFN - gamma production, and the amount of IL - 10 production was enhanced by addition of LPS in the immunization ( Figure 3A) and with higher doses of OVA ( 3 muM versus 1 muM, data not shown).	IL - 10,34,41,Protein	IFN - gamma,46,57,Protein	IL - 10,88,95,Protein	OVA,197,200,Protein	"[{""token"": ""IL - 10"", ""start_span"": 34, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 46, ""end_span"": 57, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 88, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""OVA"", ""start_span"": 197, ""end_span"": 200, ""type"": ""Protein""}]"	train
Repeated high antigen dose stimulation in the absence of exogenously added IL - 12 resulted in the production of IL - 10 by Th1 cells, suggesting that repeated strong TCR triggering may overcome the need for IL - 12 for IL - 10 induction ( Figures 4C and 4D).	IL - 12,75,82,Protein	IL - 10,113,120,Protein	IL - 12,208,215,Protein	IL - 10,220,227,Protein	"[{""token"": ""IL - 12"", ""start_span"": 75, ""end_span"": 82, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 113, ""end_span"": 120, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 208, ""end_span"": 215, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 220, ""end_span"": 227, ""type"": ""Protein""}]"	train
To determine the requirements for stability of the IL - 10 - producing Th1 cells, we differentiated CD4 + T cells for 1 week with high antigen doses with or without IL - 12 ( Figures 4A and 4C), washed them, and then restimulated them for an additional week with a low antigen dose, in the absence or presence of IL - 12 ( Figure 4F).	IL - 10,51,58,Protein	CD4,100,103,Protein	IL - 12,165,172,Protein	IL - 12,313,320,Protein	"[{""token"": ""IL - 10"", ""start_span"": 51, ""end_span"": 58, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 100, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 165, ""end_span"": 172, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 313, ""end_span"": 320, ""type"": ""Protein""}]"	train
Signaling through the TCR with high doses of antigen induced stronger ERK1 and ERK2 activation than that induced by low antigen dose, not only in naive CD4 + T cells ( data not shown) as previously demonstrated ( Jorritsma et al., 2003) but also in CD4 + T cells restimulated with the same high and low antigen doses ( Figure 5A).	ERK1,70,74,Protein	ERK2,79,83,Protein	CD4,152,155,Protein	CD4,249,252,Protein	"[{""token"": ""ERK1"", ""start_span"": 70, ""end_span"": 74, ""type"": ""Protein""}, {""token"": ""ERK2"", ""start_span"": 79, ""end_span"": 83, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 152, ""end_span"": 155, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 249, ""end_span"": 252, ""type"": ""Protein""}]"	train
To investigate further the downstream factors involved in regulating IL - 10 production, we differentiated DO11. 10 CD4 + T cells with increasing doses of OVA, in the presence or absence of IL - 12, and quantified the expression of cytokines and transcription factors by real - time RT - PCR.	IL - 10,69,76,Protein	CD4,116,119,Protein	OVA,155,158,Protein	IL - 12,190,197,Protein	"[{""token"": ""IL - 10"", ""start_span"": 69, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 116, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""OVA"", ""start_span"": 155, ""end_span"": 158, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 190, ""end_span"": 197, ""type"": ""Protein""}]"	train
CD4 + T cells differentiated with increasing doses of antigen did not express high amounts of Tbx - 21 ( T - bet) mRNA, unless they were cocultured with IL - 12 ( Figure 6B).	CD4,0,3,Protein	Tbx - 21,94,102,Protein	T - bet,105,112,Protein	IL - 12,153,160,Protein	"[{""token"": ""CD4"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Protein""}, {""token"": ""Tbx - 21"", ""start_span"": 94, ""end_span"": 102, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 105, ""end_span"": 112, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 153, ""end_span"": 160, ""type"": ""Protein""}]"	train
Our findings that ERK1 and ERK2 activation was a common pathway required for the production of IL - 10 by Th1, Th2, and Th17 cell subsets, which differentiate along distinct pathways, such that IL - 10 provides a highly regulated feedback loop to avoid the extremes of excessive inflammation or chronic infections and also allow a protective response to diverse pathogens.	ERK1,18,22,Protein	ERK2,27,31,Protein	IL - 10,95,102,Protein	IL - 10,194,201,Protein	"[{""token"": ""ERK1"", ""start_span"": 18, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""ERK2"", ""start_span"": 27, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 95, ""end_span"": 102, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 194, ""end_span"": 201, ""type"": ""Protein""}]"	train
We have found that CD4 + T cells exposed to a high dose of antigen do not express IL - 10 upon restimulation, but can be induced to produce IL - 10 upon re - exposure to a high dose of antigen in the recall phase in the absence of added IL - 12.	CD4,19,22,Protein	IL - 10,82,89,Protein	IL - 10,140,147,Protein	IL - 12,237,244,Protein	"[{""token"": ""CD4"", ""start_span"": 19, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 82, ""end_span"": 89, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 140, ""end_span"": 147, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 237, ""end_span"": 244, ""type"": ""Protein""}]"	train
The combination of both high antigen dose and IL - 12 resulted in the highest levels of IL - 10 production and correlated with the high levels of ERK1 and ERK2 activation.	IL - 12,46,53,Protein	IL - 10,88,95,Protein	ERK1,146,150,Protein	ERK2,155,159,Protein	"[{""token"": ""IL - 12"", ""start_span"": 46, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 88, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""ERK1"", ""start_span"": 146, ""end_span"": 150, ""type"": ""Protein""}, {""token"": ""ERK2"", ""start_span"": 155, ""end_span"": 159, ""type"": ""Protein""}]"	train
It is thus likely that in T. gondii infection in vivo ( Shaw et al., 2006), the requirement for IFN - gamma to induce IL - 10, was for feedback upregulation of IL - 12 by DCs, which in turn induced IL - 10 in the Th1 cells.	IFN - gamma,96,107,Protein	IL - 10,118,125,Protein	IL - 12,160,167,Protein	IL - 10,198,205,Protein	"[{""token"": ""IFN - gamma"", ""start_span"": 96, ""end_span"": 107, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 118, ""end_span"": 125, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 160, ""end_span"": 167, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 198, ""end_span"": 205, ""type"": ""Protein""}]"	train
Costimulatory OX - 40 signals have been shown to negatively regulate IL - 10 production ( Ito et al., 2005) both in Th1 and Th2 cells, whereas ICOS signaling has been suggested to induce IL - 10 ( Ito et al., 2007; Witsch et al., 2002) in both Th1 and Th2 cells.	OX - 40,14,21,Protein	IL - 10,69,76,Protein	ICOS,143,147,Protein	IL - 10,187,194,Protein	"[{""token"": ""OX - 40"", ""start_span"": 14, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 69, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""ICOS"", ""start_span"": 143, ""end_span"": 147, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 187, ""end_span"": 194, ""type"": ""Protein""}]"	train
Those positive for KJ1 - 26 - Bio and for CD4 - PerCP were gated, and IFN - gamma and IL - 10 staining was examined for this population and analyzed as before.	KJ1 - 26,19,27,Protein	CD4,42,45,Protein	IFN - gamma,70,81,Protein	IL - 10,86,93,Protein	"[{""token"": ""KJ1 - 26"", ""start_span"": 19, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 42, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 70, ""end_span"": 81, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 86, ""end_span"": 93, ""type"": ""Protein""}]"	train
The cytokine profile revealed an up - regulation of the chemokine CXCL8 and the pro - inflammatory cytokines TNF, IL - 2 and IL - 6 following treatment with both PMA and HK E. coli, while the levels of the anti - inflammatory cytokine IL - 10 were not affected by PMA but were significantly down - regulated by HK E. coli.	CXCL8,66,71,Protein	IL - 2,114,120,Protein	IL - 6,125,131,Protein	IL - 10,235,242,Protein	"[{""token"": ""CXCL8"", ""start_span"": 66, ""end_span"": 71, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 114, ""end_span"": 120, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 125, ""end_span"": 131, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 235, ""end_span"": 242, ""type"": ""Protein""}]"	train
T - cells produce a broad range of pro - and anti - inflammatory cytokines, including IL - 2, IL - 6, CXCL8, TNF and IL - 10, in response to infections or other stress factors [ 39].	IL - 2,86,92,Protein	IL - 6,94,100,Protein	CXCL8,102,107,Protein	IL - 10,117,124,Protein	"[{""token"": ""IL - 2"", ""start_span"": 86, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 94, ""end_span"": 100, ""type"": ""Protein""}, {""token"": ""CXCL8"", ""start_span"": 102, ""end_span"": 107, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 117, ""end_span"": 124, ""type"": ""Protein""}]"	train
The anti - inflammatory cytokine IL - 10 is known to inhibit T - cell activation, proliferation and the expression of pro - inflammatory cytokines, such as IL - 2, IL - 5 and INF - gamma [ 39, 43] and regulate inflammatory responses by inducing T - cell anergy [ 44].	IL - 10,33,40,Protein	IL - 2,156,162,Protein	IL - 5,164,170,Protein	INF - gamma,175,186,Protein	"[{""token"": ""IL - 10"", ""start_span"": 33, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 156, ""end_span"": 162, ""type"": ""Protein""}, {""token"": ""IL - 5"", ""start_span"": 164, ""end_span"": 170, ""type"": ""Protein""}, {""token"": ""INF - gamma"", ""start_span"": 175, ""end_span"": 186, ""type"": ""Protein""}]"	train
Quantification of the levels of cytokines IL - 2, IL - 6, IL - 10 and TNF and the chemokine CXCL8 was performed on culture supernatants using multiplexed biomarker immunoassay kits according to manufacturer ' s instructions ( Bio - Rad Laboratories, Hercules, CA).	IL - 2,42,48,Protein	IL - 6,50,56,Protein	IL - 10,58,65,Protein	CXCL8,92,97,Protein	"[{""token"": ""IL - 2"", ""start_span"": 42, ""end_span"": 48, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 50, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 58, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""CXCL8"", ""start_span"": 92, ""end_span"": 97, ""type"": ""Protein""}]"	train
Among the multiple TRAFs that associate with CD40, TRAF3 can function as a negative regulator of signaling, while TRAF2 and TRAF6 promote the activation of downstream signaling pathways [ 4].	CD40,45,49,Protein	TRAF3,51,56,Protein	TRAF2,114,119,Protein	TRAF6,124,129,Protein	"[{""token"": ""CD40"", ""start_span"": 45, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""TRAF3"", ""start_span"": 51, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 114, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 124, ""end_span"": 129, ""type"": ""Protein""}]"	train
These and other findings led us to hypothesize that HOIP functions downstream of TRAF2 in the CD40 signaling pathway and that HOIP is necessary for the activation of NF - kappaB and possibly other signaling molecules.	HOIP,52,56,Protein	TRAF2,81,86,Protein	CD40,94,98,Protein	HOIP,126,130,Protein	"[{""token"": ""HOIP"", ""start_span"": 52, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 81, ""end_span"": 86, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 94, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 126, ""end_span"": 130, ""type"": ""Protein""}]"	train
HOIP is required for CD40 - mediated CD80 upregulation and activation of germline epsilon transcription	HOIP,0,4,Protein	CD40,21,25,Protein	CD80,37,41,Protein	germline epsilon,73,89,Protein	"[{""token"": ""HOIP"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 21, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""CD80"", ""start_span"": 37, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""germline epsilon"", ""start_span"": 73, ""end_span"": 89, ""type"": ""Protein""}]"	train
Previously, we demonstrated that HOIP is recruited to the CD40 signaling complex in a TRAF2 - dependent manner, suggesting that HOIP functions downstream of TRAF2 [ 6].	HOIP,33,37,Protein	TRAF2,86,91,Protein	HOIP,128,132,Protein	TRAF2,157,162,Protein	"[{""token"": ""HOIP"", ""start_span"": 33, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 86, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 128, ""end_span"": 132, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 157, ""end_span"": 162, ""type"": ""Protein""}]"	train
To test the possibility that HOIP is responsible for the recruitment of other critical signaling proteins to CD40, we immunoprecipitated CD40 signaling complexes from HOIP - deficient and HOIP - reconstituted cells ( Fig. 5B).	HOIP,29,33,Protein	CD40,109,113,Protein	HOIP,167,171,Protein	HOIP,188,192,Protein	"[{""token"": ""HOIP"", ""start_span"": 29, ""end_span"": 33, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 109, ""end_span"": 113, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 167, ""end_span"": 171, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 188, ""end_span"": 192, ""type"": ""Protein""}]"	train
Moreover, analysis of cells expressing epitope tagged - IKKgamma confirmed that recruitment of IKKgamma to CD40 requires HOIP.	IKKgamma,56,64,Protein	IKKgamma,95,103,Protein	CD40,107,111,Protein	HOIP,121,125,Protein	"[{""token"": ""IKKgamma"", ""start_span"": 56, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""IKKgamma"", ""start_span"": 95, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 107, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 121, ""end_span"": 125, ""type"": ""Protein""}]"	train
Overall, these data demonstrate that HOIP is required for the association of IKKgamma with CD40, and suggest that this event is coupled to post - translational modifications of IKKgamma.	HOIP,37,41,Protein	IKKgamma,77,85,Protein	CD40,91,95,Protein	IKKgamma,177,185,Protein	"[{""token"": ""HOIP"", ""start_span"": 37, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""IKKgamma"", ""start_span"": 77, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 91, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""IKKgamma"", ""start_span"": 177, ""end_span"": 185, ""type"": ""Protein""}]"	train
The mechanisms by which HOIP mediates recruitment of the IKK complex to CD40 and by which HOIP is recruited to CD40 remain unclear.	HOIP,24,28,Protein	CD40,72,76,Protein	HOIP,90,94,Protein	CD40,111,115,Protein	"[{""token"": ""HOIP"", ""start_span"": 24, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 72, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 90, ""end_span"": 94, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 111, ""end_span"": 115, ""type"": ""Protein""}]"	train
Potentially, TRAF2 and HOIP directly interact, but it is possible that the ubiquitin ligase activity of TRAF2 [ 20] ( or TRAF2 - associated proteins, such as the cIAPs [ 21]) generates K63 - linked polyubiquitin chains to which HOIP can bind and thus associate with the CD40 signaling complex [ 22].	TRAF2,13,18,Protein	HOIP,23,27,Protein	TRAF2,104,109,Protein	HOIP,228,232,Protein	"[{""token"": ""TRAF2"", ""start_span"": 13, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 23, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 104, ""end_span"": 109, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 228, ""end_span"": 232, ""type"": ""Protein""}]"	train
Although the experiments presented here focus on CD40, our results and those of other groups [ 16], [ 22] support the possibility that HOIP is important in many signaling pathways in which TRAF2 or TRAF6 are involved, including those associated with various members of the TNF receptor superfamily and the Toll - like receptors.	CD40,49,53,Protein	HOIP,135,139,Protein	TRAF2,189,194,Protein	TRAF6,198,203,Protein	"[{""token"": ""CD40"", ""start_span"": 49, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 135, ""end_span"": 139, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 189, ""end_span"": 194, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 198, ""end_span"": 203, ""type"": ""Protein""}]"	train
Transduction of both HOIP - deficient ( HOIP - / -) clones with a retrovirus encoding FLAG - HOIP reversed defective CD80 upregulation, while transduction with an empty vector ( pMIP) did not.	HOIP,21,25,Protein	HOIP,40,44,Protein	HOIP,93,97,Protein	CD80,117,121,Protein	"[{""token"": ""HOIP"", ""start_span"": 21, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 40, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 93, ""end_span"": 97, ""type"": ""Protein""}, {""token"": ""CD80"", ""start_span"": 117, ""end_span"": 121, ""type"": ""Protein""}]"	train
Western blots were probed with antibodies specific for cIAP1, TRAF2, TRAF3, and HOIP ( approximate molecular weights indicated on left).	cIAP1,55,60,Protein	TRAF2,62,67,Protein	TRAF3,69,74,Protein	HOIP,80,84,Protein	"[{""token"": ""cIAP1"", ""start_span"": 55, ""end_span"": 60, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 62, ""end_span"": 67, ""type"": ""Protein""}, {""token"": ""TRAF3"", ""start_span"": 69, ""end_span"": 74, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 80, ""end_span"": 84, ""type"": ""Protein""}]"	train
The general protein kinase C ( PKC) inhibitor Ro - 31 - 8220, the conventional PKCalpha / beta inhibitor Go - 6976, overexpression of dominant negative PKCalpha constructs and PKCalpha siRNA reduced NF - kappaB activity in response to M - CSF.	PKCalpha,79,87,Protein	beta,90,94,Protein	dominant negative PKCalpha,134,160,Protein	PKCalpha siRNA,176,190,Protein	"[{""token"": ""PKCalpha"", ""start_span"": 79, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""beta"", ""start_span"": 90, ""end_span"": 94, ""type"": ""Protein""}, {""token"": ""dominant negative PKCalpha"", ""start_span"": 134, ""end_span"": 160, ""type"": ""Protein""}, {""token"": ""PKCalpha siRNA"", ""start_span"": 176, ""end_span"": 190, ""type"": ""Protein""}]"	train
PKCalpha induces IL - 1alpha, iNOS and TNFalpha mRNA production after lipopolysaccharide ( LPS) exposure [ 29].	PKCalpha,0,8,Protein	IL - 1alpha,17,28,Protein	iNOS,30,34,Protein	TNFalpha,39,47,Protein	"[{""token"": ""PKCalpha"", ""start_span"": 0, ""end_span"": 8, ""type"": ""Protein""}, {""token"": ""IL - 1alpha"", ""start_span"": 17, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""iNOS"", ""start_span"": 30, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 39, ""end_span"": 47, ""type"": ""Protein""}]"	train
Furthermore, we co - transfected the NF - kappaB - SEAP construct along with either the WT NF - kappaB p65, NF - kappaB p65 276S / A or NF - kappaB p65 536S / A constructs into a NF - kappaB p65 - / - murine fibroblast cell line and measured NF - kappaB activity.	p65,103,106,Protein	p65,120,123,Protein	p65,148,151,Protein	p65,191,194,Protein	"[{""token"": ""p65"", ""start_span"": 103, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 120, ""end_span"": 123, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 148, ""end_span"": 151, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 191, ""end_span"": 194, ""type"": ""Protein""}]"	train
Phosphorylation of NF - kappaB p65 at Ser536 occurs in response to many inflammatory stimuli as well as kinases, IKKalpha, IKKbeta and RSK1 [ 17], [ 18], [ 19], [ 20], [ 21].	p65,31,34,Protein	IKKalpha,113,121,Protein	IKKbeta,123,130,Protein	RSK1,135,139,Protein	"[{""token"": ""p65"", ""start_span"": 31, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""IKKalpha"", ""start_span"": 113, ""end_span"": 121, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 123, ""end_span"": 130, ""type"": ""Protein""}, {""token"": ""RSK1"", ""start_span"": 135, ""end_span"": 139, ""type"": ""Protein""}]"	train
During this process, expression of IKKalpha among other proteins, is elevated leading to increased p52 NF - kappaB ( relB) expression through partial proteolytic degradation of the p100 NF - kappaB protein.	IKKalpha,35,43,Protein	p52,99,102,Protein	relB,117,121,Protein	p100,181,185,Protein	"[{""token"": ""IKKalpha"", ""start_span"": 35, ""end_span"": 43, ""type"": ""Protein""}, {""token"": ""p52"", ""start_span"": 99, ""end_span"": 102, ""type"": ""Protein""}, {""token"": ""relB"", ""start_span"": 117, ""end_span"": 121, ""type"": ""Protein""}, {""token"": ""p100"", ""start_span"": 181, ""end_span"": 185, ""type"": ""Protein""}]"	train
Kinase deficient CMV - PKCalpha ( KD - PKCalpha) or wild type pCMV - PKCalpha ( WT - PKCalpha) were generous gifts from Alexandra C. Newton ( University of California, San Diego, CA).	PKCalpha,23,31,Protein	PKCalpha,39,47,Protein	PKCalpha,69,77,Protein	PKCalpha,85,93,Protein	"[{""token"": ""PKCalpha"", ""start_span"": 23, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""PKCalpha"", ""start_span"": 39, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""PKCalpha"", ""start_span"": 69, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""PKCalpha"", ""start_span"": 85, ""end_span"": 93, ""type"": ""Protein""}]"	train
( B) NF - kappaB p65 - / - cell line was transiently transfected with pNF - kappaB - SEAP along with empty vector or plasmid encoding either NF - kappaB p65 WT, NF - kappaB p65 276S / A, or NF - kappaB p65 536S / A.	p65,17,20,Protein	p65,153,156,Protein	p65,173,176,Protein	p65,202,205,Protein	"[{""token"": ""p65"", ""start_span"": 17, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 153, ""end_span"": 156, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 173, ""end_span"": 176, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 202, ""end_span"": 205, ""type"": ""Protein""}]"	train
Spontaneous mutations of the Sharpin ( SHANK - associated RH domain - interacting protein, other aliases: Rbckl1, Sipl1) gene in mice result in systemic inflammation that is characterized by chronic proliferative dermatitis and dysregulated secretion of T helper1 ( Th1) and Th2 cytokines.	Sharpin,29,36,Protein	SHANK - associated RH domain - interacting protein,39,89,Protein	Rbckl1,106,112,Protein	Sipl1,114,119,Protein	"[{""token"": ""Sharpin"", ""start_span"": 29, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""SHANK - associated RH domain - interacting protein"", ""start_span"": 39, ""end_span"": 89, ""type"": ""Protein""}, {""token"": ""Rbckl1"", ""start_span"": 106, ""end_span"": 112, ""type"": ""Protein""}, {""token"": ""Sipl1"", ""start_span"": 114, ""end_span"": 119, ""type"": ""Protein""}]"	train
BMDC were CD11c + and MHC II + with low expression of co - stimulatory molecules CD40, CD80, and CD86.	CD11c,10,15,Protein	CD40,81,85,Protein	CD80,87,91,Protein	CD86,97,101,Protein	"[{""token"": ""CD11c"", ""start_span"": 10, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 81, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""CD80"", ""start_span"": 87, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""CD86"", ""start_span"": 97, ""end_span"": 101, ""type"": ""Protein""}]"	train
In addition, the transcript levels of the inflammatory cytokines Il6, Il12p40, Gmcsf, and Ifnb were examined, and these were all significantly reduced in stimulated cpdm BMDC when compared with WT controls ( Fig. 4).	Il6,65,68,Protein	Il12p40,70,77,Protein	Gmcsf,79,84,Protein	Ifnb,90,94,Protein	"[{""token"": ""Il6"", ""start_span"": 65, ""end_span"": 68, ""type"": ""Protein""}, {""token"": ""Il12p40"", ""start_span"": 70, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""Gmcsf"", ""start_span"": 79, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""Ifnb"", ""start_span"": 90, ""end_span"": 94, ""type"": ""Protein""}]"	train
The transcription of TLR3 / 4 - induced proinflammatory intermediates is tightly regulated by cellular signaling pathways, in particular NF - kappaB, TBK1 / IRF3, and MAPK [ 23] - [ 27].	TLR3,21,25,Protein	4,28,29,Protein	TBK1,150,154,Protein	IRF3,157,161,Protein	"[{""token"": ""TLR3"", ""start_span"": 21, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""4"", ""start_span"": 28, ""end_span"": 29, ""type"": ""Protein""}, {""token"": ""TBK1"", ""start_span"": 150, ""end_span"": 154, ""type"": ""Protein""}, {""token"": ""IRF3"", ""start_span"": 157, ""end_span"": 161, ""type"": ""Protein""}]"	train
In addition to TLR3 / 4 agonists, the TLR2 ligand Pam3CYS was used since it has been shown to induce both Th1 and Th2 responses [ 28] - [ 30].	TLR3,15,19,Protein	4,22,23,Protein	TLR2,38,42,Protein	Pam3CYS,50,57,Protein	"[{""token"": ""TLR3"", ""start_span"": 15, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""4"", ""start_span"": 22, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""TLR2"", ""start_span"": 38, ""end_span"": 42, ""type"": ""Protein""}, {""token"": ""Pam3CYS"", ""start_span"": 50, ""end_span"": 57, ""type"": ""Protein""}]"	train
NF - kappaB activation was selectively inhibited in LPS and poly I: C stimulated cpdm BMDC compared to wild type, while activation of TBK1 / IRF3, ERK1 / 2, or p38 was not, indicating that disrupted NF - kappaB signaling in cpdm DC is responsible for the defective cytokine expression.	TBK1,134,138,Protein	IRF3,141,145,Protein	ERK1,147,151,Protein	2,154,155,Protein	"[{""token"": ""TBK1"", ""start_span"": 134, ""end_span"": 138, ""type"": ""Protein""}, {""token"": ""IRF3"", ""start_span"": 141, ""end_span"": 145, ""type"": ""Protein""}, {""token"": ""ERK1"", ""start_span"": 147, ""end_span"": 151, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 154, ""end_span"": 155, ""type"": ""Protein""}]"	train
After 5 days, supernatant was collected and the secretion of IFNgamma, IL4, IL2, and IL17A measured by ELISA.	IFNgamma,61,69,Protein	IL4,71,74,Protein	IL2,76,79,Protein	IL17A,85,90,Protein	"[{""token"": ""IFNgamma"", ""start_span"": 61, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""IL4"", ""start_span"": 71, ""end_span"": 74, ""type"": ""Protein""}, {""token"": ""IL2"", ""start_span"": 76, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""IL17A"", ""start_span"": 85, ""end_span"": 90, ""type"": ""Protein""}]"	train
The expression of Il6, Il12p40, Gmcsf, and Sharpin mRNA was determined by qRT - PCR.	Il6,18,21,Protein	Il12p40,23,30,Protein	Gmcsf,32,37,Protein	Sharpin,43,50,Protein	"[{""token"": ""Il6"", ""start_span"": 18, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""Il12p40"", ""start_span"": 23, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""Gmcsf"", ""start_span"": 32, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""Sharpin"", ""start_span"": 43, ""end_span"": 50, ""type"": ""Protein""}]"	train
At 0, 1 and 2 hours, total RNA was extracted and subject to qRT - PCR to measure the expression of Il12p40 ( A, B), Il6 ( C, D), Gmcsf ( E, F), and Ifnb ( G, H) mRNA.	Il12p40,99,106,Protein	Il6,116,119,Protein	Gmcsf,129,134,Protein	Ifnb,148,152,Protein	"[{""token"": ""Il12p40"", ""start_span"": 99, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""Il6"", ""start_span"": 116, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""Gmcsf"", ""start_span"": 129, ""end_span"": 134, ""type"": ""Protein""}, {""token"": ""Ifnb"", ""start_span"": 148, ""end_span"": 152, ""type"": ""Protein""}]"	train
Normal TLR4 and MD2 expression and decreased IL10 secretion and A20 expression by cpdm BMDC.	TLR4,7,11,Protein	MD2,16,19,Protein	IL10,45,49,Protein	A20,64,67,Protein	"[{""token"": ""TLR4"", ""start_span"": 7, ""end_span"": 11, ""type"": ""Protein""}, {""token"": ""MD2"", ""start_span"": 16, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""IL10"", ""start_span"": 45, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""A20"", ""start_span"": 64, ""end_span"": 67, ""type"": ""Protein""}]"	train
At 0, 15, 30, and 60 minutes, whole - cell lysates were obtained and subject to immunoblots with antibodies against proteins involved in NF - kappaB, TBK1 / IRF3, ERK1 / 2, and p38 signaling pathways.	TBK1,150,154,Protein	IRF3,157,161,Protein	ERK1,163,167,Protein	2,170,171,Protein	"[{""token"": ""TBK1"", ""start_span"": 150, ""end_span"": 154, ""type"": ""Protein""}, {""token"": ""IRF3"", ""start_span"": 157, ""end_span"": 161, ""type"": ""Protein""}, {""token"": ""ERK1"", ""start_span"": 163, ""end_span"": 167, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 170, ""end_span"": 171, ""type"": ""Protein""}]"	train
The B cells were found to express BMP type I and type II receptors and BMP - 6 rapidly induced phosphorylation of Smad1 / 5 / 8.	BMP - 6,71,78,Protein	Smad1,114,119,Protein	5,122,123,Protein	8,126,127,Protein	"[{""token"": ""BMP - 6"", ""start_span"": 71, ""end_span"": 78, ""type"": ""Protein""}, {""token"": ""Smad1"", ""start_span"": 114, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""5"", ""start_span"": 122, ""end_span"": 123, ""type"": ""Protein""}, {""token"": ""8"", ""start_span"": 126, ""end_span"": 127, ""type"": ""Protein""}]"	valid
Furthermore, BMP - 2, - 4, 6 and - 7 had an antiproliferative and a proapoptotic effect on multiple myeloma cells [ 9 - 11].	BMP - 2,13,20,Protein	- 4,22,25,Protein	6,27,28,Protein	- 7,33,36,Protein	"[{""token"": ""BMP - 2"", ""start_span"": 13, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""- 4"", ""start_span"": 22, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""6"", ""start_span"": 27, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""- 7"", ""start_span"": 33, ""end_span"": 36, ""type"": ""Protein""}]"	valid
This analysis revealed that the type I receptors Act - RIA, BMP - RIB and the type II receptors BMP - RII and Act - RIIb are expressed on resting human B - cells ( Figure 4).	Act - RIA,49,58,Protein	BMP - RIB,60,69,Protein	BMP - RII,96,105,Protein	Act - RIIb,110,120,Protein	"[{""token"": ""Act - RIA"", ""start_span"": 49, ""end_span"": 58, ""type"": ""Protein""}, {""token"": ""BMP - RIB"", ""start_span"": 60, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""BMP - RII"", ""start_span"": 96, ""end_span"": 105, ""type"": ""Protein""}, {""token"": ""Act - RIIb"", ""start_span"": 110, ""end_span"": 120, ""type"": ""Protein""}]"	valid
BMP - 6 induces phosphorylation of Smad1 / 5 / 8	BMP - 6,0,7,Protein	Smad1,35,40,Protein	5,43,44,Protein	8,47,48,Protein	"[{""token"": ""BMP - 6"", ""start_span"": 0, ""end_span"": 7, ""type"": ""Protein""}, {""token"": ""Smad1"", ""start_span"": 35, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""5"", ""start_span"": 43, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""8"", ""start_span"": 47, ""end_span"": 48, ""type"": ""Protein""}]"	valid
Next, we wanted to explore whether the BMP - 6 induced phosphorylation of Smad 1 / 5 / 8 also could induce transcriptional changes of target genes.	BMP - 6,39,46,Protein	Smad 1,74,80,Protein	5,83,84,Protein	8,87,88,Protein	"[{""token"": ""BMP - 6"", ""start_span"": 39, ""end_span"": 46, ""type"": ""Protein""}, {""token"": ""Smad 1"", ""start_span"": 74, ""end_span"": 80, ""type"": ""Protein""}, {""token"": ""5"", ""start_span"": 83, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""8"", ""start_span"": 87, ""end_span"": 88, ""type"": ""Protein""}]"	valid
Taken together, these data suggest that Id1 could be a possible target gene for mediating the effects of BMP - 6 in human B cells, whereas Id2 and Id3 not seem to be involved.	Id1,40,43,Protein	BMP - 6,105,112,Protein	Id2,139,142,Protein	Id3,147,150,Protein	"[{""token"": ""Id1"", ""start_span"": 40, ""end_span"": 43, ""type"": ""Protein""}, {""token"": ""BMP - 6"", ""start_span"": 105, ""end_span"": 112, ""type"": ""Protein""}, {""token"": ""Id2"", ""start_span"": 139, ""end_span"": 142, ""type"": ""Protein""}, {""token"": ""Id3"", ""start_span"": 147, ""end_span"": 150, ""type"": ""Protein""}]"	valid
Importantly, BMP - 6 induced a rapid and marked increase in Smad - 1 / 5 / 8 phosphorylation.	BMP - 6,13,20,Protein	Smad - 1,60,68,Protein	5,71,72,Protein	8,75,76,Protein	"[{""token"": ""BMP - 6"", ""start_span"": 13, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""Smad - 1"", ""start_span"": 60, ""end_span"": 68, ""type"": ""Protein""}, {""token"": ""5"", ""start_span"": 71, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""8"", ""start_span"": 75, ""end_span"": 76, ""type"": ""Protein""}]"	valid
Furthermore, the BMP - 6 induced Smad phosphorylation was followed by a selective upregulation of Id1 mRNA and subsequent Id1 protein.	BMP - 6,17,24,Protein	Smad,33,37,Protein	Id1,98,101,Protein	Id1,122,125,Protein	"[{""token"": ""BMP - 6"", ""start_span"": 17, ""end_span"": 24, ""type"": ""Protein""}, {""token"": ""Smad"", ""start_span"": 33, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""Id1"", ""start_span"": 98, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""Id1"", ""start_span"": 122, ""end_span"": 125, ""type"": ""Protein""}]"	valid
Thus, phosphorylation of p38, STAT3 and Smad1 / 5 / 8 represent important BMP - signalling pathways that mediated the effects of BMPs and even cross - talk between these pathways has been reported [ 29, 30].	STAT3,30,35,Protein	Smad1,40,45,Protein	5,48,49,Protein	8,52,53,Protein	"[{""token"": ""STAT3"", ""start_span"": 30, ""end_span"": 35, ""type"": ""Protein""}, {""token"": ""Smad1"", ""start_span"": 40, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""5"", ""start_span"": 48, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""8"", ""start_span"": 52, ""end_span"": 53, ""type"": ""Protein""}]"	valid
In the present study, real - time RT - PCR experiments revealed a specific four - fold upregulation for Id1 in BMP - 6 - treated B cells, while the amount of Id2 - Id4 remained unchanged.	Id1,104,107,Protein	BMP - 6,111,118,Protein	Id2,158,161,Protein	Id4,164,167,Protein	"[{""token"": ""Id1"", ""start_span"": 104, ""end_span"": 107, ""type"": ""Protein""}, {""token"": ""BMP - 6"", ""start_span"": 111, ""end_span"": 118, ""type"": ""Protein""}, {""token"": ""Id2"", ""start_span"": 158, ""end_span"": 161, ""type"": ""Protein""}, {""token"": ""Id4"", ""start_span"": 164, ""end_span"": 167, ""type"": ""Protein""}]"	valid
In that respect, it is noteworthy that TGF - beta signalling in early and mature B cells induces both Id2 and Id3 expression [ 36, 37], but not Id1 ( data not shown).	TGF - beta,39,49,Protein	Id2,102,105,Protein	Id3,110,113,Protein	Id1,144,147,Protein	"[{""token"": ""TGF - beta"", ""start_span"": 39, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""Id2"", ""start_span"": 102, ""end_span"": 105, ""type"": ""Protein""}, {""token"": ""Id3"", ""start_span"": 110, ""end_span"": 113, ""type"": ""Protein""}, {""token"": ""Id1"", ""start_span"": 144, ""end_span"": 147, ""type"": ""Protein""}]"	valid
Quantification of Id1, Id2 and Id3 protein was calculated by normalizing the specific protein bands to beta - actin using Image Quant 5. 5 software ( Molecular Dynamics).	Id1,18,21,Protein	Id2,23,26,Protein	Id3,31,34,Protein	beta - actin,103,115,Protein	"[{""token"": ""Id1"", ""start_span"": 18, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""Id2"", ""start_span"": 23, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""Id3"", ""start_span"": 31, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""beta - actin"", ""start_span"": 103, ""end_span"": 115, ""type"": ""Protein""}]"	valid
To measure mRNA expression of BMP6, Id1 - Id4 and PGK1 PCR were carried out with TaqMan ( R) universal master mix.	BMP6,30,34,Protein	Id1,36,39,Protein	Id4,42,45,Protein	PGK1,50,54,Protein	"[{""token"": ""BMP6"", ""start_span"": 30, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""Id1"", ""start_span"": 36, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""Id4"", ""start_span"": 42, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""PGK1"", ""start_span"": 50, ""end_span"": 54, ""type"": ""Protein""}]"	valid
Human APOBEC3G ( A3G), the most prominent member of the APOBEC3 family has been identified as the cellular restriction factor that is responsible for inhibition of virion infectivity factor ( Vif) - deleted human immunodeficiency virus - 1 ( HIV - 1) replication in non - permissive cells ( 4).	APOBEC3G,6,14,Protein	A3G,17,20,Protein	virion infectivity factor,164,189,Protein	Vif,192,195,Protein	"[{""token"": ""APOBEC3G"", ""start_span"": 6, ""end_span"": 14, ""type"": ""Protein""}, {""token"": ""A3G"", ""start_span"": 17, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""virion infectivity factor"", ""start_span"": 164, ""end_span"": 189, ""type"": ""Protein""}, {""token"": ""Vif"", ""start_span"": 192, ""end_span"": 195, ""type"": ""Protein""}]"	valid
Sp1 and Sp3 proteins were detected using alpha - Sp1 ( Pep2) antibody ( sc - 59, Santa Cruz) or alpha - Sp3 ( D - 20) antibody ( sc - 644, Santa Cruz) followed by incubation with alpha - rabbit - HRP ( Amersham Biosciences).	Sp1,0,3,Protein	Sp3,8,11,Protein	Sp1,49,52,Protein	Sp3,104,107,Protein	"[{""token"": ""Sp1"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Protein""}, {""token"": ""Sp3"", ""start_span"": 8, ""end_span"": 11, ""type"": ""Protein""}, {""token"": ""Sp1"", ""start_span"": 49, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""Sp3"", ""start_span"": 104, ""end_span"": 107, ""type"": ""Protein""}]"	valid
In line with these publications, we observed an induction of the A3G promoter by approximately 2 - fold after IFN - alpha or IFN - gamma stimulation ( Figure 4D) with IFN - gamma being slightly more potent.	A3G,65,68,Protein	IFN - alpha,110,121,Protein	IFN - gamma,125,136,Protein	IFN - gamma,167,178,Protein	"[{""token"": ""A3G"", ""start_span"": 65, ""end_span"": 68, ""type"": ""Protein""}, {""token"": ""IFN - alpha"", ""start_span"": 110, ""end_span"": 121, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 125, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 167, ""end_span"": 178, ""type"": ""Protein""}]"	valid
Sp1 and Sp3 antibodies, but not an actin antibody, immunoprecipitated the A3G promoter in A3. 01 T cells ( Figure 6C, upper panel).	Sp1,0,3,Protein	Sp3,8,11,Protein	actin,35,40,Protein	A3G,74,77,Protein	"[{""token"": ""Sp1"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Protein""}, {""token"": ""Sp3"", ""start_span"": 8, ""end_span"": 11, ""type"": ""Protein""}, {""token"": ""actin"", ""start_span"": 35, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""A3G"", ""start_span"": 74, ""end_span"": 77, ""type"": ""Protein""}]"	valid
Functionality of the siRNAs directed against Sp1 or Sp3 was confirmed by western blot analysis: protein levels of Sp1 as well as the long and short isoforms of Sp3 were strongly reduced in the presence of 150 or 300 ng specific siRNA ( Figure 7A).	Sp1,45,48,Protein	Sp3,52,55,Protein	Sp1,114,117,Protein	Sp3,160,163,Protein	"[{""token"": ""Sp1"", ""start_span"": 45, ""end_span"": 48, ""type"": ""Protein""}, {""token"": ""Sp3"", ""start_span"": 52, ""end_span"": 55, ""type"": ""Protein""}, {""token"": ""Sp1"", ""start_span"": 114, ""end_span"": 117, ""type"": ""Protein""}, {""token"": ""Sp3"", ""start_span"": 160, ""end_span"": 163, ""type"": ""Protein""}]"	valid
Luciferase assays revealed that A3G promoter activities remained unchanged ( data not shown), most probably due to the high basal expression level of the endogenous Sp1 and / or Sp3 proteins.	Luciferase,0,10,Protein	A3G,32,35,Protein	Sp1,165,168,Protein	Sp3,178,181,Protein	"[{""token"": ""Luciferase"", ""start_span"": 0, ""end_span"": 10, ""type"": ""Protein""}, {""token"": ""A3G"", ""start_span"": 32, ""end_span"": 35, ""type"": ""Protein""}, {""token"": ""Sp1"", ""start_span"": 165, ""end_span"": 168, ""type"": ""Protein""}, {""token"": ""Sp3"", ""start_span"": 178, ""end_span"": 181, ""type"": ""Protein""}]"	valid
EMSA was performed with a 1 - or 30 - fold molar excess of unlabeled APO - Sp1 / 3 probe ( competitor, lanes 6 and 7) or APO - Sp1 / 3mut probe ( competitor mut., lanes 12 and 13).	Sp1,75,78,Protein	3,81,82,Protein	Sp1,127,130,Protein	3mut,133,137,Protein	"[{""token"": ""Sp1"", ""start_span"": 75, ""end_span"": 78, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 81, ""end_span"": 82, ""type"": ""Protein""}, {""token"": ""Sp1"", ""start_span"": 127, ""end_span"": 130, ""type"": ""Protein""}, {""token"": ""3mut"", ""start_span"": 133, ""end_span"": 137, ""type"": ""Protein""}]"	valid
The generation, culture and activation of PKD1 - / -, PKD3 - / - and PKD1 / 3 - / - knockout DT40 B cell lines have been described previously [ 1].	PKD1,42,46,Protein	PKD3,54,58,Protein	PKD1,69,73,Protein	3,76,77,Protein	"[{""token"": ""PKD1"", ""start_span"": 42, ""end_span"": 46, ""type"": ""Protein""}, {""token"": ""PKD3"", ""start_span"": 54, ""end_span"": 58, ""type"": ""Protein""}, {""token"": ""PKD1"", ""start_span"": 69, ""end_span"": 73, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 76, ""end_span"": 77, ""type"": ""Protein""}]"	valid
DT40 B cells express two PKD isoforms, PKD1 and PKD3, and as previously described we have recently generated DT40 B cell lines that lack expression of either PKD1 or PKD3 or both enzymes [ 1].	PKD1,39,43,Protein	PKD3,48,52,Protein	PKD1,158,162,Protein	PKD3,166,170,Protein	"[{""token"": ""PKD1"", ""start_span"": 39, ""end_span"": 43, ""type"": ""Protein""}, {""token"": ""PKD3"", ""start_span"": 48, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""PKD1"", ""start_span"": 158, ""end_span"": 162, ""type"": ""Protein""}, {""token"": ""PKD3"", ""start_span"": 166, ""end_span"": 170, ""type"": ""Protein""}]"	valid
Hence, in the presence of doxycycline, Flag - PKD3 expression in PKD1 / 3 double knockout cells is comparable to endogenous PKD3 present in wild - type DT40 cells and removal of doxycycline from the culture media for 5 days results in a completely null PKD phenotype ( Fig. 1A).	PKD3,46,50,Protein	PKD1,65,69,Protein	3,72,73,Protein	PKD3,124,128,Protein	"[{""token"": ""PKD3"", ""start_span"": 46, ""end_span"": 50, ""type"": ""Protein""}, {""token"": ""PKD1"", ""start_span"": 65, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 72, ""end_span"": 73, ""type"": ""Protein""}, {""token"": ""PKD3"", ""start_span"": 124, ""end_span"": 128, ""type"": ""Protein""}]"	valid
The small heat shock protein HSP27 has recently been proposed as a PKD1 substrate [ 24] and we accordingly assessed whether PKD - null DT40 cells have defective phosphorylation of HSP27 on serine 82, the proposed PKD1 substrate sequence.	HSP27,29,34,Protein	PKD1,67,71,Protein	HSP27,180,185,Protein	PKD1,213,217,Protein	"[{""token"": ""HSP27"", ""start_span"": 29, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""PKD1"", ""start_span"": 67, ""end_span"": 71, ""type"": ""Protein""}, {""token"": ""HSP27"", ""start_span"": 180, ""end_span"": 185, ""type"": ""Protein""}, {""token"": ""PKD1"", ""start_span"": 213, ""end_span"": 217, ""type"": ""Protein""}]"	valid
Hence, PKD3 as well as PKD1 can regulate HSP27 phosphorylation and in DT40 B cells they are functionally redundant as HSP27 kinases.	PKD3,7,11,Protein	PKD1,23,27,Protein	HSP27,41,46,Protein	HSP27,118,123,Protein	"[{""token"": ""PKD3"", ""start_span"": 7, ""end_span"": 11, ""type"": ""Protein""}, {""token"": ""PKD1"", ""start_span"": 23, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""HSP27"", ""start_span"": 41, ""end_span"": 46, ""type"": ""Protein""}, {""token"": ""HSP27"", ""start_span"": 118, ""end_span"": 123, ""type"": ""Protein""}]"	valid
We did observe that the strength of BCR ( but not phorbol ester) - induced regulation of the Erk1 - RSK1 signalling pathway was reduced in PKD1 / 3 - / - B cells compared to wild - type B cells ( Fig. 3B).	Erk1,93,97,Protein	RSK1,100,104,Protein	PKD1,139,143,Protein	3,146,147,Protein	"[{""token"": ""Erk1"", ""start_span"": 93, ""end_span"": 97, ""type"": ""Protein""}, {""token"": ""RSK1"", ""start_span"": 100, ""end_span"": 104, ""type"": ""Protein""}, {""token"": ""PKD1"", ""start_span"": 139, ""end_span"": 143, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 146, ""end_span"": 147, ""type"": ""Protein""}]"	valid
Specifically interleukin 4 ( IL - 4) - induced STAT6 and GATA3 inhibit differentiation into Th1 cells in the early phase of commitment [ 1, 2].	interleukin 4,13,26,Protein	IL - 4,29,35,Protein	STAT6,47,52,Protein	GATA3,57,62,Protein	"[{""token"": ""interleukin 4"", ""start_span"": 13, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 29, ""end_span"": 35, ""type"": ""Protein""}, {""token"": ""STAT6"", ""start_span"": 47, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 57, ""end_span"": 62, ""type"": ""Protein""}]"	valid
GATA3 is sufficient to induce a Th2 phenotype [ 3] and acts not only through the induction of IL - 4, IL - 5 and IL - 13, the Th2 cytokines, but also through the inhibition of Th1 cell - specific factors [ 3].	GATA3,0,5,Protein	IL - 4,94,100,Protein	IL - 5,102,108,Protein	IL - 13,113,120,Protein	"[{""token"": ""GATA3"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 94, ""end_span"": 100, ""type"": ""Protein""}, {""token"": ""IL - 5"", ""start_span"": 102, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""IL - 13"", ""start_span"": 113, ""end_span"": 120, ""type"": ""Protein""}]"	valid
The current study provides evidence that GATA3 and FOXP3 play a competitive role in iTreg cell commitment as T - bet and GATA3 for Th1 and Th2 differentiation, respectively.	GATA3,41,46,Protein	FOXP3,51,56,Protein	T - bet,109,116,Protein	GATA3,121,126,Protein	"[{""token"": ""GATA3"", ""start_span"": 41, ""end_span"": 46, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 51, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 109, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 121, ""end_span"": 126, ""type"": ""Protein""}]"	valid
Naturally occurring Th2 cells such as CRTH2 + T cells, T cells isolated according to their IL - 4 secretion, or an IL - 4 - producing T cell clone ( BR8) were also lacking FOXP3 expression ( Figure 2B).	CRTH2,38,43,Protein	IL - 4,91,97,Protein	IL - 4,115,121,Protein	FOXP3,172,177,Protein	"[{""token"": ""CRTH2"", ""start_span"": 38, ""end_span"": 43, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 91, ""end_span"": 97, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 115, ""end_span"": 121, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 172, ""end_span"": 177, ""type"": ""Protein""}]"	valid
Because IL - 4 is the key Th2 cytokine, the expression of IL - 4 and FOXP3 in freshly isolated CD4 + T cells was analyzed by fluorescence activated cell sorting ( FACS).	IL - 4,8,14,Protein	IL - 4,58,64,Protein	FOXP3,69,74,Protein	CD4,95,98,Protein	"[{""token"": ""IL - 4"", ""start_span"": 8, ""end_span"": 14, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 58, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 69, ""end_span"": 74, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 95, ""end_span"": 98, ""type"": ""Protein""}]"	valid
IL - 4 - expressing cells were most abundant among CD45RO + CD25 - cells, which did not co - express FOXP3 ( Figure 3A, left panel).	IL - 4,0,6,Protein	CD45RO,51,57,Protein	CD25,60,64,Protein	FOXP3,101,106,Protein	"[{""token"": ""IL - 4"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Protein""}, {""token"": ""CD45RO"", ""start_span"": 51, ""end_span"": 57, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 60, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 101, ""end_span"": 106, ""type"": ""Protein""}]"	valid
In contrast, CD45RO + CD25 + cells abundantly expressed FOXP3, while lacking IL - 4 ( Figure 3A, right panel).	CD45RO,13,19,Protein	CD25,22,26,Protein	FOXP3,56,61,Protein	IL - 4,77,83,Protein	"[{""token"": ""CD45RO"", ""start_span"": 13, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 22, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 56, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 77, ""end_span"": 83, ""type"": ""Protein""}]"	valid
To study the effects of IL - 4 on already - existing human natural or inducible Treg cells, we exposed sorted CD25 + T cells ( nTreg cells) to IL - 4 and analyzed FOXP3 expression and suppressive capacity.	IL - 4,24,30,Protein	CD25,110,114,Protein	IL - 4,143,149,Protein	FOXP3,163,168,Protein	"[{""token"": ""IL - 4"", ""start_span"": 24, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 110, ""end_span"": 114, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 143, ""end_span"": 149, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 163, ""end_span"": 168, ""type"": ""Protein""}]"	valid
CD25 was down - regulated in TGF - beta - treated cells compare to activated T cells, which was even more pronounced in cells cultured with TGF - beta and IL - 4.	CD25,0,4,Protein	TGF - beta,29,39,Protein	TGF - beta,140,150,Protein	IL - 4,155,161,Protein	"[{""token"": ""CD25"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 29, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 140, ""end_span"": 150, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 155, ""end_span"": 161, ""type"": ""Protein""}]"	valid
These results showed that IL - 4 acts in vitro as an inhibitor of FOXP3 expression, without interfering with TGF - beta signaling, probably acting at the level of transcription factors, and possibly by a GATA3 - dependent mechanism.	IL - 4,26,32,Protein	FOXP3,66,71,Protein	TGF - beta,109,119,Protein	GATA3,204,209,Protein	"[{""token"": ""IL - 4"", ""start_span"": 26, ""end_span"": 32, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 66, ""end_span"": 71, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 109, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 204, ""end_span"": 209, ""type"": ""Protein""}]"	valid
FOXP3 expression decreased once GATA3 expression is high; therefore, we hypothesized a potential role for GATA3 in repressing FOXP3.	FOXP3,0,5,Protein	GATA3,32,37,Protein	GATA3,106,111,Protein	FOXP3,126,131,Protein	"[{""token"": ""FOXP3"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 32, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 106, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 126, ""end_span"": 131, ""type"": ""Protein""}]"	valid
Besides GATA3 ' s well - known positive effect on gene regulation, GATA3 ' s repressive capabilities were previously shown to restrict Th1 commitment by inhibiting STAT4 expression [ 2, 21], and therefore GATA3 prevents differentiation into Th1 cells.	GATA3,8,13,Protein	GATA3,67,72,Protein	STAT4,164,169,Protein	GATA3,205,210,Protein	"[{""token"": ""GATA3"", ""start_span"": 8, ""end_span"": 13, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 67, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""STAT4"", ""start_span"": 164, ""end_span"": 169, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 205, ""end_span"": 210, ""type"": ""Protein""}]"	valid
TAT - GATA3 reduced FOXP3 expression in a dose - dependent manner, whereas a DNA - binding domain truncated version ( TAT - deltaDBD - GATA3) did not affect FOXP3 expression as compared with expression in untransduced cells ( Figure 7A).	TAT - GATA3,0,11,Protein	FOXP3,20,25,Protein	GATA3,135,140,Protein	FOXP3,157,162,Protein	"[{""token"": ""TAT - GATA3"", ""start_span"": 0, ""end_span"": 11, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 20, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 135, ""end_span"": 140, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 157, ""end_span"": 162, ""type"": ""Protein""}]"	valid
In contrast, cells from the CD2 - GATA3xDO11. 10 mice showed dramatically reduced Foxp3 expression when activated with TGF - beta and OVA ( Figure 7B).	CD2,28,31,Protein	GATA3xDO11,34,44,Protein	Foxp3,82,87,Protein	TGF - beta,119,129,Protein	"[{""token"": ""CD2"", ""start_span"": 28, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""GATA3xDO11"", ""start_span"": 34, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 82, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 119, ""end_span"": 129, ""type"": ""Protein""}]"	valid
To investigate the molecular mechanism of GATA3 - mediated repression of human FOXP3, the human FOXP3 promoter was studied and a palindromic binding site for GATA3 was discovered.	GATA3,42,47,Protein	FOXP3,79,84,Protein	FOXP3,96,101,Protein	GATA3,158,163,Protein	"[{""token"": ""GATA3"", ""start_span"": 42, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 79, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 96, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 158, ""end_span"": 163, ""type"": ""Protein""}]"	valid
In this competitive process TGF - beta appeared to be mandatory for the induction of FOXP3, possibly by keeping the expression of GATA3 and T - bet low [ 37, 38].	TGF - beta,28,38,Protein	FOXP3,85,90,Protein	GATA3,130,135,Protein	T - bet,140,147,Protein	"[{""token"": ""TGF - beta"", ""start_span"": 28, ""end_span"": 38, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 85, ""end_span"": 90, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 130, ""end_span"": 135, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 140, ""end_span"": 147, ""type"": ""Protein""}]"	valid
The Th2 cytokine IL - 4 but not IL - 13 ( unpublished data) was able to inhibit TGF - beta - mediated FOXP3 induction and therefore prevented conversion into the regulatory phenotype.	IL - 4,17,23,Protein	IL - 13,32,39,Protein	TGF - beta,80,90,Protein	FOXP3,102,107,Protein	"[{""token"": ""IL - 4"", ""start_span"": 17, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""IL - 13"", ""start_span"": 32, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 80, ""end_span"": 90, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 102, ""end_span"": 107, ""type"": ""Protein""}]"	valid
Only the IL - 4 / IL - 4 mAb complex resulted in a decrease of the amount of natural or inducible Treg ( CD25 + and Foxp3 +) cells 7 d after treatment.	IL - 4,9,15,Protein	IL - 4,18,24,Protein	CD25,105,109,Protein	Foxp3,116,121,Protein	"[{""token"": ""IL - 4"", ""start_span"": 9, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 18, ""end_span"": 24, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 105, ""end_span"": 109, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 116, ""end_span"": 121, ""type"": ""Protein""}]"	valid
But since a distinction of nTreg and iTreg cells is currently not possible, because iTreg cells also transiently express CD25 after activation, we cannot exclude that IL - 4 may also inhibit Foxp3 expression in nTreg cells in vivo or that additional effects may contribute to the observed drop in Foxp3 expression.	CD25,121,125,Protein	IL - 4,167,173,Protein	Foxp3,191,196,Protein	Foxp3,297,302,Protein	"[{""token"": ""CD25"", ""start_span"": 121, ""end_span"": 125, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 167, ""end_span"": 173, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 191, ""end_span"": 196, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 297, ""end_span"": 302, ""type"": ""Protein""}]"	valid
IL - 4 has been previously shown to induce the generation of FOXP3 + Treg cells out of CD4 + CD25 - [ 50].	IL - 4,0,6,Protein	FOXP3,61,66,Protein	CD4,87,90,Protein	CD25,93,97,Protein	"[{""token"": ""IL - 4"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 61, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 87, ""end_span"": 90, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 93, ""end_span"": 97, ""type"": ""Protein""}]"	valid
This inhibitory effect of GATA3 was further confirmed in BALB / c transgenic mice, expressing GATA3 in T cells ( DO11. 10: CD2 - GATA3 transgenic mice).	GATA3,26,31,Protein	GATA3,94,99,Protein	CD2,123,126,Protein	GATA3,129,134,Protein	"[{""token"": ""GATA3"", ""start_span"": 26, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 94, ""end_span"": 99, ""type"": ""Protein""}, {""token"": ""CD2"", ""start_span"": 123, ""end_span"": 126, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 129, ""end_span"": 134, ""type"": ""Protein""}]"	valid
The PCR primers and probes were designed based on the sequences reported in GenBank with the Primer Express software version 1. 2 ( Applied Biosystems) as follows: FOXP3 forward primer 5 ' - GAA ACA GCA CAT TCC CAG AGT TC - 3 '; FOXP3 reverse primer 5 ' - ATG GCC CAG CGG ATG AG - 3 '; EF - 1alpha forward primer and reverse primer as described [ 61]; GATA3 forward primer 5 ' - GCG GGC TCT ATC ACA AAA TGA - 3 ' and rwd 5 ' - GCT CTC CTG GCT GCA GAC AGC - 3 '.	FOXP3,164,169,Protein	FOXP3,229,234,Protein	EF - 1alpha,286,297,Protein	GATA3,352,357,Protein	"[{""token"": ""FOXP3"", ""start_span"": 164, ""end_span"": 169, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 229, ""end_span"": 234, ""type"": ""Protein""}, {""token"": ""EF - 1alpha"", ""start_span"": 286, ""end_span"": 297, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 352, ""end_span"": 357, ""type"": ""Protein""}]"	valid
Naive CD4 + T cells ( CD4 +, CD62L +, and CD25 -) were isolated from pooled lymph nodes and spleens by FACS ( FACS Aria, BD Biosciences).	CD4,6,9,Protein	CD4,22,25,Protein	CD62L,29,34,Protein	CD25,42,46,Protein	"[{""token"": ""CD4"", ""start_span"": 6, ""end_span"": 9, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 22, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""CD62L"", ""start_span"": 29, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 42, ""end_span"": 46, ""type"": ""Protein""}]"	valid
( B) In vitro differentiated Th1, Th2, or iTreg cells were activated with anti - CD3 / CD28, TGF - beta, or anti - IL - 4 as indicated.	CD3,81,84,Protein	CD28,87,91,Protein	TGF - beta,93,103,Protein	IL - 4,115,121,Protein	"[{""token"": ""CD3"", ""start_span"": 81, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""CD28"", ""start_span"": 87, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 93, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 115, ""end_span"": 121, ""type"": ""Protein""}]"	valid
( B) Intracellular GATA3 and FOXP3 staining is shown after exposure of CD4 + CD45RA + T cells to differentiating conditions as in part A of the figure.	GATA3,19,24,Protein	FOXP3,29,34,Protein	CD4,71,74,Protein	CD45RA,77,83,Protein	"[{""token"": ""GATA3"", ""start_span"": 19, ""end_span"": 24, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 29, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 71, ""end_span"": 74, ""type"": ""Protein""}, {""token"": ""CD45RA"", ""start_span"": 77, ""end_span"": 83, ""type"": ""Protein""}]"	valid
( B) CD4 + CD45RA + cells were activated in the presence of a constant concentration of TGF - beta ( 5 ng / ml) with an increasing concentration of IL - 4, as indicated.	CD4,5,8,Protein	CD45RA,11,17,Protein	TGF - beta,88,98,Protein	IL - 4,148,154,Protein	"[{""token"": ""CD4"", ""start_span"": 5, ""end_span"": 8, ""type"": ""Protein""}, {""token"": ""CD45RA"", ""start_span"": 11, ""end_span"": 17, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 88, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 148, ""end_span"": 154, ""type"": ""Protein""}]"	valid
GATA - 3 determines Th2 cell differentiation and selectively activates the promoters of IL - 4, IL - 5, and IL - 13 through chromatin remodelling [ 4] - [ 7].	GATA - 3,0,8,Protein	IL - 4,88,94,Protein	IL - 5,96,102,Protein	IL - 13,108,115,Protein	"[{""token"": ""GATA - 3"", ""start_span"": 0, ""end_span"": 8, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 88, ""end_span"": 94, ""type"": ""Protein""}, {""token"": ""IL - 5"", ""start_span"": 96, ""end_span"": 102, ""type"": ""Protein""}, {""token"": ""IL - 13"", ""start_span"": 108, ""end_span"": 115, ""type"": ""Protein""}]"	valid
This effect was concentration - and time - dependent, with a peak effect of 11. 6 - fold at 30 min at a concentration of 10 - 8 M ( Figure 1C) and was associated with marked reductions in anti - CD3 / CD28 - stimulated IL - 4 and IL - 5 mRNA expression ( Figure 1D) and a loss of GATA - 3 binding to the native IL - 5 promoter ( Figure 1E).	IL - 4,219,225,Protein	IL - 5,230,236,Protein	GATA - 3,280,288,Protein	IL - 5,311,317,Protein	"[{""token"": ""IL - 4"", ""start_span"": 219, ""end_span"": 225, ""type"": ""Protein""}, {""token"": ""IL - 5"", ""start_span"": 230, ""end_span"": 236, ""type"": ""Protein""}, {""token"": ""GATA - 3"", ""start_span"": 280, ""end_span"": 288, ""type"": ""Protein""}, {""token"": ""IL - 5"", ""start_span"": 311, ""end_span"": 317, ""type"": ""Protein""}]"	valid
These data also suggest that both activated GR and phospho - GATA - 3 can directly associate with importin - alpha ( Figure 4D) and that activated GR attenuates the phospho - GATA - 3 / importin - alpha interaction in a concentration - dependent manner ( Figure 4E).	GR,44,46,Protein	GATA - 3,61,69,Protein	GR,147,149,Protein	GATA - 3,175,183,Protein	"[{""token"": ""GR"", ""start_span"": 44, ""end_span"": 46, ""type"": ""Protein""}, {""token"": ""GATA - 3"", ""start_span"": 61, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""GR"", ""start_span"": 147, ""end_span"": 149, ""type"": ""Protein""}, {""token"": ""GATA - 3"", ""start_span"": 175, ""end_span"": 183, ""type"": ""Protein""}]"	valid
Firstly, corticosteroid - activated GR appears to compete with activated GATA - 3 for nuclear import via importin - alpha, which is required for the nuclear transport of both GATA - 3 and GR.	GR,36,38,Protein	GATA - 3,73,81,Protein	GATA - 3,175,183,Protein	GR,188,190,Protein	"[{""token"": ""GR"", ""start_span"": 36, ""end_span"": 38, ""type"": ""Protein""}, {""token"": ""GATA - 3"", ""start_span"": 73, ""end_span"": 81, ""type"": ""Protein""}, {""token"": ""GATA - 3"", ""start_span"": 175, ""end_span"": 183, ""type"": ""Protein""}, {""token"": ""GR"", ""start_span"": 188, ""end_span"": 190, ""type"": ""Protein""}]"	valid
We have also previously reported that GATA - 3 knockdown using siRNA results in suppression of anti - CD3 / CD28 - stimulated IL - 4 / IL - 5 mRNA induction, thus implicating an essential role for GATA - 3 in the transcription of these genes [ 12].	GATA - 3,38,46,Protein	IL - 4,126,132,Protein	IL - 5,135,141,Protein	GATA - 3,197,205,Protein	"[{""token"": ""GATA - 3"", ""start_span"": 38, ""end_span"": 46, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 126, ""end_span"": 132, ""type"": ""Protein""}, {""token"": ""IL - 5"", ""start_span"": 135, ""end_span"": 141, ""type"": ""Protein""}, {""token"": ""GATA - 3"", ""start_span"": 197, ""end_span"": 205, ""type"": ""Protein""}]"	valid
In summary, our data provide evidence for a novel action of corticosteroids: suppression of allergic inflammation through a rapid inhibitory effect on GATA - 3 nuclear translocation by preferential binding to the shared nuclear import protein importin - alpha and by a second mechanism involving increased synthesis of MKP - 1, which inhibits p38 MAPK, thus preventing the phosphorylation of GATA - 3 that is necessary for nuclear translocation of GATA - 3.	GATA - 3,151,159,Protein	MKP - 1,319,326,Protein	GATA - 3,392,400,Protein	GATA - 3,448,456,Protein	"[{""token"": ""GATA - 3"", ""start_span"": 151, ""end_span"": 159, ""type"": ""Protein""}, {""token"": ""MKP - 1"", ""start_span"": 319, ""end_span"": 326, ""type"": ""Protein""}, {""token"": ""GATA - 3"", ""start_span"": 392, ""end_span"": 400, ""type"": ""Protein""}, {""token"": ""GATA - 3"", ""start_span"": 448, ""end_span"": 456, ""type"": ""Protein""}]"	valid
( D) RT - PCR showing that FP inhibits IL - 4 and IL - 5 mRNA expression in CD3 / CD28 - costimulated cells.	IL - 4,39,45,Protein	IL - 5,50,56,Protein	CD3,76,79,Protein	CD28,82,86,Protein	"[{""token"": ""IL - 4"", ""start_span"": 39, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""IL - 5"", ""start_span"": 50, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""CD3"", ""start_span"": 76, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""CD28"", ""start_span"": 82, ""end_span"": 86, ""type"": ""Protein""}]"	valid
Indeed, dCGN induced NF - kappaB activation as shown by degradation of IkappaBalpha, translocation of p65 and p50 sub - units to the nucleus and by activation of an NF - kappaB - responsive luciferase reporter plasmid.	IkappaBalpha,71,83,Protein	p65,102,105,Protein	p50,110,113,Protein	luciferase,190,200,Protein	"[{""token"": ""IkappaBalpha"", ""start_span"": 71, ""end_span"": 83, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 102, ""end_span"": 105, ""type"": ""Protein""}, {""token"": ""p50"", ""start_span"": 110, ""end_span"": 113, ""type"": ""Protein""}, {""token"": ""luciferase"", ""start_span"": 190, ""end_span"": 200, ""type"": ""Protein""}]"	valid
Proteins in nuclear extracts were resolved by SDS - PAGE and then Western blotted for NF - kappaB p50 subunit ( p50) or NF - kappaB p65 subunit ( p65).	p50,98,101,Protein	p50,112,115,Protein	p65,132,135,Protein	p65,146,149,Protein	"[{""token"": ""p50"", ""start_span"": 98, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""p50"", ""start_span"": 112, ""end_span"": 115, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 132, ""end_span"": 135, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 146, ""end_span"": 149, ""type"": ""Protein""}]"	valid
Forkhead box P3 ( FOXP3) + CD4 + CD25 + inducible regulatory T ( iT reg) cells play an important role in immune tolerance and homeostasis.	Forkhead box P3,0,15,Protein	FOXP3,18,23,Protein	CD4,27,30,Protein	CD25,33,37,Protein	"[{""token"": ""Forkhead box P3"", ""start_span"": 0, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 18, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 27, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 33, ""end_span"": 37, ""type"": ""Protein""}]"	valid
This study demonstrates that RUNX1 and RUNX3 induced by TGF - beta are involved in the development and suppressive function of Foxp3 + iT reg cells.	RUNX1,29,34,Protein	RUNX3,39,44,Protein	TGF - beta,56,66,Protein	Foxp3,127,132,Protein	"[{""token"": ""RUNX1"", ""start_span"": 29, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 39, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 56, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 127, ""end_span"": 132, ""type"": ""Protein""}]"	valid
The level of FOXP3 mRNA was further reduced when both RUNX1 and RUNX3 were knocked down in naive CD4 + T cells during their differentiation to iT reg cells ( Fig. 1 B).	FOXP3,13,18,Protein	RUNX1,54,59,Protein	RUNX3,64,69,Protein	CD4,97,100,Protein	"[{""token"": ""FOXP3"", ""start_span"": 13, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""RUNX1"", ""start_span"": 54, ""end_span"": 59, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 64, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 97, ""end_span"": 100, ""type"": ""Protein""}]"	valid
The biotinylated FOXP3 promoter oligonucleotides were linked to a streptavidin - coated microtiter plate, and bound RUNX1 or RUNX3 was detected by using anti - RUNX antibodies and a peroxidase - labeled secondary antibody.	FOXP3,17,22,Protein	RUNX1,116,121,Protein	RUNX3,125,130,Protein	RUNX,160,164,Protein	"[{""token"": ""FOXP3"", ""start_span"": 17, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""RUNX1"", ""start_span"": 116, ""end_span"": 121, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 125, ""end_span"": 130, ""type"": ""Protein""}, {""token"": ""RUNX"", ""start_span"": 160, ""end_span"": 164, ""type"": ""Protein""}]"	valid
Chromatin immunoprecipitation ( ChIP) assay results confirmed the binding of RUNX1 and RUNX3 complexes containing CBFbeta to FOXP3 promoter during the differentiation of naive T cells toward T reg cells.	RUNX1,77,82,Protein	RUNX3,87,92,Protein	CBFbeta,114,121,Protein	FOXP3,125,130,Protein	"[{""token"": ""RUNX1"", ""start_span"": 77, ""end_span"": 82, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 87, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""CBFbeta"", ""start_span"": 114, ""end_span"": 121, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 125, ""end_span"": 130, ""type"": ""Protein""}]"	valid
Regulation of FOXP3 promoter activity and FOXP3 protein expression by RUNX1 and RUNX3	FOXP3,14,19,Protein	FOXP3,42,47,Protein	RUNX1,70,75,Protein	RUNX3,80,85,Protein	"[{""token"": ""FOXP3"", ""start_span"": 14, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 42, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""RUNX1"", ""start_span"": 70, ""end_span"": 75, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 80, ""end_span"": 85, ""type"": ""Protein""}]"	valid
In these experiments, the overexpression of RUNX1 and RUNX3 eliminated the need of TGF - beta for FOXP3 promoter activation and PMA / ionomycin stimulation was sufficient.	RUNX1,44,49,Protein	RUNX3,54,59,Protein	TGF - beta,83,93,Protein	FOXP3,98,103,Protein	"[{""token"": ""RUNX1"", ""start_span"": 44, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 54, ""end_span"": 59, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 83, ""end_span"": 93, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 98, ""end_span"": 103, ""type"": ""Protein""}]"	valid
To target all Runx proteins that might be involved in the induction of Foxp3, we used mice in which loxP - flanked Cbfb alleles were inactivated in T cells through expression of a CD4 - cre transgene.	Runx,14,18,Protein	Foxp3,71,76,Protein	Cbfb,115,119,Protein	CD4 - cre,180,189,Protein	"[{""token"": ""Runx"", ""start_span"": 14, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 71, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""Cbfb"", ""start_span"": 115, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""CD4 - cre"", ""start_span"": 180, ""end_span"": 189, ""type"": ""Protein""}]"	valid
There was a consistently lower percentage of CD4 + T cells that had developed Foxp3 expression in the mesenteric lymph node and lamina propria of mice transferred with CbfbF / F CD4 - cre cells compared with control cells ( Fig. 5, B and C).	CD4,45,48,Protein	Foxp3,78,83,Protein	CbfbF,168,173,Protein	CD4 - cre,178,187,Protein	"[{""token"": ""CD4"", ""start_span"": 45, ""end_span"": 48, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 78, ""end_span"": 83, ""type"": ""Protein""}, {""token"": ""CbfbF"", ""start_span"": 168, ""end_span"": 173, ""type"": ""Protein""}, {""token"": ""CD4 - cre"", ""start_span"": 178, ""end_span"": 187, ""type"": ""Protein""}]"	valid
The suppression was significantly reduced when cells from CbfbF / F CD4 - cre mice were used, demonstrating that TGF - beta - induced Runx complexes are important for the suppressive activity of Foxp3 + T reg cells ( Fig. 6 B).	CbfbF,58,63,Protein	CD4 - cre,68,77,Protein	TGF - beta,113,123,Protein	Foxp3,195,200,Protein	"[{""token"": ""CbfbF"", ""start_span"": 58, ""end_span"": 63, ""type"": ""Protein""}, {""token"": ""CD4 - cre"", ""start_span"": 68, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 113, ""end_span"": 123, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 195, ""end_span"": 200, ""type"": ""Protein""}]"	valid
Cells in which RUNX1 and RUNX3 were knocked down showed markedly lower suppressive activity compared with control iT reg cells at a T reg / CD4 + T responder cell ratio of 1: 20, but not when the T reg / CD4 + T responder cell ratio was increased to 1: 5 ( Fig. 6 D).	RUNX1,15,20,Protein	RUNX3,25,30,Protein	CD4,140,143,Protein	CD4,204,207,Protein	"[{""token"": ""RUNX1"", ""start_span"": 15, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 25, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 140, ""end_span"": 143, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 204, ""end_span"": 207, ""type"": ""Protein""}]"	valid
RUNX3 plays an important role in TGF - beta - mediated growth control in epithelial cells, as loss of RUNX3 leads to decreased sensitivity to TGF - beta and hyperproliferation of the gastric mucosa ( Blyth et al., 2005).	RUNX3,0,5,Protein	TGF - beta,33,43,Protein	RUNX3,102,107,Protein	TGF - beta,142,152,Protein	"[{""token"": ""RUNX3"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 33, ""end_span"": 43, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 102, ""end_span"": 107, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 142, ""end_span"": 152, ""type"": ""Protein""}]"	valid
Runx3 / Cbfbeta are both required for the activation of the Ifng gene and silencing of the Il4 gene in Th1 cells ( Djuretic et al., 2007; Naoe et al., 2007).	Runx3,0,5,Protein	Cbfbeta,8,15,Protein	Ifng,60,64,Protein	Il4,91,94,Protein	"[{""token"": ""Runx3"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""Cbfbeta"", ""start_span"": 8, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""Ifng"", ""start_span"": 60, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""Il4"", ""start_span"": 91, ""end_span"": 94, ""type"": ""Protein""}]"	valid
Runx1 and Runx3 deficiencies caused marked reductions in mature thymocytes and T cells of the CD4 + helper and CD8 + cytotoxic T cell lineages.	Runx1,0,5,Protein	Runx3,10,15,Protein	CD4,94,97,Protein	CD8,111,114,Protein	"[{""token"": ""Runx1"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 10, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 94, ""end_span"": 97, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 111, ""end_span"": 114, ""type"": ""Protein""}]"	valid
Furthermore, it was shown that Runx1 activates IL - 2 and IFN - gamma gene expression in conventional CD4 + T cells by binding to their respective promoter.	Runx1,31,36,Protein	IL - 2,47,53,Protein	IFN - gamma,58,69,Protein	CD4,102,105,Protein	"[{""token"": ""Runx1"", ""start_span"": 31, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 47, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 58, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 102, ""end_span"": 105, ""type"": ""Protein""}]"	valid
RUNX1 interacts physically with Foxp3 protein, and it was demonstrated that this interaction might be responsible for the suppression of IL - 2 and IFN - gamma production and up - regulation of T reg cell - associated molecules ( Ono et al., 2007).	RUNX1,0,5,Protein	Foxp3,32,37,Protein	IL - 2,137,143,Protein	IFN - gamma,148,159,Protein	"[{""token"": ""RUNX1"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 32, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 137, ""end_span"": 143, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 148, ""end_span"": 159, ""type"": ""Protein""}]"	valid
The initial induction of RUNX1 and RUNX3 and the subsequent binding of these transcription factors to the Foxp3 promoter that we showed here might explain the relatively late induction of Foxp3 mRNA that peaks 24 - 48 h after stimulation.	RUNX1,25,30,Protein	RUNX3,35,40,Protein	Foxp3,106,111,Protein	Foxp3,188,193,Protein	"[{""token"": ""RUNX1"", ""start_span"": 25, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 35, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 106, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 188, ""end_span"": 193, ""type"": ""Protein""}]"	valid
RUNX1 alone, or together with its interacting partners p300 and CREB - binding protein, may cooperate with the NFAT transcription complex to activate the IL - 2 promoter ( Sakaguchi et al., 2008).	RUNX1,0,5,Protein	p300,55,59,Protein	CREB,64,68,Protein	IL - 2,154,160,Protein	"[{""token"": ""RUNX1"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""p300"", ""start_span"": 55, ""end_span"": 59, ""type"": ""Protein""}, {""token"": ""CREB"", ""start_span"": 64, ""end_span"": 68, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 154, ""end_span"": 160, ""type"": ""Protein""}]"	valid
The induction of the transcription factors RUNX1 and RUNX3 by TGF - beta and the subsequent up - regulation of Foxp3 play a role in iT reg cell generation and its suppressive capacity.	RUNX1,43,48,Protein	RUNX3,53,58,Protein	TGF - beta,62,72,Protein	Foxp3,111,116,Protein	"[{""token"": ""RUNX1"", ""start_span"": 43, ""end_span"": 48, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 53, ""end_span"": 58, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 62, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 111, ""end_span"": 116, ""type"": ""Protein""}]"	valid
CbfbF / F CD4 - cre and Foxp3GFP mice have previously been described ( Bettelli et al., 2006; Naoe et al., 2007).	CbfbF,0,5,Protein	CD4,10,13,Protein	cre,16,19,Protein	Foxp3GFP,24,32,Protein	"[{""token"": ""CbfbF"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 10, ""end_span"": 13, ""type"": ""Protein""}, {""token"": ""cre"", ""start_span"": 16, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""Foxp3GFP"", ""start_span"": 24, ""end_span"": 32, ""type"": ""Protein""}]"	valid
Cells were stimulated with the following combination of mAbs to T cell surface molecules ( Meiler et al., 2008): anti - CD2 ( clone 4B2 and 6G4; 0. 5 microg / ml), anti - CD3 ( clone OKT3; 0. 5 microg / ml), and anti - CD28 mAb ( clone B7G5; 0. 5 microg / ml; all from Sanquin) and cultured in serum - free AIM - V medium ( Life Technologies) with the addition of 1 nmol / liter IL - 2 ( Roche).	CD2,120,123,Protein	CD3,171,174,Protein	CD28,219,223,Protein	IL - 2,379,385,Protein	"[{""token"": ""CD2"", ""start_span"": 120, ""end_span"": 123, ""type"": ""Protein""}, {""token"": ""CD3"", ""start_span"": 171, ""end_span"": 174, ""type"": ""Protein""}, {""token"": ""CD28"", ""start_span"": 219, ""end_span"": 223, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 379, ""end_span"": 385, ""type"": ""Protein""}]"	valid
Mouse naive ( CD62Lhi44lo25 -) CD4 + T cells were purified by flow cytometry and activated in vitro with 5 microg / ml plate - bound anti - CD3 and 1 microg / ml soluble anti - CD28 antibodies ( eBioscience) in RPMI supplemented with 10% FCS, 5 mM beta - mercaptoethanol, and antibiotics.	CD62Lhi44lo25,14,27,Protein	CD4,31,34,Protein	CD3,140,143,Protein	CD28,177,181,Protein	"[{""token"": ""CD62Lhi44lo25"", ""start_span"": 14, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 31, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""CD3"", ""start_span"": 140, ""end_span"": 143, ""type"": ""Protein""}, {""token"": ""CD28"", ""start_span"": 177, ""end_span"": 181, ""type"": ""Protein""}]"	valid
For T reg cell conditions, cells were stimulated with the following: 40 ng / ml IL - 2, 5 ng / ml TGF - beta, 5 microg / ml anti - IL - 12, 5 microg / ml anti - IL - 4.	IL - 2,80,86,Protein	TGF - beta,98,108,Protein	IL - 12,131,138,Protein	IL - 4,161,167,Protein	"[{""token"": ""IL - 2"", ""start_span"": 80, ""end_span"": 86, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 98, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 131, ""end_span"": 138, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 161, ""end_span"": 167, ""type"": ""Protein""}]"	valid
The cytokine profile of these cells demonstrated that IFN - gamma is the predominant cytokine in Th1 cells, IL - 4 and IL - 13 in Th2 cells, and IL - 17 in Th17 cells ( Akdis et al., 2000; Burgler et al., 2009).	IFN - gamma,54,65,Protein	IL - 4,108,114,Protein	IL - 13,119,126,Protein	IL - 17,145,152,Protein	"[{""token"": ""IFN - gamma"", ""start_span"": 54, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 108, ""end_span"": 114, ""type"": ""Protein""}, {""token"": ""IL - 13"", ""start_span"": 119, ""end_span"": 126, ""type"": ""Protein""}, {""token"": ""IL - 17"", ""start_span"": 145, ""end_span"": 152, ""type"": ""Protein""}]"	valid
A total of 4 x 105 CD4 + cells ( CFSE - loaded CD25 - plus Foxp3 - GFP +) was mixed with 105 APCs + 1 microg / ml anti - CD3 mAb per well of a 96 well round bottom plate.	CD4,19,22,Protein	CD25,47,51,Protein	Foxp3 - GFP,59,70,Protein	CD3,121,124,Protein	"[{""token"": ""CD4"", ""start_span"": 19, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 47, ""end_span"": 51, ""type"": ""Protein""}, {""token"": ""Foxp3 - GFP"", ""start_span"": 59, ""end_span"": 70, ""type"": ""Protein""}, {""token"": ""CD3"", ""start_span"": 121, ""end_span"": 124, ""type"": ""Protein""}]"	valid
PCR primers and probes were designed based on the sequences reported in GenBank with the Primer Express software version 1. 2 ( Applied Biosystems) as follows: FOXP3 forward primer, 5 ' - GAAACAGCACATTCCCAGAGTTC - 3 '; FOXP3 reverse primer, 5 ' - ATGGCCCAGCGGATGAG - 3 '; EF - 1a forward primer, 5 ' - CTGAACCATCCAGGCCAAAT - 3 '; and EF - 1a reverse primer, 5 ' - GCCGTGTGGCAATCCAAT - 3 ', as previously described ( Mantel et al., 2007).	FOXP3,160,165,Protein	FOXP3,219,224,Protein	EF - 1a,272,279,Protein	EF - 1a,334,341,Protein	"[{""token"": ""FOXP3"", ""start_span"": 160, ""end_span"": 165, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 219, ""end_span"": 224, ""type"": ""Protein""}, {""token"": ""EF - 1a"", ""start_span"": 272, ""end_span"": 279, ""type"": ""Protein""}, {""token"": ""EF - 1a"", ""start_span"": 334, ""end_span"": 341, ""type"": ""Protein""}]"	valid
T - bet forward primer, 5 ' - GATGCGCCAGGAAGTTTCAT - 3 '; T - bet reverse primer, 5 ' - GCACAATCATCTGGGTCACATT - 3 '; RORC2 forward primer, 5 ' - CAGTCATGAGAACACAAATTGAAGTG - 3 '; and RORC2 reverse primer 5 ' - CAGGTGATAACCCCGTAGTGGAT - 3 '.	T - bet,0,7,Protein	T - bet,58,65,Protein	RORC2,118,123,Protein	RORC2,184,189,Protein	"[{""token"": ""T - bet"", ""start_span"": 0, ""end_span"": 7, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 58, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""RORC2"", ""start_span"": 118, ""end_span"": 123, ""type"": ""Protein""}, {""token"": ""RORC2"", ""start_span"": 184, ""end_span"": 189, ""type"": ""Protein""}]"	valid
Cells were cultured with IL - 2, and then left unstimulated or stimulated with anti - CD2 / - CD3 / - CD28 mAb.	IL - 2,25,31,Protein	CD2,86,89,Protein	CD3,94,97,Protein	CD28,102,106,Protein	"[{""token"": ""IL - 2"", ""start_span"": 25, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""CD2"", ""start_span"": 86, ""end_span"": 89, ""type"": ""Protein""}, {""token"": ""CD3"", ""start_span"": 94, ""end_span"": 97, ""type"": ""Protein""}, {""token"": ""CD28"", ""start_span"": 102, ""end_span"": 106, ""type"": ""Protein""}]"	valid
Cells were lysed with immunoprecipitation buffer ( 150 mM NaCl, 50 mM Tris - HCl, pH 7. 5, 5 mM EDTA, NP - 40 [ 0. 5% vol / vol]) containing phosphatase ( Roche) and protease inhibitors cocktails ( Roche), the nuclear pellet was washed, the chromatin was sheared by sonication and incubated with antibodies for RUNX1 ( H - 65 X; Santa Cruz Biotechnology, Inc.), RUNX3 ( H - 50 X; Santa Cruz Biotechnology, Inc.), CBFbeta ( PEBP2beta; FL - 182 X; Santa Cruz Biotechnology, Inc.), and as controls normal rabbit IgG ( Santa Cruz Biotechnology, Inc.), anti - human RNA polymerase II antibody, and mouse control IgG ( both from SA Biosciences).	RUNX1,311,316,Protein	RUNX3,362,367,Protein	CBFbeta,413,420,Protein	RNA polymerase II,561,578,Protein	"[{""token"": ""RUNX1"", ""start_span"": 311, ""end_span"": 316, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 362, ""end_span"": 367, ""type"": ""Protein""}, {""token"": ""CBFbeta"", ""start_span"": 413, ""end_span"": 420, ""type"": ""Protein""}, {""token"": ""RNA polymerase II"", ""start_span"": 561, ""end_span"": 578, ""type"": ""Protein""}]"	valid
S5 shows the induction of FOXP3 protein after overexpression of RUNX1 and RUNX3 in human CD4 + T cells.	FOXP3,26,31,Protein	RUNX1,64,69,Protein	RUNX3,74,79,Protein	CD4,89,92,Protein	"[{""token"": ""FOXP3"", ""start_span"": 26, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""RUNX1"", ""start_span"": 64, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 74, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 89, ""end_span"": 92, ""type"": ""Protein""}]"	valid
Diminished capacity of Cbfb - deficient CD4 - cre mice T cells in the generation of Foxp3 + CD4 + T cells.	Cbfb,23,27,Protein	CD4 - cre,40,49,Protein	Foxp3,84,89,Protein	CD4,92,95,Protein	"[{""token"": ""Cbfb"", ""start_span"": 23, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""CD4 - cre"", ""start_span"": 40, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 84, ""end_span"": 89, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 92, ""end_span"": 95, ""type"": ""Protein""}]"	valid
Results from one of four CbfbF / F CD4 - cre and control CbfbF / + CD4 - cre mice with same findings are shown.	CbfbF,25,30,Protein	CD4 - cre,35,44,Protein	CbfbF,57,62,Protein	CD4 - cre,67,76,Protein	"[{""token"": ""CbfbF"", ""start_span"": 25, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""CD4 - cre"", ""start_span"": 35, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""CbfbF"", ""start_span"": 57, ""end_span"": 62, ""type"": ""Protein""}, {""token"": ""CD4 - cre"", ""start_span"": 67, ""end_span"": 76, ""type"": ""Protein""}]"	valid
Whereas RPS3 remained cytosolic in IKKbeta ( SSAA) - expressing cells ( Fig. 2c, right), a substantial proportion of RPS3 translocated to the nucleus in cells expressing IKKbeta ( SSEE) ( Fig. 2c, right).	RPS3,8,12,Protein	IKKbeta,35,42,Protein	RPS3,117,121,Protein	IKKbeta,170,177,Protein	"[{""token"": ""RPS3"", ""start_span"": 8, ""end_span"": 12, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 35, ""end_span"": 42, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 117, ""end_span"": 121, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 170, ""end_span"": 177, ""type"": ""Protein""}]"	valid
We measured the association of RPS3 with importin - alpha in 293T cells overexpressing wild - type IkappaBalpha or an IkappaBalpha mutant ( SSAA) resistant to IKKbeta - induced phosphorylation and degradation.	RPS3,31,35,Protein	IkappaBalpha,99,111,Protein	IkappaBalpha,118,130,Protein	IKKbeta,159,166,Protein	"[{""token"": ""RPS3"", ""start_span"": 31, ""end_span"": 35, ""type"": ""Protein""}, {""token"": ""IkappaBalpha"", ""start_span"": 99, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""IkappaBalpha"", ""start_span"": 118, ""end_span"": 130, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 159, ""end_span"": 166, ""type"": ""Protein""}]"	valid
Moreover, cells treated with sodium pervanadate ( Pv) to induce IkappaBalpha degradation through an IKK - independent mechanism25 - 27 did not show increased association between RPS3 and importin - alpha ( Fig. 3e and Supplementary Fig. 3b) or nuclear accumulation of RPS3, despite complete IkappaBalpha degradation ( Supplementary Fig. 3c).	IkappaBalpha,64,76,Protein	RPS3,178,182,Protein	RPS3,268,272,Protein	IkappaBalpha,291,303,Protein	"[{""token"": ""IkappaBalpha"", ""start_span"": 64, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 178, ""end_span"": 182, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 268, ""end_span"": 272, ""type"": ""Protein""}, {""token"": ""IkappaBalpha"", ""start_span"": 291, ""end_span"": 303, ""type"": ""Protein""}]"	valid
To determine whether S209 is the critical site at which IKKbeta phosphorylates RPS3 in living cells, we transfected the wild - type or S209A mutant Flag - RPS3 alone, or together with IKKbeta into cells.	IKKbeta,56,63,Protein	RPS3,79,83,Protein	Flag - RPS3,148,159,Protein	IKKbeta,184,191,Protein	"[{""token"": ""IKKbeta"", ""start_span"": 56, ""end_span"": 63, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 79, ""end_span"": 83, ""type"": ""Protein""}, {""token"": ""Flag - RPS3"", ""start_span"": 148, ""end_span"": 159, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 184, ""end_span"": 191, ""type"": ""Protein""}]"	valid
To examine the role of S209 phosphorylation of RPS3 to its NF - kappaB function6, 7, 30, we silenced endogenous RPS3 expression using an siRNA that targets the 3 ' untranslated region ( 3 ' UTR) of RPS3 mRNA, followed by complementation with either wild - type or S209A mutant RPS3 via transfection.	RPS3,47,51,Protein	RPS3,112,116,Protein	RPS3,198,202,Protein	RPS3,277,281,Protein	"[{""token"": ""RPS3"", ""start_span"": 47, ""end_span"": 51, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 112, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 198, ""end_span"": 202, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 277, ""end_span"": 281, ""type"": ""Protein""}]"	valid
In RPS3 knockdown cells, PMA + I stimulated the recruitment of ectopically expressed, Flag - tagged wild - type, but not S209A RPS3 to the kappaB sites of the NFKBIA and IL8 promoters ( Fig. 5e).	RPS3,3,7,Protein	RPS3,127,131,Protein	NFKBIA,159,165,Protein	IL8,170,173,Protein	"[{""token"": ""RPS3"", ""start_span"": 3, ""end_span"": 7, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 127, ""end_span"": 131, ""type"": ""Protein""}, {""token"": ""NFKBIA"", ""start_span"": 159, ""end_span"": 165, ""type"": ""Protein""}, {""token"": ""IL8"", ""start_span"": 170, ""end_span"": 173, ""type"": ""Protein""}]"	valid
However, TNF - induced RPS3 S209 phosphorylation was unimpaired in cells infected with either deltanleH1 or deltaescN ( Fig. 6d).	TNF,9,12,Protein	RPS3,23,27,Protein	deltanleH1,94,104,Protein	deltaescN,108,117,Protein	"[{""token"": ""TNF"", ""start_span"": 9, ""end_span"": 12, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 23, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""deltanleH1"", ""start_span"": 94, ""end_span"": 104, ""type"": ""Protein""}, {""token"": ""deltaescN"", ""start_span"": 108, ""end_span"": 117, ""type"": ""Protein""}]"	valid
We showed previously that wild - type, but not deltanleH1 or deltaescN E. coli O157: H7 significantly attenuated TNF - induced RPS3 nuclear translocation9.	deltanleH1,47,57,Protein	deltaescN,61,70,Protein	TNF,113,116,Protein	RPS3,127,131,Protein	"[{""token"": ""deltanleH1"", ""start_span"": 47, ""end_span"": 57, ""type"": ""Protein""}, {""token"": ""deltaescN"", ""start_span"": 61, ""end_span"": 70, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 113, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 127, ""end_span"": 131, ""type"": ""Protein""}]"	valid
To examine whether the kinase activity is required for NleH1 to inhibit IKKbeta phosphorlyation of RPS3 on S209, we ectopically expressing either wild - type or K159A NleH1 in 293T cells.	NleH1,55,60,Protein	IKKbeta,72,79,Protein	RPS3,99,103,Protein	NleH1,167,172,Protein	"[{""token"": ""NleH1"", ""start_span"": 55, ""end_span"": 60, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 72, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 99, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""NleH1"", ""start_span"": 167, ""end_span"": 172, ""type"": ""Protein""}]"	valid
We next examined whether the inhibitory activity of NleH1 is sufficiently robust to impair the strong nuclear translocation of RPS3 trigged by the constitutively - active IKKbeta ( IKKbeta [ SSEE]) ( Fig. 2d).	NleH1,52,57,Protein	RPS3,127,131,Protein	IKKbeta,171,178,Protein	IKKbeta,181,188,Protein	"[{""token"": ""NleH1"", ""start_span"": 52, ""end_span"": 57, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 127, ""end_span"": 131, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 171, ""end_span"": 178, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 181, ""end_span"": 188, ""type"": ""Protein""}]"	valid
We examined whether NleH1 could directly phosphorylate IKKbeta thus inhibiting IKKbeta - mediated RPS3 S209 phosphorylation.	NleH1,20,25,Protein	IKKbeta,55,62,Protein	IKKbeta,79,86,Protein	RPS3,98,102,Protein	"[{""token"": ""NleH1"", ""start_span"": 20, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 55, ""end_span"": 62, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 79, ""end_span"": 86, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 98, ""end_span"": 102, ""type"": ""Protein""}]"	valid
Taken together, NleH1 blocks the CK2 substrate specificity of IKKbeta thus inhibiting the IKKbeta - mediated RPS3 S209 phosphorylation thus representing a novel strategy by E. coli O157: H7 to alter the host innate immune response.	NleH1,16,21,Protein	IKKbeta,62,69,Protein	IKKbeta,90,97,Protein	RPS3,109,113,Protein	"[{""token"": ""NleH1"", ""start_span"": 16, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 62, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 90, ""end_span"": 97, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 109, ""end_span"": 113, ""type"": ""Protein""}]"	valid
The recent observation that human IKKbeta displayed CK2 - like phosphorylation specificity29 coincides with our evidence that recombinant IKKbeta, but not IKKalpha, phosphorylated RPS3.	IKKbeta,34,41,Protein	IKKbeta,138,145,Protein	IKKalpha,155,163,Protein	RPS3,180,184,Protein	"[{""token"": ""IKKbeta"", ""start_span"": 34, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 138, ""end_span"": 145, ""type"": ""Protein""}, {""token"": ""IKKalpha"", ""start_span"": 155, ""end_span"": 163, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 180, ""end_span"": 184, ""type"": ""Protein""}]"	valid
Although NleH1 did not directly phosphorylate IKKbeta, its kinase activity was required to inhibit IKKbeta - mediated RPS3 S209 phosphorylation.	NleH1,9,14,Protein	IKKbeta,46,53,Protein	IKKbeta,99,106,Protein	RPS3,118,122,Protein	"[{""token"": ""NleH1"", ""start_span"": 9, ""end_span"": 14, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 46, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 99, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 118, ""end_span"": 122, ""type"": ""Protein""}]"	valid
In contrast, NleH1 does not block NF - kappaB p65 nuclear translocation, which suggests that certain p65 - dependent but RPS3 - independent NF - kappaB target genes might thus be beneficial for E. coli O157: H7 to replicate and disseminate in the host.	NleH1,13,18,Protein	p65,46,49,Protein	p65,101,104,Protein	RPS3,121,125,Protein	"[{""token"": ""NleH1"", ""start_span"": 13, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 46, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 101, ""end_span"": 104, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 121, ""end_span"": 125, ""type"": ""Protein""}]"	valid
The siRNA ( sense - strand sequence) IKKalpha, 5 ' - AUGACAGAGAAUGAUCAUGUUCUGC - 3 '; IKKbeta, 5 ' - GCAGCAAGGAGAACAGAGGUUAAUA - 3 '; IkappaBalpha, 5 ' - GAGCUCCGAGACUUUCGAGGAAAUA - 3 '; RPS3 - 3 ' UTR, 5 ' - GGAUGUUGCUCUCUAAAGACC - 3 ' ( Invitrogen).	IKKalpha,37,45,Protein	IKKbeta,86,93,Protein	IkappaBalpha,134,146,Protein	RPS3,187,191,Protein	"[{""token"": ""IKKalpha"", ""start_span"": 37, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 86, ""end_span"": 93, ""type"": ""Protein""}, {""token"": ""IkappaBalpha"", ""start_span"": 134, ""end_span"": 146, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 187, ""end_span"": 191, ""type"": ""Protein""}]"	valid
The NF - kappaB activity is enhanced by phosphorylation of p65 at Ser276 by PKA and MSK1 ( 7, 8), Ser311 by PKCzeta ( 9) and Ser536 by IKKalpha ( 10, 11).	p65,59,62,Protein	MSK1,84,88,Protein	PKCzeta,108,115,Protein	IKKalpha,135,143,Protein	"[{""token"": ""p65"", ""start_span"": 59, ""end_span"": 62, ""type"": ""Protein""}, {""token"": ""MSK1"", ""start_span"": 84, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""PKCzeta"", ""start_span"": 108, ""end_span"": 115, ""type"": ""Protein""}, {""token"": ""IKKalpha"", ""start_span"": 135, ""end_span"": 143, ""type"": ""Protein""}]"	valid
Deacetylation of p65 by histone deacetylase - 3 or SIRT1, or acetylation of p65 at Lys122 and Lys123 down - regulate the NF - kappaB activity ( 12, 21, 22).	p65,17,20,Protein	histone deacetylase - 3,24,47,Protein	SIRT1,51,56,Protein	p65,76,79,Protein	"[{""token"": ""p65"", ""start_span"": 17, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""histone deacetylase - 3"", ""start_span"": 24, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""SIRT1"", ""start_span"": 51, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 76, ""end_span"": 79, ""type"": ""Protein""}]"	valid
The plasmids pRc / CMV - 3xHA - p65, pRc / CMV - 3xHA - p65deltaC ( 1 - 318), pRc / CMV - 3xHA - p65deltaN ( 122 - 551), p3xFLAG - CMV - Tat T, N ( 23, 24) A, p3xFLAG - CMV - Tat K ( 50, 51) A, pGEX - 2T - Tat T, N ( 23, 24) A, pGEX - 2T - Tat K ( 50, 51) A and pNL4 - 3. FLAG - Tat. R - E - were generated as described in Supplementary Data.	3xHA - p65,25,35,Protein	3xHA - p65deltaC,49,65,Protein	3xHA - p65deltaN,90,106,Protein	Tat,137,140,Protein	"[{""token"": ""3xHA - p65"", ""start_span"": 25, ""end_span"": 35, ""type"": ""Protein""}, {""token"": ""3xHA - p65deltaC"", ""start_span"": 49, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""3xHA - p65deltaN"", ""start_span"": 90, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 137, ""end_span"": 140, ""type"": ""Protein""}]"	valid
RNA interference of p65 and IkappaB - alpha was performed with SMART pool siRNA p65 and IkappaB - alpha ( Dharmacon, Chicago, IL, USA).	p65,20,23,Protein	IkappaB - alpha,28,43,Protein	siRNA p65,74,83,Protein	IkappaB - alpha,88,103,Protein	"[{""token"": ""p65"", ""start_span"": 20, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 28, ""end_span"": 43, ""type"": ""Protein""}, {""token"": ""siRNA p65"", ""start_span"": 74, ""end_span"": 83, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 88, ""end_span"": 103, ""type"": ""Protein""}]"	valid
Real - time PCR of CSF3, LTA, NFKBIA and TLR2 were performed using the Custom ChIP array ( QIAGEN).	CSF3,19,23,Protein	LTA,25,28,Protein	NFKBIA,30,36,Protein	TLR2,41,45,Protein	"[{""token"": ""CSF3"", ""start_span"": 19, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""LTA"", ""start_span"": 25, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""NFKBIA"", ""start_span"": 30, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""TLR2"", ""start_span"": 41, ""end_span"": 45, ""type"": ""Protein""}]"	valid
These results indicated that in single - round HIV - 1 infection the NF - kappaB activation initially correlated with the IKK activation and IkappaB - alpha degradation independently of the presence of Tat, and it was kept elevated in presence of Tat following the decay of the IKK activity and new synthesis of IkappaB - alpha.	IkappaB - alpha,141,156,Protein	Tat,202,205,Protein	Tat,247,250,Protein	IkappaB - alpha,312,327,Protein	"[{""token"": ""IkappaB - alpha"", ""start_span"": 141, ""end_span"": 156, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 202, ""end_span"": 205, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 247, ""end_span"": 250, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 312, ""end_span"": 327, ""type"": ""Protein""}]"	valid
In un - stimulated cells, the p65 DNA binding ( Figure 2A) and nuclear p65 ( Figure 2B, nucleus) were slightly enhanced by Tat, while the IkappaB - alpha content was not significantly affected ( Figure 2B, cytosol).	p65,30,33,Protein	p65,71,74,Protein	Tat,123,126,Protein	IkappaB - alpha,138,153,Protein	"[{""token"": ""p65"", ""start_span"": 30, ""end_span"": 33, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 71, ""end_span"": 74, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 123, ""end_span"": 126, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 138, ""end_span"": 153, ""type"": ""Protein""}]"	valid
As we previously found that Tat binds to the sixth ankyrin of IkappaB - alpha ( 50, 51), we tested whether Tat counteracted the generation of the IkappaB - alpha / NF - kappaB complex.	Tat,28,31,Protein	IkappaB - alpha,62,77,Protein	Tat,107,110,Protein	IkappaB - alpha,146,161,Protein	"[{""token"": ""Tat"", ""start_span"": 28, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 62, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 107, ""end_span"": 110, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 146, ""end_span"": 161, ""type"": ""Protein""}]"	valid
IkappaB - alpha inhibited the p65 - dependent expression of the luciferase gene, which was restored in a dose - dependent manner by wild - type Tat, and not by Tat R ( 49 - 57) A ( Figure 3E).	IkappaB - alpha,0,15,Protein	p65,30,33,Protein	luciferase,64,74,Protein	Tat,144,147,Protein	"[{""token"": ""IkappaB - alpha"", ""start_span"": 0, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 30, ""end_span"": 33, ""type"": ""Protein""}, {""token"": ""luciferase"", ""start_span"": 64, ""end_span"": 74, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 144, ""end_span"": 147, ""type"": ""Protein""}]"	valid
To identify the p65 domain required for binding to Tat, HeLa cells were transfected with FLAG - Tat together with HA - p65 mutants, which were deleted of the transactivation domain [ p65deltaC ( 1 - 318)], or the RHD [ p65deltaN ( 122 - 551)] ( Figure 4C).	p65,16,19,Protein	Tat,51,54,Protein	FLAG - Tat,89,99,Protein	HA - p65,114,122,Protein	"[{""token"": ""p65"", ""start_span"": 16, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 51, ""end_span"": 54, ""type"": ""Protein""}, {""token"": ""FLAG - Tat"", ""start_span"": 89, ""end_span"": 99, ""type"": ""Protein""}, {""token"": ""HA - p65"", ""start_span"": 114, ""end_span"": 122, ""type"": ""Protein""}]"	valid
Tat activates the p65 - dependent expression of NF - kappaB - responsive genes, occupies the NF - kappaB enhancers and promotes the p65 recruitment with IkappaB - alpha displacement	Tat,0,3,Protein	p65,18,21,Protein	p65,132,135,Protein	IkappaB - alpha,153,168,Protein	"[{""token"": ""Tat"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 18, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 132, ""end_span"": 135, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 153, ""end_span"": 168, ""type"": ""Protein""}]"	valid
The Tat - dependent transactivation of the NF - kappaB - dependent genes was abolished when cells were transfected with siRNA p65, indicating that the Tat transcriptional activation was mediated by p65 ( Figure 5A - E).	Tat,4,7,Protein	siRNA p65,120,129,Protein	Tat,151,154,Protein	p65,198,201,Protein	"[{""token"": ""Tat"", ""start_span"": 4, ""end_span"": 7, ""type"": ""Protein""}, {""token"": ""siRNA p65"", ""start_span"": 120, ""end_span"": 129, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 151, ""end_span"": 154, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 198, ""end_span"": 201, ""type"": ""Protein""}]"	valid
These results were consistent with the requirement of both the cysteine - rich and arginine - rich domains of Tat to enhance the NF - kappaB activity, suggesting that the up - regulation of NF - kappaB - responsive genes by Tat might occur through physical interaction of the viral protein with p65 and IkappaB - alpha.	Tat,110,113,Protein	Tat,224,227,Protein	p65,295,298,Protein	IkappaB - alpha,303,318,Protein	"[{""token"": ""Tat"", ""start_span"": 110, ""end_span"": 113, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 224, ""end_span"": 227, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 295, ""end_span"": 298, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 303, ""end_span"": 318, ""type"": ""Protein""}]"	valid
To validate the predicted NF - kappaB binding sites of the MIP - 1alpha promoter, we stimulated HeLa cells with TNF - alpha, a well - known NF - kappaB inducer, and measured the expression levels of MIP - 1alpha by real - time PCR, and the p65 occupancy of the NF - kappaB sites by ChIP.	MIP - 1alpha,59,71,Protein	TNF - alpha,112,123,Protein	MIP - 1alpha,199,211,Protein	p65,240,243,Protein	"[{""token"": ""MIP - 1alpha"", ""start_span"": 59, ""end_span"": 71, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 112, ""end_span"": 123, ""type"": ""Protein""}, {""token"": ""MIP - 1alpha"", ""start_span"": 199, ""end_span"": 211, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 240, ""end_span"": 243, ""type"": ""Protein""}]"	valid
TNF - alpha activated the expression of MIP - 1alpha and induced the p65 recruitment to the NF - kappaB1 site of MIP - 1alpha without affecting the occupancy of the putative NF - kappaB2 and NF - kappaB3 sites ( Supplementary Figure S3B and S3C).	TNF - alpha,0,11,Protein	MIP - 1alpha,40,52,Protein	p65,69,72,Protein	MIP - 1alpha,113,125,Protein	"[{""token"": ""TNF - alpha"", ""start_span"": 0, ""end_span"": 11, ""type"": ""Protein""}, {""token"": ""MIP - 1alpha"", ""start_span"": 40, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 69, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""MIP - 1alpha"", ""start_span"": 113, ""end_span"": 125, ""type"": ""Protein""}]"	valid
In HIV - 1 - infected monocytes Tat sustains the NF - kappaB activity and promotes the transcriptional activation of MIP - 1alpha by interacting with IkappaB - alpha and p65	Tat,32,35,Protein	MIP - 1alpha,117,129,Protein	IkappaB - alpha,150,165,Protein	p65,170,173,Protein	"[{""token"": ""Tat"", ""start_span"": 32, ""end_span"": 35, ""type"": ""Protein""}, {""token"": ""MIP - 1alpha"", ""start_span"": 117, ""end_span"": 129, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 150, ""end_span"": 165, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 170, ""end_span"": 173, ""type"": ""Protein""}]"	valid
The Tat - dependent activation of NF - kappaB correlated with the association of the viral protein with IkappaB - alpha, which interfered with the generation of the IkappaB - alpha / p65 complex.	Tat,4,7,Protein	IkappaB - alpha,104,119,Protein	IkappaB - alpha,165,180,Protein	p65,183,186,Protein	"[{""token"": ""Tat"", ""start_span"": 4, ""end_span"": 7, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 104, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 165, ""end_span"": 180, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 183, ""end_span"": 186, ""type"": ""Protein""}]"	valid
Differently, the Tat arginine - rich sequence ( R49, 52, 53, 55, 56, 57) was required for the binding to the sixth ankyrin of IkappaB - alpha ( 50, 51), and for releasing p65 from the IkappaB - alpha inhibition.	Tat,17,20,Protein	IkappaB - alpha,126,141,Protein	p65,171,174,Protein	IkappaB - alpha,184,199,Protein	"[{""token"": ""Tat"", ""start_span"": 17, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 126, ""end_span"": 141, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 171, ""end_span"": 174, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 184, ""end_span"": 199, ""type"": ""Protein""}]"	valid
RNA interference of p65 abolished the Tat occupancy of the NF - kappaB enhancers indicating that the Tat binding to the NF - kappaB sites was mediated by p65.	p65,20,23,Protein	Tat,38,41,Protein	Tat,101,104,Protein	p65,154,157,Protein	"[{""token"": ""p65"", ""start_span"": 20, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 38, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 101, ""end_span"": 104, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 154, ""end_span"": 157, ""type"": ""Protein""}]"	valid
These results were consistent with the evidence that Tat displaced p65 from the binding to IkappaB - alpha ( Figures 2D and 3C), and increased the p65 DNA binding affinity through association ( Figure 4E and F).	Tat,53,56,Protein	p65,67,70,Protein	IkappaB - alpha,91,106,Protein	p65,147,150,Protein	"[{""token"": ""Tat"", ""start_span"": 53, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 67, ""end_span"": 70, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 91, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 147, ""end_span"": 150, ""type"": ""Protein""}]"	valid
Indeed, IkappaB - alpha was found associated with hystone deacetylases at the hes1 promoter, from where it was removed following TNF - alpha stimulation causing histone acetylation and hes1 transcriptional activation ( 65).	IkappaB - alpha,8,23,Protein	hes1,78,82,Protein	TNF - alpha,129,140,Protein	hes1,185,189,Protein	"[{""token"": ""IkappaB - alpha"", ""start_span"": 8, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""hes1"", ""start_span"": 78, ""end_span"": 82, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 129, ""end_span"": 140, ""type"": ""Protein""}, {""token"": ""hes1"", ""start_span"": 185, ""end_span"": 189, ""type"": ""Protein""}]"	valid
Here, we have shown that the Tat - dependent transcriptional activation of a number of pro - inflammatory genes required the assembly of Tat with p65 at the NF - kappaB enhancer together with the displacement of IkappaB - alpha ( Figure 5).	Tat,29,32,Protein	Tat,137,140,Protein	p65,146,149,Protein	IkappaB - alpha,212,227,Protein	"[{""token"": ""Tat"", ""start_span"": 29, ""end_span"": 32, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 137, ""end_span"": 140, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 146, ""end_span"": 149, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 212, ""end_span"": 227, ""type"": ""Protein""}]"	valid
The evidence that Tat activates NF - kappaB through direct interaction with IkappaB - alpha and p65 may lead to specific inhibitors to counteract the Tat pro - inflammatory action.	Tat,18,21,Protein	IkappaB - alpha,76,91,Protein	p65,96,99,Protein	Tat,150,153,Protein	"[{""token"": ""Tat"", ""start_span"": 18, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 76, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 96, ""end_span"": 99, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 150, ""end_span"": 153, ""type"": ""Protein""}]"	valid
( D) HeLa cells were transfected with p3xFLAG - Tat ( 5 microg) in the presence or absence of pRc / CMV - 3xHA - p65, pRc / CMV - 3xHA - p65deltaC ( 1 - 318), or pRc / CMV - 3xHA - p65deltaN ( 122 - 551) ( 5 microg).	Tat,48,51,Protein	3xHA - p65,106,116,Protein	3xHA - p65deltaC,130,146,Protein	3xHA - p65deltaN,174,190,Protein	"[{""token"": ""Tat"", ""start_span"": 48, ""end_span"": 51, ""type"": ""Protein""}, {""token"": ""3xHA - p65"", ""start_span"": 106, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""3xHA - p65deltaC"", ""start_span"": 130, ""end_span"": 146, ""type"": ""Protein""}, {""token"": ""3xHA - p65deltaN"", ""start_span"": 174, ""end_span"": 190, ""type"": ""Protein""}]"	valid
Tat activates the p65 - dependent expression of NF - kappaB - responsive genes by occupying the NF - kappaB enhancers and promoting the p65 recruitment with IkappaB - alpha displacement.	Tat,0,3,Protein	p65,18,21,Protein	p65,136,139,Protein	IkappaB - alpha,157,172,Protein	"[{""token"": ""Tat"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 18, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 136, ""end_span"": 139, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 157, ""end_span"": 172, ""type"": ""Protein""}]"	valid
HeLa cells ( 5 x 106) were transfected with p3xFLAG - Tat, p3xFLAG - Tat C ( 22, 25, 27), p3xFLAG - Tat R ( 49 - 57) or empty vector ( 10 microg); for p65 RNA interference, cells ( 5 x 106) were transfected with p3xFLAG - Tat ( 10 microg) and siRNA p65 or siRNA control ( 200 pmol).	Tat,54,57,Protein	p65,151,154,Protein	Tat,222,225,Protein	siRNA p65,243,252,Protein	"[{""token"": ""Tat"", ""start_span"": 54, ""end_span"": 57, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 151, ""end_span"": 154, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 222, ""end_span"": 225, ""type"": ""Protein""}, {""token"": ""siRNA p65"", ""start_span"": 243, ""end_span"": 252, ""type"": ""Protein""}]"	valid
In HIV - 1 infection Tat sustains the NF - kappaB activity and enhances the MIP - 1alpha expression via interaction with IkappaB - alpha and p65.	Tat,21,24,Protein	MIP - 1alpha,76,88,Protein	IkappaB - alpha,121,136,Protein	p65,141,144,Protein	"[{""token"": ""Tat"", ""start_span"": 21, ""end_span"": 24, ""type"": ""Protein""}, {""token"": ""MIP - 1alpha"", ""start_span"": 76, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 121, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 141, ""end_span"": 144, ""type"": ""Protein""}]"	valid
Resistance to IL - 10 inhibition of interferon gamma production and expression of suppressor of cytokine signaling 1 in CD4 + T cells from patients with rheumatoid arthritis	IL - 10,14,21,Protein	interferon gamma,36,52,Protein	suppressor of cytokine signaling 1,82,116,Protein	CD4,120,123,Protein	"[{""token"": ""IL - 10"", ""start_span"": 14, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""interferon gamma"", ""start_span"": 36, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""suppressor of cytokine signaling 1"", ""start_span"": 82, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 120, ""end_span"": 123, ""type"": ""Protein""}]"	test
Preincubation of normal CD4 + T cells with IL - 6 reduced IL - 10 - mediated inhibition of interferon gamma production.	CD4,24,27,Protein	IL - 6,43,49,Protein	IL - 10,58,65,Protein	interferon gamma,91,107,Protein	"[{""token"": ""CD4"", ""start_span"": 24, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 43, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 58, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""interferon gamma"", ""start_span"": 91, ""end_span"": 107, ""type"": ""Protein""}]"	test
Blood CD4 + T cells from RA patients contained higher levels of suppressor of cytokine signaling 1 but lower levels of suppressor of cytokine signaling 3 mRNA compared with control CD4 + T cells, as determined by real - time PCR.	CD4,6,9,Protein	suppressor of cytokine signaling 1,64,98,Protein	suppressor of cytokine signaling 3,119,153,Protein	CD4,181,184,Protein	"[{""token"": ""CD4"", ""start_span"": 6, ""end_span"": 9, ""type"": ""Protein""}, {""token"": ""suppressor of cytokine signaling 1"", ""start_span"": 64, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""suppressor of cytokine signaling 3"", ""start_span"": 119, ""end_span"": 153, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 181, ""end_span"": 184, ""type"": ""Protein""}]"	test
Studies of cell - type - specific STAT3 - deficient mice have shown that STAT3 activation is essential for IL - 10 - mediated anti - inflammatory reactions in macrophages and neutrophils [ 5], but is responsible for IL - 6 - mediated prevention of apoptosis in T cells [ 6].	STAT3,34,39,Protein	STAT3,73,78,Protein	IL - 10,107,114,Protein	IL - 6,216,222,Protein	"[{""token"": ""STAT3"", ""start_span"": 34, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 73, ""end_span"": 78, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 107, ""end_span"": 114, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 216, ""end_span"": 222, ""type"": ""Protein""}]"	test
Cell surface expression of IL - 10R1 is decreased in synovial fluid dendritic cells due to the presence of TNF - alpha, IL - 1, and granulocyte - macrophage colony - stimulating factor [ 15].	IL - 10R1,27,36,Protein	TNF - alpha,107,118,Protein	IL - 1,120,126,Protein	granulocyte - macrophage colony - stimulating factor,132,184,Protein	"[{""token"": ""IL - 10R1"", ""start_span"": 27, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 107, ""end_span"": 118, ""type"": ""Protein""}, {""token"": ""IL - 1"", ""start_span"": 120, ""end_span"": 126, ""type"": ""Protein""}, {""token"": ""granulocyte - macrophage colony - stimulating factor"", ""start_span"": 132, ""end_span"": 184, ""type"": ""Protein""}]"	test
To examine the effect of IL - 6 on T - cell responsiveness to IL - 10, CD4 + T cells from healthy controls were incubated in culture medium with 10% FCS in the presence or absence of 10 ng / ml IL - 6 ( Becton Dickinson) for 36 hours.	IL - 6,25,31,Protein	IL - 10,62,69,Protein	CD4,71,74,Protein	IL - 6,194,200,Protein	"[{""token"": ""IL - 6"", ""start_span"": 25, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 62, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 71, ""end_span"": 74, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 194, ""end_span"": 200, ""type"": ""Protein""}]"	test
Briefly, the membrane was incubated with the antibodies ( rabbit IgG) anti - STAT1 antibody, anti - phosphorylated tyrosine 701 of STAT1 antibody, anti - STAT3 antibody, and anti - phosphorylated tyrosine 705 of STAT3 antibody, diluted as recommended at 1 / 2000 with Tris - buffered saline with 0. 1% Tween 20 with 5% BSA.	STAT1,77,82,Protein	STAT1,131,136,Protein	STAT3,154,159,Protein	STAT3,212,217,Protein	"[{""token"": ""STAT1"", ""start_span"": 77, ""end_span"": 82, ""type"": ""Protein""}, {""token"": ""STAT1"", ""start_span"": 131, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 154, ""end_span"": 159, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 212, ""end_span"": 217, ""type"": ""Protein""}]"	test
However, RA CD4 + T cells were able to produce significant amounts of IFN - gamma in the presence of 1 ng / ml IL - 10, and the maximal but not complete inhibition by IL - 10 was obtained at 10 - 100 ng / ml.	CD4,12,15,Protein	IFN - gamma,70,81,Protein	IL - 10,111,118,Protein	IL - 10,167,174,Protein	"[{""token"": ""CD4"", ""start_span"": 12, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 70, ""end_span"": 81, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 111, ""end_span"": 118, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 167, ""end_span"": 174, ""type"": ""Protein""}]"	test
There were no statistically significant differences in IFN - gamma production without IL - 10 among these three groups ( Fig. 2a), but the inhibitory effect of IL - 10 on IFN - gamma production was significantly limited in the active RA group as compared with the inactive RA group and healthy controls ( percentage decrease: active RA, 2. 9 + / - 14. 4%; inactive RA, 45. 6 + / - 14. 4%; controls, 65. 8 + / - 7. 9%) ( Fig. 2b).	IFN - gamma,55,66,Protein	IL - 10,86,93,Protein	IL - 10,160,167,Protein	IFN - gamma,171,182,Protein	"[{""token"": ""IFN - gamma"", ""start_span"": 55, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 86, ""end_span"": 93, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 160, ""end_span"": 167, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 171, ""end_span"": 182, ""type"": ""Protein""}]"	test
As a consequence, CD4 + T cells from active RA patients produced higher levels of IFN - gamma in the presence of 1 ng / ml IL - 10 than did normal CD4 + T cells ( Fig. 2a).	CD4,18,21,Protein	IFN - gamma,82,93,Protein	IL - 10,123,130,Protein	CD4,147,150,Protein	"[{""token"": ""CD4"", ""start_span"": 18, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 82, ""end_span"": 93, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 123, ""end_span"": 130, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 147, ""end_span"": 150, ""type"": ""Protein""}]"	test
In addition, we compared IL - 2 production by CD4 + T cells after CD3 and CD28 costimulation in the presence of IL - 10 in active RA patients and in healthy controls.	IL - 2,25,31,Protein	CD4,46,49,Protein	CD28,74,78,Protein	IL - 10,112,119,Protein	"[{""token"": ""IL - 2"", ""start_span"": 25, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 46, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""CD28"", ""start_span"": 74, ""end_span"": 78, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 112, ""end_span"": 119, ""type"": ""Protein""}]"	test
To examine whether the resistance to IL - 10 inhibition in RA CD4 + T cells was due to limited receptor expression, the cell surface expression of IL - 10R1 on PB CD4 + T cells from active RA patients and from healthy controls was determined by flow cytometric analysis.	IL - 10,37,44,Protein	CD4,62,65,Protein	IL - 10R1,147,156,Protein	CD4,163,166,Protein	"[{""token"": ""IL - 10"", ""start_span"": 37, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 62, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""IL - 10R1"", ""start_span"": 147, ""end_span"": 156, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 163, ""end_span"": 166, ""type"": ""Protein""}]"	test
The interaction of IL - 10R with IL - 10 induces tyrosine phosphorylation and activation of the latent transcription factors STAT1 and STAT3 [ 3].	IL - 10R,19,27,Protein	IL - 10,33,40,Protein	STAT1,125,130,Protein	STAT3,135,140,Protein	"[{""token"": ""IL - 10R"", ""start_span"": 19, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 33, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""STAT1"", ""start_span"": 125, ""end_span"": 130, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 135, ""end_span"": 140, ""type"": ""Protein""}]"	test
Macrophage - specific STAT3 - deficient mice demonstrated that STAT3 plays a dominant role in IL - 10 - mediated anti - inflammatory responses [ 5], which has recently been confirmed in human macrophages by studies of dominant - negative STAT3 overexpression [ 30].	STAT3,22,27,Protein	STAT3,63,68,Protein	IL - 10,94,101,Protein	STAT3,238,243,Protein	"[{""token"": ""STAT3"", ""start_span"": 22, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 63, ""end_span"": 68, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 94, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 238, ""end_span"": 243, ""type"": ""Protein""}]"	test
The induction of STAT1 and STAT3 phosphorylation by IL - 10 in PB CD4 + T cells from active RA patients and from healthy controls was examined using western blotting.	STAT1,17,22,Protein	STAT3,27,32,Protein	IL - 10,52,59,Protein	CD4,66,69,Protein	"[{""token"": ""STAT1"", ""start_span"": 17, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 27, ""end_span"": 32, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 52, ""end_span"": 59, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 66, ""end_span"": 69, ""type"": ""Protein""}]"	test
Both sustained STAT3 phosphorylation and defective IL - 10 - induced STAT3 phosphorylation were found in RA ST CD4 + T cells ( Fig. 4c).	STAT3,15,20,Protein	IL - 10,51,58,Protein	STAT3,69,74,Protein	CD4,111,114,Protein	"[{""token"": ""STAT3"", ""start_span"": 15, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 51, ""end_span"": 58, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 69, ""end_span"": 74, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 111, ""end_span"": 114, ""type"": ""Protein""}]"	test
On the other hand, IL - 10 - induced STAT1 phosphorylation was not detected in either RA CD4 + T cells or normal CD4 + T cells ( Fig. 4a).	IL - 10,19,26,Protein	STAT1,37,42,Protein	CD4,89,92,Protein	CD4,113,116,Protein	"[{""token"": ""IL - 10"", ""start_span"": 19, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""STAT1"", ""start_span"": 37, ""end_span"": 42, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 89, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 113, ""end_span"": 116, ""type"": ""Protein""}]"	test
IL - 6 - mediated STAT3 phosphorylation and inhibition of IL - 10 effect in normal CD4 + T cells	IL - 6,0,6,Protein	STAT3,18,23,Protein	IL - 10,58,65,Protein	CD4,83,86,Protein	"[{""token"": ""IL - 6"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 18, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 58, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 83, ""end_span"": 86, ""type"": ""Protein""}]"	test
Both STAT1 and STAT3 phosphorylation was activated by IL - 6 in normal CD4 + T cells ( data not shown), in agreement with previous observations [ 4].	STAT1,5,10,Protein	STAT3,15,20,Protein	IL - 6,54,60,Protein	CD4,71,74,Protein	"[{""token"": ""STAT1"", ""start_span"": 5, ""end_span"": 10, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 15, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 54, ""end_span"": 60, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 71, ""end_span"": 74, ""type"": ""Protein""}]"	test
RA serum was able to induce tyrosine phosphorylation of STAT3 but not STAT1, and this STAT3 activation was mostly abolished by neutralization of IL - 6 activity ( Fig. 5a).	STAT3,56,61,Protein	STAT1,70,75,Protein	STAT3,86,91,Protein	IL - 6,145,151,Protein	"[{""token"": ""STAT3"", ""start_span"": 56, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""STAT1"", ""start_span"": 70, ""end_span"": 75, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 86, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 145, ""end_span"": 151, ""type"": ""Protein""}]"	test
We next examined whether IL - 6 could suppress the effect of IL - 10 to inhibit IFN - gamma production by CD4 + T cells.	IL - 6,25,31,Protein	IL - 10,61,68,Protein	IFN - gamma,80,91,Protein	CD4,106,109,Protein	"[{""token"": ""IL - 6"", ""start_span"": 25, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 61, ""end_span"": 68, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 80, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 106, ""end_span"": 109, ""type"": ""Protein""}]"	test
Taken together, these findings suggest that persistent exposure to serum IL - 6 may have a role in both the induction of STAT3 activation and the resistance to the inhibitory effect of IL - 10 in RA CD4 + T cells.	IL - 6,73,79,Protein	STAT3,121,126,Protein	IL - 10,185,192,Protein	CD4,199,202,Protein	"[{""token"": ""IL - 6"", ""start_span"": 73, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 121, ""end_span"": 126, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 185, ""end_span"": 192, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 199, ""end_span"": 202, ""type"": ""Protein""}]"	test
The RA CD4 + T cells contained higher levels of SOCS1 but lower levels of SOCS3 transcripts than did control CD4 + T cells ( Fig. 6a).	CD4,7,10,Protein	SOCS1,48,53,Protein	SOCS3,74,79,Protein	CD4,109,112,Protein	"[{""token"": ""CD4"", ""start_span"": 7, ""end_span"": 10, ""type"": ""Protein""}, {""token"": ""SOCS1"", ""start_span"": 48, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""SOCS3"", ""start_span"": 74, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 109, ""end_span"": 112, ""type"": ""Protein""}]"	test
Constitutive expression of SOCS1 mRNA in RA CD4 + T cells was comparable with the expression in normal CD4 + T cells stimulated by 10 ng / ml IL - 6 ( Fig. 6b), supporting its functional significance.	SOCS1,27,32,Protein	CD4,44,47,Protein	CD4,103,106,Protein	IL - 6,142,148,Protein	"[{""token"": ""SOCS1"", ""start_span"": 27, ""end_span"": 32, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 44, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 103, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 142, ""end_span"": 148, ""type"": ""Protein""}]"	test
Defective IL - 10 - induced STAT3 activation therefore appears to be due at least in part to an abundance of SOCS1 in RA CD4 + T cells.	IL - 10,10,17,Protein	STAT3,28,33,Protein	SOCS1,109,114,Protein	CD4,121,124,Protein	"[{""token"": ""IL - 10"", ""start_span"": 10, ""end_span"": 17, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 28, ""end_span"": 33, ""type"": ""Protein""}, {""token"": ""SOCS1"", ""start_span"": 109, ""end_span"": 114, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 121, ""end_span"": 124, ""type"": ""Protein""}]"	test
RA CD4 + T cells contain higher levels of SOCS1 but contain lower levels of SOCS3 transcripts in comparison with normal CD4 + T cells.	CD4,3,6,Protein	SOCS1,42,47,Protein	SOCS3,76,81,Protein	CD4,120,123,Protein	"[{""token"": ""CD4"", ""start_span"": 3, ""end_span"": 6, ""type"": ""Protein""}, {""token"": ""SOCS1"", ""start_span"": 42, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""SOCS3"", ""start_span"": 76, ""end_span"": 81, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 120, ""end_span"": 123, ""type"": ""Protein""}]"	test
In association with impaired IL - 10 - mediated STAT3 activation, STAT3 was found to be tyrosine phosphorylated persistently ( up to 6 hours) in freshly isolated PB and ST CD4 + T cells from RA patients.	IL - 10,29,36,Protein	STAT3,48,53,Protein	STAT3,66,71,Protein	CD4,172,175,Protein	"[{""token"": ""IL - 10"", ""start_span"": 29, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 48, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 66, ""end_span"": 71, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 172, ""end_span"": 175, ""type"": ""Protein""}]"	test
These results suggest that both the sustained STAT3 activation and the resistance to IL - 10 inhibition found in RA CD4 + T cells may be induced after chronic exposure in vivo to high concentrations of serum IL - 6.	STAT3,46,51,Protein	IL - 10,85,92,Protein	CD4,116,119,Protein	IL - 6,208,214,Protein	"[{""token"": ""STAT3"", ""start_span"": 46, ""end_span"": 51, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 85, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 116, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 208, ""end_span"": 214, ""type"": ""Protein""}]"	test
Furthermore, IFN - gamma and IL - 10 produced by CD4 + T cells themselves could be responsible for impaired IL - 10 signaling in the ST, because T - cell infiltrates produce both cytokines [ 34, 35].	IFN - gamma,13,24,Protein	IL - 10,29,36,Protein	CD4,49,52,Protein	IL - 10,108,115,Protein	"[{""token"": ""IFN - gamma"", ""start_span"": 13, ""end_span"": 24, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 29, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 49, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 108, ""end_span"": 115, ""type"": ""Protein""}]"	test
IL - 6 is the major STAT3 - activating factor present in synovial fluid, which has a crucial role in the activation of monocyte functions such as gene expression of the Fc gamma receptor type I and type III and of HLA - DR [ 31].	IL - 6,0,6,Protein	STAT3,20,25,Protein	Fc gamma receptor type I,169,193,Protein	type III,198,206,Protein	"[{""token"": ""IL - 6"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 20, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""Fc gamma receptor type I"", ""start_span"": 169, ""end_span"": 193, ""type"": ""Protein""}, {""token"": ""type III"", ""start_span"": 198, ""end_span"": 206, ""type"": ""Protein""}]"	test
More recently, high levels of activated STAT3, thought to be induced mainly by IL - 6, have been detected in the ST, and STAT3 activation has been shown to be involved in synovial fibroblast proliferation and IL - 6 production [ 37].	STAT3,40,45,Protein	IL - 6,79,85,Protein	STAT3,121,126,Protein	IL - 6,209,215,Protein	"[{""token"": ""STAT3"", ""start_span"": 40, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 79, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 121, ""end_span"": 126, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 209, ""end_span"": 215, ""type"": ""Protein""}]"	test
Furthermore, the significance of persistent STAT3 signaling in Th1 - cell - dominated autoimmune arthritis has been suggested by studies of the gp130F759 / F759 mice, in which the Src homology phosphatase - 2 binding site of gp130 ( the transmembrane glycoprotein beta subunit of the IL - 6 family cytokine receptor), tyrosine 759, was mutated to phenylalanine [ 39].	STAT3,44,49,Protein	gp130F759,144,153,Protein	gp130,225,230,Protein	transmembrane glycoprotein beta subunit of the IL - 6 family cytokine receptor,237,315,Protein	"[{""token"": ""STAT3"", ""start_span"": 44, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""gp130F759"", ""start_span"": 144, ""end_span"": 153, ""type"": ""Protein""}, {""token"": ""gp130"", ""start_span"": 225, ""end_span"": 230, ""type"": ""Protein""}, {""token"": ""transmembrane glycoprotein beta subunit of the IL - 6 family cytokine receptor"", ""start_span"": 237, ""end_span"": 315, ""type"": ""Protein""}]"	test
In the gp130F759 / F759 mice, T cells, particularly the CD4 + T - cell subset, are chronically activated and resistant to activation - induced cell death through gp130 - mediated STAT3 activation.	gp130F759,7,16,Protein	CD4,56,59,Protein	gp130,162,167,Protein	STAT3,179,184,Protein	"[{""token"": ""gp130F759"", ""start_span"": 7, ""end_span"": 16, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 56, ""end_span"": 59, ""type"": ""Protein""}, {""token"": ""gp130"", ""start_span"": 162, ""end_span"": 167, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 179, ""end_span"": 184, ""type"": ""Protein""}]"	test
We found that CD4 + T cells from patients with active RA expressed higher levels of SOCS1, but lower levels of SOCS3, compared with normal CD4 + T cells.	CD4,14,17,Protein	SOCS1,84,89,Protein	SOCS3,111,116,Protein	CD4,139,142,Protein	"[{""token"": ""CD4"", ""start_span"": 14, ""end_span"": 17, ""type"": ""Protein""}, {""token"": ""SOCS1"", ""start_span"": 84, ""end_span"": 89, ""type"": ""Protein""}, {""token"": ""SOCS3"", ""start_span"": 111, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 139, ""end_span"": 142, ""type"": ""Protein""}]"	test
SOCS1 and SOCS3 are induced by various cytokines, including IL - 6 and IL - 10, as mediators of negative feedback and crosstalk inhibition [ 7].	SOCS1,0,5,Protein	SOCS3,10,15,Protein	IL - 6,60,66,Protein	IL - 10,71,78,Protein	"[{""token"": ""SOCS1"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""SOCS3"", ""start_span"": 10, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 60, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 71, ""end_span"": 78, ""type"": ""Protein""}]"	test
Although some cytokines ( IL - 15 and IL - 23) have been reported to regulate IL - 17 production, the intracellular signaling pathways that regulate IL - 17 production remain unknown.	IL - 15,26,33,Protein	IL - 23,38,45,Protein	IL - 17,78,85,Protein	IL - 17,149,156,Protein	"[{""token"": ""IL - 15"", ""start_span"": 26, ""end_span"": 33, ""type"": ""Protein""}, {""token"": ""IL - 23"", ""start_span"": 38, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""IL - 17"", ""start_span"": 78, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""IL - 17"", ""start_span"": 149, ""end_span"": 156, ""type"": ""Protein""}]"	test
However, inhibition of activator protein - 1 and extracellular signal - regulated kinase 1 / 2 did not affect IL - 17 production.	activator protein - 1,23,44,Protein	extracellular signal - regulated kinase 1,49,90,Protein	2,93,94,Protein	IL - 17,110,117,Protein	"[{""token"": ""activator protein - 1"", ""start_span"": 23, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""extracellular signal - regulated kinase 1"", ""start_span"": 49, ""end_span"": 90, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 93, ""end_span"": 94, ""type"": ""Protein""}, {""token"": ""IL - 17"", ""start_span"": 110, ""end_span"": 117, ""type"": ""Protein""}]"	test
Recently, Happel and colleagues also showed that IL - 23 could be an efficient trigger of IL - 17 production from both CD4 + and CD8 + T cells [ 14].	IL - 23,49,56,Protein	IL - 17,90,97,Protein	CD4,119,122,Protein	CD8,129,132,Protein	"[{""token"": ""IL - 23"", ""start_span"": 49, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""IL - 17"", ""start_span"": 90, ""end_span"": 97, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 119, ""end_span"": 122, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 129, ""end_span"": 132, ""type"": ""Protein""}]"	test
The following sense and antisense primers for each molecules were used: IL - 17 sense, 5 ' - ATG ACT CCT GGG AAG ACC TCA TTG - 3 '; IL - 17 antisense, 5 ' - TTA GGC CAC ATG GTG GAC AAT CGG - 3 '; glyceraldehyde - 3 - phosphate dehydrogenase ( GAPDH) sense, 5 ' - CGA TGC TGG GCG TGA GTA C - 3 '; GAPDH antisense, 5 ' - CGT TCA GCT CAG GGA TGA CC - 3 '.	IL - 17,72,79,Protein	glyceraldehyde - 3 - phosphate dehydrogenase,196,240,Protein	GAPDH,243,248,Protein	GAPDH,296,301,Protein	"[{""token"": ""IL - 17"", ""start_span"": 72, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""glyceraldehyde - 3 - phosphate dehydrogenase"", ""start_span"": 196, ""end_span"": 240, ""type"": ""Protein""}, {""token"": ""GAPDH"", ""start_span"": 243, ""end_span"": 248, ""type"": ""Protein""}, {""token"": ""GAPDH"", ""start_span"": 296, ""end_span"": 301, ""type"": ""Protein""}]"	test
Proinflammatory cytokines such as IL - 1 and TNF - alpha are abundant in rheumatoid synovium, whereas the T cell - derived cytokines, especially IL - 4 and interferon - gamma, have often proved difficult to detect in RA synovium [ 24].	IL - 1,34,40,Protein	TNF - alpha,45,56,Protein	IL - 4,145,151,Protein	interferon - gamma,156,174,Protein	"[{""token"": ""IL - 1"", ""start_span"": 34, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 45, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 145, ""end_span"": 151, ""type"": ""Protein""}, {""token"": ""interferon - gamma"", ""start_span"": 156, ""end_span"": 174, ""type"": ""Protein""}]"	test
For example, IL - 17 stimulates rheumatoid synoviocytes to secrete several cytokines such as IL - 6, IL - 8 and tumor necrosis factor - stimulated gene 6 as well as prostaglandin E2 in vitro [ 12, 28, 29].	IL - 17,13,20,Protein	IL - 6,93,99,Protein	IL - 8,101,107,Protein	tumor necrosis factor - stimulated gene 6,112,153,Protein	"[{""token"": ""IL - 17"", ""start_span"": 13, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 93, ""end_span"": 99, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 101, ""end_span"": 107, ""type"": ""Protein""}, {""token"": ""tumor necrosis factor - stimulated gene 6"", ""start_span"": 112, ""end_span"": 153, ""type"": ""Protein""}]"	test
There are as yet few data available on the agents that stimulate IL - 17 production in RA, although some cytokines ( IL - 15 and IL - 23) have been known to regulate IL - 17 production [ 13, 14].	IL - 17,65,72,Protein	IL - 15,117,124,Protein	IL - 23,129,136,Protein	IL - 17,166,173,Protein	"[{""token"": ""IL - 17"", ""start_span"": 65, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""IL - 15"", ""start_span"": 117, ""end_span"": 124, ""type"": ""Protein""}, {""token"": ""IL - 23"", ""start_span"": 129, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""IL - 17"", ""start_span"": 166, ""end_span"": 173, ""type"": ""Protein""}]"	test
We have detected a more pronounced production of IL - 17 from RA PBMC in response to IL - 15 and MCP - 1 as well as stimulation by anti - CD3 / anti - CD28.	IL - 17,49,56,Protein	IL - 15,85,92,Protein	MCP - 1,97,104,Protein	CD28,151,155,Protein	"[{""token"": ""IL - 17"", ""start_span"": 49, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""IL - 15"", ""start_span"": 85, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""MCP - 1"", ""start_span"": 97, ""end_span"": 104, ""type"": ""Protein""}, {""token"": ""CD28"", ""start_span"": 151, ""end_span"": 155, ""type"": ""Protein""}]"	test
Depletion of Sox6 in HeLa cell extracts blocked splicing of multiple substrates, and expression of the HMG domain of either Sox6, Sox9, or Sry in the extracts restored splicing, indicating functional overlap of these proteins [ 7].	Sox6,13,17,Protein	Sox6,124,128,Protein	Sox9,130,134,Protein	Sry,139,142,Protein	"[{""token"": ""Sox6"", ""start_span"": 13, ""end_span"": 17, ""type"": ""Protein""}, {""token"": ""Sox6"", ""start_span"": 124, ""end_span"": 128, ""type"": ""Protein""}, {""token"": ""Sox9"", ""start_span"": 130, ""end_span"": 134, ""type"": ""Protein""}, {""token"": ""Sry"", ""start_span"": 139, ""end_span"": 142, ""type"": ""Protein""}]"	test
The mouse beta - globin genes { epsilony, betah1, beta - major, and beta - minor} are clustered on Chromosome 7 and they are highly homologous to their human counterparts in organizational structure and function [ 22].	epsilony,32,40,Protein	betah1,42,48,Protein	beta - major,50,62,Protein	beta - minor,68,80,Protein	"[{""token"": ""epsilony"", ""start_span"": 32, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""betah1"", ""start_span"": 42, ""end_span"": 48, ""type"": ""Protein""}, {""token"": ""beta - major"", ""start_span"": 50, ""end_span"": 62, ""type"": ""Protein""}, {""token"": ""beta - minor"", ""start_span"": 68, ""end_span"": 80, ""type"": ""Protein""}]"	test
To investigate whether Sox6 directly acts on the epsilony gene promoter at the transcriptional level, we used an in vitro transient transfection assay and GM979 cells, a murine erythroleukemic cell line that expresses both epsilony and adult beta globins [ 30].	Sox6,23,27,Protein	epsilony,49,57,Protein	epsilony,223,231,Protein	beta globins,242,254,Protein	"[{""token"": ""Sox6"", ""start_span"": 23, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""epsilony"", ""start_span"": 49, ""end_span"": 57, ""type"": ""Protein""}, {""token"": ""epsilony"", ""start_span"": 223, ""end_span"": 231, ""type"": ""Protein""}, {""token"": ""beta globins"", ""start_span"": 242, ""end_span"": 254, ""type"": ""Protein""}]"	test
To investigate whether Sox6 is directly associated with the epsilony promoter, we first performed electrophoretic mobility shift assays ( EMSA) using a c - Myc - tagged Sox6 in a reticulocyte lysate - based transcription / translation in vitro system.	Sox6,23,27,Protein	epsilony,60,68,Protein	c - Myc,152,159,Protein	Sox6,169,173,Protein	"[{""token"": ""Sox6"", ""start_span"": 23, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""epsilony"", ""start_span"": 60, ""end_span"": 68, ""type"": ""Protein""}, {""token"": ""c - Myc"", ""start_span"": 152, ""end_span"": 159, ""type"": ""Protein""}, {""token"": ""Sox6"", ""start_span"": 169, ""end_span"": 173, ""type"": ""Protein""}]"	test
In the Sox6 null mouse, there is a transient effect on the embryonic globin genes, zeta and betaH1, and a persistent upregulation of the epsilony globin gene.	Sox6,7,11,Protein	zeta,83,87,Protein	betaH1,92,98,Protein	epsilony globin,137,152,Protein	"[{""token"": ""Sox6"", ""start_span"": 7, ""end_span"": 11, ""type"": ""Protein""}, {""token"": ""zeta"", ""start_span"": 83, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""betaH1"", ""start_span"": 92, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""epsilony globin"", ""start_span"": 137, ""end_span"": 152, ""type"": ""Protein""}]"	test
A few other epsilony globin repressors have been reported to bind to DNA sequences near the Sox / Sox6 consensus sites, including the DRED complex [ 37] and COUP - TF [ 38].	epsilony globin,12,27,Protein	DRED,134,138,Protein	COUP,157,161,Protein	TF,164,166,Protein	"[{""token"": ""epsilony globin"", ""start_span"": 12, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""DRED"", ""start_span"": 134, ""end_span"": 138, ""type"": ""Protein""}, {""token"": ""COUP"", ""start_span"": 157, ""end_span"": 161, ""type"": ""Protein""}, {""token"": ""TF"", ""start_span"": 164, ""end_span"": 166, ""type"": ""Protein""}]"	test
Two HMG architectural proteins ( distantly related to the Sox family of transcription factors), HMG - I and HMG - Y, were demonstrated to bind to the human adult beta globin silencers ( silencers I and II) and cause bending of the DNA, facilitating the binding of other repressors [ 40].	HMG - I,96,103,Protein	HMG - Y,108,115,Protein	silencers I,186,197,Protein	II,202,204,Protein	"[{""token"": ""HMG - I"", ""start_span"": 96, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""HMG - Y"", ""start_span"": 108, ""end_span"": 115, ""type"": ""Protein""}, {""token"": ""silencers I"", ""start_span"": 186, ""end_span"": 197, ""type"": ""Protein""}, {""token"": ""II"", ""start_span"": 202, ""end_span"": 204, ""type"": ""Protein""}]"	test
The expression level of epsilony globin in homozygous Sox6 null mice at 15. 5 dpc and 18. 5 dpc is statistically equivalent to the level of betamaj / min expression in the livers of 15. 5 - dpc and 18. 5 - dpc homozygous WT mice ( Figure 1).	epsilony globin,24,39,Protein	Sox6,54,58,Protein	betamaj,140,147,Protein	min,150,153,Protein	"[{""token"": ""epsilony globin"", ""start_span"": 24, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""Sox6"", ""start_span"": 54, ""end_span"": 58, ""type"": ""Protein""}, {""token"": ""betamaj"", ""start_span"": 140, ""end_span"": 147, ""type"": ""Protein""}, {""token"": ""min"", ""start_span"": 150, ""end_span"": 153, ""type"": ""Protein""}]"	test
In the murine system, binding of zymosan to Dectin - 1 resulted in production of TNFalpha through Toll - like receptor 2 and the adaptor protein MyD88 [ 12].	Dectin - 1,44,54,Protein	TNFalpha,81,89,Protein	Toll - like receptor 2,98,120,Protein	MyD88,145,150,Protein	"[{""token"": ""Dectin - 1"", ""start_span"": 44, ""end_span"": 54, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 81, ""end_span"": 89, ""type"": ""Protein""}, {""token"": ""Toll - like receptor 2"", ""start_span"": 98, ""end_span"": 120, ""type"": ""Protein""}, {""token"": ""MyD88"", ""start_span"": 145, ""end_span"": 150, ""type"": ""Protein""}]"	test
Correspondingly, four NFkappaB sites from the TNFalpha promoter ( kappa consensus, kappa1, kappa2, kappa3) [ 27], a kappa consensus site from the IL - 8 promoter [ 28], an NFAT site from the IFNgamma promoter ( ATP2) [ 29] and a consensus NFIL - 6 site from the IL - 6 promoter [ 13] were examined.	TNFalpha,46,54,Protein	IL - 8,146,152,Protein	IFNgamma,191,199,Protein	IL - 6,241,247,Protein	"[{""token"": ""TNFalpha"", ""start_span"": 46, ""end_span"": 54, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 146, ""end_span"": 152, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 191, ""end_span"": 199, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 241, ""end_span"": 247, ""type"": ""Protein""}]"	test
GP induced band shifts, indicating binding of NFkappaB as well as of NFIL - 6 to the corresponding DNA oligonucleotides ( kappa consensus, kappa1, kappa2, kappa3 sites from the TNFalpha promoter; kappa consensus from the IL - 8 promoter; NFIL - 6consensus from the IL - 6 promoter; Table 1; Fig. 1A).	NFIL - 6,69,77,Protein	TNFalpha,177,185,Protein	IL - 8,221,227,Protein	IL - 6,240,246,Protein	"[{""token"": ""NFIL - 6"", ""start_span"": 69, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 177, ""end_span"": 185, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 221, ""end_span"": 227, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 240, ""end_span"": 246, ""type"": ""Protein""}]"	test
Simultaneous co - treatment of PBMC with GP did not change the LPS - induced NFkappaB binding to oligos from the TNFalpha promoter significantly ( Fig. 1B), but substantially decreased the TSST - 1 - induced NFkappaB binding when compared to TSST - 1 or GP ( 100 mug) and thus differed completely from the theoretical value of GP / TSST - 1 calc.	TNFalpha,113,121,Protein	TSST - 1,189,197,Protein	TSST - 1,242,250,Protein	TSST - 1,332,340,Protein	"[{""token"": ""TNFalpha"", ""start_span"": 113, ""end_span"": 121, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 189, ""end_span"": 197, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 242, ""end_span"": 250, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 332, ""end_span"": 340, ""type"": ""Protein""}]"	test
For GP + TSST - 1 we found a significant reduction in IL - 1beta from 18 h - 24 h, for the latter by about 40% when compared to TSST - 1 or the theoretical value of GP / TSST - 1 calc.	TSST - 1,9,17,Protein	IL - 1beta,54,64,Protein	TSST - 1,128,136,Protein	TSST - 1,170,178,Protein	"[{""token"": ""TSST - 1"", ""start_span"": 9, ""end_span"": 17, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 54, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 128, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 170, ""end_span"": 178, ""type"": ""Protein""}]"	test
On the contrary, we observed a decreased IL - 6 production for GP + TSST - 1 when compared to TSST - 1 or GP / TSST - 1 calc., especially at 24 h by about 40% ( n = 5; both p = 0. 02), ( data not shown in detail).	IL - 6,41,47,Protein	TSST - 1,68,76,Protein	TSST - 1,94,102,Protein	TSST - 1,111,119,Protein	"[{""token"": ""IL - 6"", ""start_span"": 41, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 68, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 94, ""end_span"": 102, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 111, ""end_span"": 119, ""type"": ""Protein""}]"	test
There was no significant alteration in IL - 8 production following GP + TSST - 1 when compared to TSST - 1 or GP / TSST - 1 calc.	IL - 8,39,45,Protein	TSST - 1,72,80,Protein	TSST - 1,98,106,Protein	TSST - 1,115,123,Protein	"[{""token"": ""IL - 8"", ""start_span"": 39, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 72, ""end_span"": 80, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 98, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 115, ""end_span"": 123, ""type"": ""Protein""}]"	test
However, following GP + TSST - 1 we found a synergistic increase in IL - 1RA production from 18 h to 48 h, when compared to TSST - 1 ( for instance at 24 h: n = 6; p = 0. 01) or to the theoretical value of GP / TSST - 1 calc.	TSST - 1,24,32,Protein	IL - 1RA,68,76,Protein	TSST - 1,124,132,Protein	TSST - 1,211,219,Protein	"[{""token"": ""TSST - 1"", ""start_span"": 24, ""end_span"": 32, ""type"": ""Protein""}, {""token"": ""IL - 1RA"", ""start_span"": 68, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 124, ""end_span"": 132, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 211, ""end_span"": 219, ""type"": ""Protein""}]"	test
There was a minor increase in IFNgamma production following GP + LPS at 36 h, when compared to LPS or GP / LPS calc., and a slight down - regulation following GP + TSST - 1 at 24 h and 36 h, when compared to TSST - 1 or GP / TSST - 1 calc.	IFNgamma,30,38,Protein	TSST - 1,164,172,Protein	TSST - 1,208,216,Protein	TSST - 1,225,233,Protein	"[{""token"": ""IFNgamma"", ""start_span"": 30, ""end_span"": 38, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 164, ""end_span"": 172, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 208, ""end_span"": 216, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 225, ""end_span"": 233, ""type"": ""Protein""}]"	test
Because GP induced band shifts to NFkappaB, NFIL - 6 and NFAT sites, but no TNFalpha, IL - 6 or IFNgamma, we hypothesized that the activated transcription factors might bind to sites in the IL - 1RA promoter.	TNFalpha,76,84,Protein	IL - 6,86,92,Protein	IFNgamma,96,104,Protein	IL - 1RA,190,198,Protein	"[{""token"": ""TNFalpha"", ""start_span"": 76, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 86, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 96, ""end_span"": 104, ""type"": ""Protein""}, {""token"": ""IL - 1RA"", ""start_span"": 190, ""end_span"": 198, ""type"": ""Protein""}]"	test
A new kappaB3 site ( - 100 and - 130) within the LRE - 1 [ 30] showed increased binding induced by TSST - 1 ( + 30% vs. control), but GP co - treatment up - regulated the LPS ( + 65% vs. control) - and the TSST - 1 ( + 110% vs. control) - induced binding in a superadditive synergistic fashion, when compared to medium control as well as to LPS, TSST - 1 or GP or the theoretical values of GP / LPS calc. or GP / TSST - 1 calc.	TSST - 1,99,107,Protein	TSST - 1,206,214,Protein	TSST - 1,346,354,Protein	TSST - 1,413,421,Protein	"[{""token"": ""TSST - 1"", ""start_span"": 99, ""end_span"": 107, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 206, ""end_span"": 214, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 346, ""end_span"": 354, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 413, ""end_span"": 421, ""type"": ""Protein""}]"	test
The IL - 8kappaB consensus site exhibits a preferentially p65 binding half site and thus differs from the kappaB half site described for TNFalpha and IL - 1beta [ 27, 40], supporting the idea of regulating NFkappaB binding through combinatorial associations of the subunits and the specific sequence of the decameric kappaB motif [ 41, 42].	IL - 8kappaB,4,16,Protein	p65,58,61,Protein	TNFalpha,137,145,Protein	IL - 1beta,150,160,Protein	"[{""token"": ""IL - 8kappaB"", ""start_span"": 4, ""end_span"": 16, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 58, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 137, ""end_span"": 145, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 150, ""end_span"": 160, ""type"": ""Protein""}]"	test
A bacterial superantigen like TSST - 1 acts through binding to MHC - II molecules and subsequently the T cell receptor, leading to release of mainly IFNgamma and TNFalpha, the latter via both, PI3K and p38 mitogen - activated kinase signaling [ 44, 45].	TSST - 1,30,38,Protein	IFNgamma,149,157,Protein	TNFalpha,162,170,Protein	p38 mitogen - activated kinase,202,232,Protein	"[{""token"": ""TSST - 1"", ""start_span"": 30, ""end_span"": 38, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 149, ""end_span"": 157, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 162, ""end_span"": 170, ""type"": ""Protein""}, {""token"": ""p38 mitogen - activated kinase"", ""start_span"": 202, ""end_span"": 232, ""type"": ""Protein""}]"	test
Accordingly, we found that the TSST - 1 - induced binding of NFkappaB to sites from the TNFalpha promoter negatively correlated with the GP - mediated enhancement of the TSST - 1 - induced IL - 1RA production ( r = - 0. 88; p < 0. 01; data not shown in detail).	TSST - 1,31,39,Protein	TNFalpha,88,96,Protein	TSST - 1,170,178,Protein	IL - 1RA,189,197,Protein	"[{""token"": ""TSST - 1"", ""start_span"": 31, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 88, ""end_span"": 96, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 170, ""end_span"": 178, ""type"": ""Protein""}, {""token"": ""IL - 1RA"", ""start_span"": 189, ""end_span"": 197, ""type"": ""Protein""}]"	test
Since, in fact, the IL - 1beta / IL - 1RA ratio following GP + TSST - 1 is partially less than 0. 01, it is not unreasonable to assume that IL - 1beta bioactivity is inactivated in our system.	IL - 1beta,20,30,Protein	IL - 1RA,33,41,Protein	TSST - 1,63,71,Protein	IL - 1beta,140,150,Protein	"[{""token"": ""IL - 1beta"", ""start_span"": 20, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""IL - 1RA"", ""start_span"": 33, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 63, ""end_span"": 71, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 140, ""end_span"": 150, ""type"": ""Protein""}]"	test
The complementary double - stranded ( ds) oligonucleotides ( oligos) from the TNFalpha, IL - 8, IFNgamma and IL - 6 promoters were synthesised from single stranded ( ss) oligos ( illustrated in Table 1), ( TIB Molbiol, Berlin, Germany) and 32P - labeled with 5 ' gamma - P - ATP ( 3, 000 Ci / mmol, Amersham, Braunschweig, Germany) using the Ready - To - Go - Polynucleotide - Kinase Kit ( PNK Kit, Pharmacia LKB, Freiburg, Germany) according to the manufacturer ' s instructions.	TNFalpha,78,86,Protein	IL - 8,88,94,Protein	IFNgamma,96,104,Protein	IL - 6,109,115,Protein	"[{""token"": ""TNFalpha"", ""start_span"": 78, ""end_span"": 86, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 88, ""end_span"": 94, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 96, ""end_span"": 104, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 109, ""end_span"": 115, ""type"": ""Protein""}]"	test
Band shifts were determined after 1 h incubation with GP as described before, including mutated oligos for NFIL - 6 ( TTA CAA CAG TGG ATT GCG ACA CTT AGT GGG) and NFATP2 / 3 ( GGC GCA GAA AAG GTA AAA TAT TTA CTA TCT) binding sites within the IL - 1RA promoter.	NFIL - 6,107,115,Protein	NFATP2,163,169,Protein	3,172,173,Protein	IL - 1RA,242,250,Protein	"[{""token"": ""NFIL - 6"", ""start_span"": 107, ""end_span"": 115, ""type"": ""Protein""}, {""token"": ""NFATP2"", ""start_span"": 163, ""end_span"": 169, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 172, ""end_span"": 173, ""type"": ""Protein""}, {""token"": ""IL - 1RA"", ""start_span"": 242, ""end_span"": 250, ""type"": ""Protein""}]"	test
NFkappaB p65 / p50 and NFATc2 / c1 were involved in GP - induced DNA binding.	p65,9,12,Protein	p50,15,18,Protein	NFATc2,23,29,Protein	c1,32,34,Protein	"[{""token"": ""p65"", ""start_span"": 9, ""end_span"": 12, ""type"": ""Protein""}, {""token"": ""p50"", ""start_span"": 15, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""NFATc2"", ""start_span"": 23, ""end_span"": 29, ""type"": ""Protein""}, {""token"": ""c1"", ""start_span"": 32, ""end_span"": 34, ""type"": ""Protein""}]"	test
Decreased IL - 1beta / IL - 1RA ratio following GP + TSST - 1 when compared to TSST - 1.	IL - 1beta,10,20,Protein	IL - 1RA,23,31,Protein	TSST - 1,53,61,Protein	TSST - 1,79,87,Protein	"[{""token"": ""IL - 1beta"", ""start_span"": 10, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""IL - 1RA"", ""start_span"": 23, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 53, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 79, ""end_span"": 87, ""type"": ""Protein""}]"	test
Finally, recent discoveries revealing a genetic association with several genes relevant to NF - kappaB signalling, including CD40, TRAF1, TNFAIP3, and c - REL, further highlight the importance of NF - kappaB activation in RA pathogenesis [ 8].	CD40,125,129,Protein	TRAF1,131,136,Protein	TNFAIP3,138,145,Protein	c - REL,151,158,Protein	"[{""token"": ""CD40"", ""start_span"": 125, ""end_span"": 129, ""type"": ""Protein""}, {""token"": ""TRAF1"", ""start_span"": 131, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""TNFAIP3"", ""start_span"": 138, ""end_span"": 145, ""type"": ""Protein""}, {""token"": ""c - REL"", ""start_span"": 151, ""end_span"": 158, ""type"": ""Protein""}]"	test
High mobility group box chromosomal protein 1 ( HMGB1), a highly conserved chromatin component that can be actively secreted by macrophages or passively released by necrotic cells, is one of the most putative endogenous TLR4 ligands involved in RA pathology.	High mobility group box chromosomal protein 1,0,45,Protein	HMGB1,48,53,Protein	chromatin component,75,94,Protein	TLR4 ligands,220,232,Protein	"[{""token"": ""High mobility group box chromosomal protein 1"", ""start_span"": 0, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""HMGB1"", ""start_span"": 48, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""chromatin component"", ""start_span"": 75, ""end_span"": 94, ""type"": ""Protein""}, {""token"": ""TLR4 ligands"", ""start_span"": 220, ""end_span"": 232, ""type"": ""Protein""}]"	test
p100 and p105 are precursors of the p52 and p50 NF - kappaB subunits, respectively.	p100,0,4,Protein	p105,9,13,Protein	p52,36,39,Protein	p50,44,47,Protein	"[{""token"": ""p100"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""p105"", ""start_span"": 9, ""end_span"": 13, ""type"": ""Protein""}, {""token"": ""p52"", ""start_span"": 36, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""p50"", ""start_span"": 44, ""end_span"": 47, ""type"": ""Protein""}]"	test
The noncanonical NF - kappaB pathway can be activated by the lymphotoxin beta receptor, BAFF receptor, CD40, and RANK ( Figure 2).	lymphotoxin beta receptor,61,86,Protein	BAFF receptor,88,101,Protein	CD40,103,107,Protein	RANK,113,117,Protein	"[{""token"": ""lymphotoxin beta receptor"", ""start_span"": 61, ""end_span"": 86, ""type"": ""Protein""}, {""token"": ""BAFF receptor"", ""start_span"": 88, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 103, ""end_span"": 107, ""type"": ""Protein""}, {""token"": ""RANK"", ""start_span"": 113, ""end_span"": 117, ""type"": ""Protein""}]"	test
Macrophages from IKK1 - deficient mice or knockin mice expressing inactive IKK1 show increased production of proinflammatory cytokines as a result of enhanced IKK2 activation and IkappaBalpha degradation [ 34].	IKK1,17,21,Protein	IKK1,75,79,Protein	IKK2,159,163,Protein	IkappaBalpha,179,191,Protein	"[{""token"": ""IKK1"", ""start_span"": 17, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""IKK1"", ""start_span"": 75, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""IKK2"", ""start_span"": 159, ""end_span"": 163, ""type"": ""Protein""}, {""token"": ""IkappaBalpha"", ""start_span"": 179, ""end_span"": 191, ""type"": ""Protein""}]"	test
Similar to A20, ABIN - 1 and ABIN - 3 expression is NF - kappaB dependent, implicating a potential role for the A20 / ABIN complex in the negative feedback regulation of NF - kappaB activation ( reviewed in [ 54]).	A20,11,14,Protein	ABIN - 1,16,24,Protein	ABIN - 3,29,37,Protein	A20,112,115,Protein	"[{""token"": ""A20"", ""start_span"": 11, ""end_span"": 14, ""type"": ""Protein""}, {""token"": ""ABIN - 1"", ""start_span"": 16, ""end_span"": 24, ""type"": ""Protein""}, {""token"": ""ABIN - 3"", ""start_span"": 29, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""A20"", ""start_span"": 112, ""end_span"": 115, ""type"": ""Protein""}]"	test
Expression of TRAF1 is inducible by TNF and overexpression of TRAF1 inhibits TNF - induced NF - kappaB activation.	TRAF1,14,19,Protein	TNF,36,39,Protein	TRAF1,62,67,Protein	TNF,77,80,Protein	"[{""token"": ""TRAF1"", ""start_span"": 14, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 36, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""TRAF1"", ""start_span"": 62, ""end_span"": 67, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 77, ""end_span"": 80, ""type"": ""Protein""}]"	test
In addition, miR - 146a is an NF - kappaB - dependent gene, and the NF - kappaB signalling molecules IRAK1 and TRAF6 were identified as target genes of miR - 146a [ 78] ( Figure 1).	miR - 146a,13,23,Protein	IRAK1,101,106,Protein	TRAF6,111,116,Protein	miR - 146a,152,162,Protein	"[{""token"": ""miR - 146a"", ""start_span"": 13, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""IRAK1"", ""start_span"": 101, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 111, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""miR - 146a"", ""start_span"": 152, ""end_span"": 162, ""type"": ""Protein""}]"	test
Finally, TLR signalling can also be inhibited by the transmembrane protein SIGIRR, which has been proposed to compete with TLR4 for binding to IRAK1 and TRAF6.	SIGIRR,75,81,Protein	TLR4,123,127,Protein	IRAK1,143,148,Protein	TRAF6,153,158,Protein	"[{""token"": ""SIGIRR"", ""start_span"": 75, ""end_span"": 81, ""type"": ""Protein""}, {""token"": ""TLR4"", ""start_span"": 123, ""end_span"": 127, ""type"": ""Protein""}, {""token"": ""IRAK1"", ""start_span"": 143, ""end_span"": 148, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 153, ""end_span"": 158, ""type"": ""Protein""}]"	test
CD40 and RANK can activate the noncanonical NF - kappaB pathway that is dependent on NF - kappaB inducing kinase ( NIK) expression levels.	CD40,0,4,Protein	RANK,9,13,Protein	NF - kappaB inducing kinase,85,112,Protein	NIK,115,118,Protein	"[{""token"": ""CD40"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""RANK"", ""start_span"": 9, ""end_span"": 13, ""type"": ""Protein""}, {""token"": ""NF - kappaB inducing kinase"", ""start_span"": 85, ""end_span"": 112, ""type"": ""Protein""}, {""token"": ""NIK"", ""start_span"": 115, ""end_span"": 118, ""type"": ""Protein""}]"	test
Upon ligand binding, TRAF3 is recruited to the receptor, where TRAF2 directs nondegradative K63 - linked polyubiquitination of cIAP1 / 2, resulting in their activation.	TRAF3,21,26,Protein	TRAF2,63,68,Protein	cIAP1,127,132,Protein	2,135,136,Protein	"[{""token"": ""TRAF3"", ""start_span"": 21, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 63, ""end_span"": 68, ""type"": ""Protein""}, {""token"": ""cIAP1"", ""start_span"": 127, ""end_span"": 132, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 135, ""end_span"": 136, ""type"": ""Protein""}]"	test
Subsequently cIAP1 / 2 directs its K48 - linked polyubiquitination to TRAF3, rather than NIK.	cIAP1,13,18,Protein	2,21,22,Protein	TRAF3,70,75,Protein	NIK,89,92,Protein	"[{""token"": ""cIAP1"", ""start_span"": 13, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 21, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""TRAF3"", ""start_span"": 70, ""end_span"": 75, ""type"": ""Protein""}, {""token"": ""NIK"", ""start_span"": 89, ""end_span"": 92, ""type"": ""Protein""}]"	test
cIAP, cellular inhibitor of apoptosis; IKK, IkappaB kinase; NF, nuclear factor; RANK, receptor activator of NF - kappaB; TRAF, TNF receptor - associated factor; TNF, tumour necrosis factor.	RANK,80,84,Protein	receptor activator of NF - kappaB,86,119,Protein	TNF,127,130,Protein	tumour necrosis factor,166,188,Protein	"[{""token"": ""RANK"", ""start_span"": 80, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""receptor activator of NF - kappaB"", ""start_span"": 86, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 127, ""end_span"": 130, ""type"": ""Protein""}, {""token"": ""tumour necrosis factor"", ""start_span"": 166, ""end_span"": 188, ""type"": ""Protein""}]"	test
Intracellular DNA sensors that mediate antiviral immune responses to DNA viruses include TLR9, DAI [ 4] and the PYHIN domain containing proteins AIM2 [ 5], [ 6], [ 7] and IFI16 [ 8].	TLR9,89,93,Protein	DAI,95,98,Protein	AIM2,145,149,Protein	IFI16,171,176,Protein	"[{""token"": ""TLR9"", ""start_span"": 89, ""end_span"": 93, ""type"": ""Protein""}, {""token"": ""DAI"", ""start_span"": 95, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""AIM2"", ""start_span"": 145, ""end_span"": 149, ""type"": ""Protein""}, {""token"": ""IFI16"", ""start_span"": 171, ""end_span"": 176, ""type"": ""Protein""}]"	test
In addition, well characterized ubiquitin ligases such as TRAF6 [ 25], [ 26] and TRAF3 [ 27] mediate respectively NF - kappaB and IRF3 activation upon RIG - I stimulation.	TRAF6,58,63,Protein	TRAF3,81,86,Protein	IRF3,130,134,Protein	RIG - I,151,158,Protein	"[{""token"": ""TRAF6"", ""start_span"": 58, ""end_span"": 63, ""type"": ""Protein""}, {""token"": ""TRAF3"", ""start_span"": 81, ""end_span"": 86, ""type"": ""Protein""}, {""token"": ""IRF3"", ""start_span"": 130, ""end_span"": 134, ""type"": ""Protein""}, {""token"": ""RIG - I"", ""start_span"": 151, ""end_span"": 158, ""type"": ""Protein""}]"	test
Furthermore, various K48 - specific ubiquitin ligases, such as AIP4 [ 32] and TRIAD3A [ 33] mark respectively MAVS and TRAF3 for proteasome mediated degradation, thus inhibiting further downstream signaling.	AIP4,63,67,Protein	TRIAD3A,78,85,Protein	MAVS,110,114,Protein	TRAF3,119,124,Protein	"[{""token"": ""AIP4"", ""start_span"": 63, ""end_span"": 67, ""type"": ""Protein""}, {""token"": ""TRIAD3A"", ""start_span"": 78, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""MAVS"", ""start_span"": 110, ""end_span"": 114, ""type"": ""Protein""}, {""token"": ""TRAF3"", ""start_span"": 119, ""end_span"": 124, ""type"": ""Protein""}]"	test
Unlike IRF3, IRF7 is not or weakly expressed under naive conditions and IRF7 protein levels are rapidly upregulated upon virus - induced IRF3 activation [ 54], [ 55].	IRF3,7,11,Protein	IRF7,13,17,Protein	IRF7,72,76,Protein	IRF3,137,141,Protein	"[{""token"": ""IRF3"", ""start_span"": 7, ""end_span"": 11, ""type"": ""Protein""}, {""token"": ""IRF7"", ""start_span"": 13, ""end_span"": 17, ""type"": ""Protein""}, {""token"": ""IRF7"", ""start_span"": 72, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""IRF3"", ""start_span"": 137, ""end_span"": 141, ""type"": ""Protein""}]"	test
To determine the effect of A20 on IRF7 activation, we therefore transfected minor amounts of an IRF7 expression plasmid together with plasmids encoding RIG - I ( 2CARD), A20 and an IRF7 - specific IFNalpha4 luciferase reporter construct.	IRF7,34,38,Protein	IRF7,96,100,Protein	IRF7,181,185,Protein	luciferase,207,217,Protein	"[{""token"": ""IRF7"", ""start_span"": 34, ""end_span"": 38, ""type"": ""Protein""}, {""token"": ""IRF7"", ""start_span"": 96, ""end_span"": 100, ""type"": ""Protein""}, {""token"": ""IRF7"", ""start_span"": 181, ""end_span"": 185, ""type"": ""Protein""}, {""token"": ""luciferase"", ""start_span"": 207, ""end_span"": 217, ""type"": ""Protein""}]"	test
NF - kappaB controls the expression of IL - 6 and TNF, and NF - kappaB and IRF3 control the expression of IFNbeta.	IL - 6,39,45,Protein	TNF,50,53,Protein	IRF3,75,79,Protein	IFNbeta,106,113,Protein	"[{""token"": ""IL - 6"", ""start_span"": 39, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 50, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""IRF3"", ""start_span"": 75, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""IFNbeta"", ""start_span"": 106, ""end_span"": 113, ""type"": ""Protein""}]"	test
In line with the enhanced activation of NF - kappaB and IRF3 as described above, A20myel - KO BMDM secreted increased amounts of IL - 6, TNF and IFNbeta ( figure 1D).	IRF3,56,60,Protein	IL - 6,129,135,Protein	TNF,137,140,Protein	IFNbeta,145,152,Protein	"[{""token"": ""IRF3"", ""start_span"": 56, ""end_span"": 60, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 129, ""end_span"": 135, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 137, ""end_span"": 140, ""type"": ""Protein""}, {""token"": ""IFNbeta"", ""start_span"": 145, ""end_span"": 152, ""type"": ""Protein""}]"	test
KC is the murine orthologue of IL - 8 and serves together with MIP - 2 as a chemoattractant for neutrophils, while MCP - 1 is mainly known as a chemoattractant for monocytes, which eventually develop into macrophages upon entering the alveolar lumen [ 60].	KC,0,2,Protein	IL - 8,31,37,Protein	MIP - 2,63,70,Protein	MCP - 1,115,122,Protein	"[{""token"": ""KC"", ""start_span"": 0, ""end_span"": 2, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 31, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""MIP - 2"", ""start_span"": 63, ""end_span"": 70, ""type"": ""Protein""}, {""token"": ""MCP - 1"", ""start_span"": 115, ""end_span"": 122, ""type"": ""Protein""}]"	test
In this context, it was recently shown that A20 cooperates with the ubiquitin - binding proteins TAX1BP1 and ABIN1 to to disrupt the TRAF3 - TBK1 - IKKepsilon complex, thereby negatively affecting K63 - polyubiquitination of TBK1 and IKKepsilon, and their ability to activity IRF3 [ 81], [ 82].	ABIN1,109,114,Protein	TBK1,141,145,Protein	IKKepsilon,148,158,Protein	IRF3,276,280,Protein	"[{""token"": ""ABIN1"", ""start_span"": 109, ""end_span"": 114, ""type"": ""Protein""}, {""token"": ""TBK1"", ""start_span"": 141, ""end_span"": 145, ""type"": ""Protein""}, {""token"": ""IKKepsilon"", ""start_span"": 148, ""end_span"": 158, ""type"": ""Protein""}, {""token"": ""IRF3"", ""start_span"": 276, ""end_span"": 280, ""type"": ""Protein""}]"	test
( A) HEK293T cells were transfected with NF - kappaB ( left), IRF3 ( middle) or IRF7 dependent luciferase reporter ( right) plasmids, together with plasmids expressing RIG - I ( 2CARD), IRF7 ( right) and increasing amounts of A20.	IRF3,62,66,Protein	IRF7,80,84,Protein	luciferase,95,105,Protein	IRF7,186,190,Protein	"[{""token"": ""IRF3"", ""start_span"": 62, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""IRF7"", ""start_span"": 80, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""luciferase"", ""start_span"": 95, ""end_span"": 105, ""type"": ""Protein""}, {""token"": ""IRF7"", ""start_span"": 186, ""end_span"": 190, ""type"": ""Protein""}]"	test
BAL was isolated from IAV infected mice at 4, 7 and 10 days p. i. and KC, MIP - 2, MCP - 1, IL - 6 and IFNalpha protein levels were analyzed by ELISA and multiplexing technologies ( C).	KC,70,72,Protein	MIP - 2,74,81,Protein	MCP - 1,83,90,Protein	IL - 6,92,98,Protein	"[{""token"": ""KC"", ""start_span"": 70, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""MIP - 2"", ""start_span"": 74, ""end_span"": 81, ""type"": ""Protein""}, {""token"": ""MCP - 1"", ""start_span"": 83, ""end_span"": 90, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 92, ""end_span"": 98, ""type"": ""Protein""}]"	test
Neutralization of TNF - alpha by soluble TNF p55 receptor ( sTNFp55R) infusion attenuated SE - induced vasogenic edema and neuronal damages via inhibition of p65 - Thr435 phosphorylation in endothelial cells.	TNF - alpha,18,29,Protein	TNF p55 receptor,41,57,Protein	sTNFp55R,60,68,Protein	p65,158,161,Protein	"[{""token"": ""TNF - alpha"", ""start_span"": 18, ""end_span"": 29, ""type"": ""Protein""}, {""token"": ""TNF p55 receptor"", ""start_span"": 41, ""end_span"": 57, ""type"": ""Protein""}, {""token"": ""sTNFp55R"", ""start_span"": 60, ""end_span"": 68, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 158, ""end_span"": 161, ""type"": ""Protein""}]"	test
Neurons, microglia, and astrocytes produce MIP - 2 when incubated with pro - inflammatory cytokines such as TNF - alpha and / or interleukin - 1beta ( IL - 1beta) or after injury [ 21 - 23].	MIP - 2,43,50,Protein	TNF - alpha,108,119,Protein	interleukin - 1beta,129,148,Protein	IL - 1beta,151,161,Protein	"[{""token"": ""MIP - 2"", ""start_span"": 43, ""end_span"": 50, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 108, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""interleukin - 1beta"", ""start_span"": 129, ""end_span"": 148, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 151, ""end_span"": 161, ""type"": ""Protein""}]"	test
Compared to non - SE animals ( data not shown), 12 hr - post SE animals of the saline - infused group showed p65 - Ser276, p65 - Ser311, p65 - Ser529, and p65 - Ser536 phosphorylation in astrocytes ( not endothelial cells).	p65,109,112,Protein	p65,123,126,Protein	p65,137,140,Protein	p65,155,158,Protein	"[{""token"": ""p65"", ""start_span"": 109, ""end_span"": 112, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 123, ""end_span"": 126, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 137, ""end_span"": 140, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 155, ""end_span"": 158, ""type"": ""Protein""}]"	test
MIP - 2 is undetectable or present at low levels under physiological conditions, and shows transient increases under pathological conditions via TNF - alpha and / or interleukin - 1beta ( IL - 1beta) - dependent mechanisms [ 14].	MIP - 2,0,7,Protein	TNF - alpha,145,156,Protein	interleukin - 1beta,166,185,Protein	IL - 1beta,188,198,Protein	"[{""token"": ""MIP - 2"", ""start_span"": 0, ""end_span"": 7, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 145, ""end_span"": 156, ""type"": ""Protein""}, {""token"": ""interleukin - 1beta"", ""start_span"": 166, ""end_span"": 185, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 188, ""end_span"": 198, ""type"": ""Protein""}]"	test
Although the number of MIP - 2 positive cells per unit area in the PC region of sTNFp55R - infused animals was significantly lower than that of the saline - infused group due to reduction of the area of vasogenic edema, there was no difference in the number of MIP - 2 positive cells per unit area of vasogenic edema between sTNFp55R - infused animals and saline - infused animals ( Figure 6F).	MIP - 2,23,30,Protein	sTNFp55R,80,88,Protein	MIP - 2,261,268,Protein	sTNFp55R,325,333,Protein	"[{""token"": ""MIP - 2"", ""start_span"": 23, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""sTNFp55R"", ""start_span"": 80, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""MIP - 2"", ""start_span"": 261, ""end_span"": 268, ""type"": ""Protein""}, {""token"": ""sTNFp55R"", ""start_span"": 325, ""end_span"": 333, ""type"": ""Protein""}]"	test
Therefore, together with reduction in neutrophil infiltration in the PC region of sTNFp55R - infused animals, our findings provide evidence that TNF - alpha may regulate SE - induced neutrophil infiltration at least in the PC via vasogenic edema formation and not via direct TNF - alpha - mediated MIP - 2 expression in astrocytes.	sTNFp55R,82,90,Protein	TNF - alpha,145,156,Protein	TNF - alpha,275,286,Protein	MIP - 2,298,305,Protein	"[{""token"": ""sTNFp55R"", ""start_span"": 82, ""end_span"": 90, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 145, ""end_span"": 156, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 275, ""end_span"": 286, ""type"": ""Protein""}, {""token"": ""MIP - 2"", ""start_span"": 298, ""end_span"": 305, ""type"": ""Protein""}]"	test
With respect to the phosphorylation of p65 - Thr435 by TNF - alpha [ 39], our findings indicate that TNF - alpha - mediated p65 - Thr435 phosphorylation in endothelial cells may play an important role in vasogenic edema induction via SMI - 71 degradation or its posttranslational dysfunction influencing BBB permeability.	p65,39,42,Protein	TNF - alpha,55,66,Protein	TNF - alpha,101,112,Protein	p65,124,127,Protein	"[{""token"": ""p65"", ""start_span"": 39, ""end_span"": 42, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 55, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 101, ""end_span"": 112, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 124, ""end_span"": 127, ""type"": ""Protein""}]"	test
In the present study, p65 - Ser276, p65 - Ser311, p65 - Ser529, and p65 - Ser536 phosphorylation was observed in astrocytes following SE.	p65,22,25,Protein	p65,36,39,Protein	p65,50,53,Protein	p65,68,71,Protein	"[{""token"": ""p65"", ""start_span"": 22, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 36, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 50, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 68, ""end_span"": 71, ""type"": ""Protein""}]"	test
In 12 hr - post SE animals of the saline - infused group ( A, C, E and G), astrocytes show p65 - Ser276 ( A), p65 - Ser311 ( C), p65 - Ser529 ( E), and p65 - Ser536 ( G) phosphorylation ( arrows).	p65,91,94,Protein	p65,110,113,Protein	p65,129,132,Protein	p65,152,155,Protein	"[{""token"": ""p65"", ""start_span"": 91, ""end_span"": 94, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 110, ""end_span"": 113, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 129, ""end_span"": 132, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 152, ""end_span"": 155, ""type"": ""Protein""}]"	test
Levels of tumor necrosis factor - alpha ( TNF - alpha), interleukin - 1 beta ( IL - 1beta), and interleukin - 6 ( IL - 6) protein were quantified using ELISA kits specific for mouse according to the manufacturer ' s instructions ( Bender MedSystems Inc. CA, USA).	interleukin - 1 beta,56,76,Protein	IL - 1beta,79,89,Protein	interleukin - 6,96,111,Protein	IL - 6,114,120,Protein	"[{""token"": ""interleukin - 1 beta"", ""start_span"": 56, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 79, ""end_span"": 89, ""type"": ""Protein""}, {""token"": ""interleukin - 6"", ""start_span"": 96, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 114, ""end_span"": 120, ""type"": ""Protein""}]"	test
Furthermore, silencing by RNAi of key components of the TLR pathway in human monocytes, including the downstream signaling molecules MyD88, IRAK1, and TRAF6, significantly inhibits MTb - induced NFAT5 gene expression.	MyD88,133,138,Protein	IRAK1,140,145,Protein	TRAF6,151,156,Protein	NFAT5,195,200,Protein	"[{""token"": ""MyD88"", ""start_span"": 133, ""end_span"": 138, ""type"": ""Protein""}, {""token"": ""IRAK1"", ""start_span"": 140, ""end_span"": 145, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 151, ""end_span"": 156, ""type"": ""Protein""}, {""token"": ""NFAT5"", ""start_span"": 195, ""end_span"": 200, ""type"": ""Protein""}]"	test
shRNA targeting human IRAK1 ( forward primer 5 ' - CCGGAGCAGCTGTCCAGGTTTCGTCTCATAAAACCTGGACAGCTGCTCCTTTTTG - 3 ', reverse primer 5 ' - AATTCAAAAAGGAGCAGCTGTCCAGGTTTTATGAGACGAAACCTGGACAGCTGCT - 3 ' mRNA ( IRAK1 mRNA target sequence is underlined) and human TRAF6 ( forward primer 5 ' - CCGGAGAAACCTGTTGTGATTCGTCTCATAAATCACAACAGGTTTCTCCTTTTTG - 3 ', reverse primer 5 ' - AATTCAAAAAGGAGAAACCTGTTGTGATTTATGAGACGAATCACAACAGGTTTCT - 3 ' ( TRAF6 mRNA target sequence is underlined) were designed in our laboratory and were cloned into the pLKO. 1 plasmid.	IRAK1,22,27,Protein	IRAK1,204,209,Protein	TRAF6,256,261,Protein	TRAF6,433,438,Protein	"[{""token"": ""IRAK1"", ""start_span"": 22, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""IRAK1"", ""start_span"": 204, ""end_span"": 209, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 256, ""end_span"": 261, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 433, ""end_span"": 438, ""type"": ""Protein""}]"	test
MDM in which NFAT5 expression had been inhibited with NFAT5 siRNA or that were transfected with control GFP siRNA were then infected with 1000 TCID50 of HIV - 1Lai / Bal - env.	NFAT5,13,18,Protein	NFAT5,54,59,Protein	GFP,104,107,Protein	env,172,175,Protein	"[{""token"": ""NFAT5"", ""start_span"": 13, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""NFAT5"", ""start_span"": 54, ""end_span"": 59, ""type"": ""Protein""}, {""token"": ""GFP"", ""start_span"": 104, ""end_span"": 107, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 172, ""end_span"": 175, ""type"": ""Protein""}]"	test
To demonstrate that the impact of NFAT5 silencing on MTb - induced viral replication was a direct effect due to modulation of recruitment of NFAT5 to the HIV - 1 LTR and not due to secondary, NFAT5 - regulated effects, we set out to disrupt NFAT5 binding to the viral LTR in the context of HIV - 1 / MTb co - infection.	NFAT5,34,39,Protein	NFAT5,141,146,Protein	NFAT5,192,197,Protein	NFAT5,241,246,Protein	"[{""token"": ""NFAT5"", ""start_span"": 34, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""NFAT5"", ""start_span"": 141, ""end_span"": 146, ""type"": ""Protein""}, {""token"": ""NFAT5"", ""start_span"": 192, ""end_span"": 197, ""type"": ""Protein""}, {""token"": ""NFAT5"", ""start_span"": 241, ""end_span"": 246, ""type"": ""Protein""}]"	test
As depicted in the histograms displayed in Figure 4C, at day 12 post - HIV - 1 infection in MTb - co - infected cells there was a significant reduction in levels of HIV - 1Lai / Bal - env - kappaB I - Mut, HIV - 1Lai / Bal - env - kappaB II - Mut, HIV - 1Lai / Bal - env - kappaB I + II - Mut, and HIV - 1Lai / Bal - env - N5 - Mut in comparison to wild - type virus ( Figure 4C).	env,184,187,Protein	env,225,228,Protein	env,267,270,Protein	env,317,320,Protein	"[{""token"": ""env"", ""start_span"": 184, ""end_span"": 187, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 225, ""end_span"": 228, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 267, ""end_span"": 270, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 317, ""end_span"": 320, ""type"": ""Protein""}]"	test
As shown in Figures 5A and 5C, in the absence of MTb co - infection, replication of mutant viral molecular clones ( HIV - 1Lai / Bal - env - kappaB I - Mut ( p < 0. 05), HIV - 1Lai / Bal - env - kappaB II - Mut ( p < 0. 01), and HIV - 1Lai / Bal - env - kappaB I + II - Mut ( p < 0. 01) as well as HIV - 1Lai / Bal - env - N5 - Mut ( p < 0. 01) were significantly reduced in comparison to the wild - type virus ( Figures 5A - 5C).	env,135,138,Protein	env,189,192,Protein	env,248,251,Protein	env,317,320,Protein	"[{""token"": ""env"", ""start_span"": 135, ""end_span"": 138, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 189, ""end_span"": 192, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 248, ""end_span"": 251, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 317, ""end_span"": 320, ""type"": ""Protein""}]"	test
As shown in Figure 7B, knockdown of MyD88 specifically inhibited MTb - induced NFAT5 and TNF mRNA levels and had no impact on CD86 mRNA levels.	MyD88,36,41,Protein	NFAT5,79,84,Protein	TNF,89,92,Protein	CD86,126,130,Protein	"[{""token"": ""MyD88"", ""start_span"": 36, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""NFAT5"", ""start_span"": 79, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 89, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""CD86"", ""start_span"": 126, ""end_span"": 130, ""type"": ""Protein""}]"	test
To futher dissect the pathway mediating MTb upregulation of NFAT5 transcription, we also constructed THP - 1 cells transduced with lentivirally - delivered shRNAs targeting IRAK1 or TRAF6, two signaling molecules downstream of MyD88.	NFAT5,60,65,Protein	IRAK1,173,178,Protein	TRAF6,182,187,Protein	MyD88,227,232,Protein	"[{""token"": ""NFAT5"", ""start_span"": 60, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""IRAK1"", ""start_span"": 173, ""end_span"": 178, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 182, ""end_span"": 187, ""type"": ""Protein""}, {""token"": ""MyD88"", ""start_span"": 227, ""end_span"": 232, ""type"": ""Protein""}]"	test
As expected, MTb - induced TNF gene expression was also significantly reduced ( Figures 7C - 7D), consistent with a role for IRAK1 and TRAF6 in TNF gene expression secondary to MTb infection as previously reported.	TNF,27,30,Protein	IRAK1,125,130,Protein	TRAF6,135,140,Protein	TNF,144,147,Protein	"[{""token"": ""TNF"", ""start_span"": 27, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""IRAK1"", ""start_span"": 125, ""end_span"": 130, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 135, ""end_span"": 140, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 144, ""end_span"": 147, ""type"": ""Protein""}]"	test
Furthermore, we have shown that MTb stimulation of NFAT5 depends on TLR pathway signaling molecules, including MyD88, IRAK1, and TRAF6.	NFAT5,51,56,Protein	MyD88,111,116,Protein	IRAK1,118,123,Protein	TRAF6,129,134,Protein	"[{""token"": ""NFAT5"", ""start_span"": 51, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""MyD88"", ""start_span"": 111, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""IRAK1"", ""start_span"": 118, ""end_span"": 123, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 129, ""end_span"": 134, ""type"": ""Protein""}]"	test
NFAT5 expression was significantly inhibited in the MTb - infected cells expressing either IRAK1 ( C) or TRAF6 ( D) shRNA ( black bars) compared to cells expressing control shRNA ( open bars).	NFAT5,0,5,Protein	IRAK1,91,96,Protein	TRAF6,105,110,Protein	shRNA,116,121,Protein	"[{""token"": ""NFAT5"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""IRAK1"", ""start_span"": 91, ""end_span"": 96, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 105, ""end_span"": 110, ""type"": ""Protein""}, {""token"": ""shRNA"", ""start_span"": 116, ""end_span"": 121, ""type"": ""Protein""}]"	test
TNF and CD86 mRNAs, both of which require IRAK1 and TRAF6 to be induced by PRR activation, were measured as controls.	TNF,0,3,Protein	CD86,8,12,Protein	IRAK1,42,47,Protein	TRAF6,52,57,Protein	"[{""token"": ""TNF"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Protein""}, {""token"": ""CD86"", ""start_span"": 8, ""end_span"": 12, ""type"": ""Protein""}, {""token"": ""IRAK1"", ""start_span"": 42, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 52, ""end_span"": 57, ""type"": ""Protein""}]"	test
Significant inhibition of DNA binding activity of NF - kappaB, and translocation of p50 and p65 into the nucleus through the inhibition of phosphorylation of IkappaB was found in the melanoma tissues of CCR5 - / - mice compared to melanoma tissues of CCR5 + / + mice.	p50,84,87,Protein	p65,92,95,Protein	CCR5,203,207,Protein	CCR5,251,255,Protein	"[{""token"": ""p50"", ""start_span"": 84, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 92, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""CCR5"", ""start_span"": 203, ""end_span"": 207, ""type"": ""Protein""}, {""token"": ""CCR5"", ""start_span"": 251, ""end_span"": 255, ""type"": ""Protein""}]"	test
NF - kappaB transcription factor binding sites are present in the promoter region of proinflammatory cytokine genes, such as IL - 1alpha, IL - 6, GM - CSF, and KC [ 34].	IL - 1alpha,125,136,Protein	IL - 6,138,144,Protein	GM - CSF,146,154,Protein	KC,160,162,Protein	"[{""token"": ""IL - 1alpha"", ""start_span"": 125, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 138, ""end_span"": 144, ""type"": ""Protein""}, {""token"": ""GM - CSF"", ""start_span"": 146, ""end_span"": 154, ""type"": ""Protein""}, {""token"": ""KC"", ""start_span"": 160, ""end_span"": 162, ""type"": ""Protein""}]"	test
The lymphocytes that infiltrated the tumor tissue of the CCR5 - / - mice also had higher levels of CD19, CD3, CD4, CD8 and CD57 when compared to the CCR5 + / + mice.	CCR5,57,61,Protein	CD19,99,103,Protein	CD4,110,113,Protein	CCR5,149,153,Protein	"[{""token"": ""CCR5"", ""start_span"": 57, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""CD19"", ""start_span"": 99, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 110, ""end_span"": 113, ""type"": ""Protein""}, {""token"": ""CCR5"", ""start_span"": 149, ""end_span"": 153, ""type"": ""Protein""}]"	test
Additionally, Tan MC et al. suggested that disruption of CCR5 / CCL5 signaling, either by reducing CCL5 production by tumor cells or by systemic administration of a CCR5 inhibitor ( TAK - 779), reduced Treg ( regulatory T cells) migration to tumors so that tumors are smaller in control mice [ 9].	CCR5,57,61,Protein	CCL5,64,68,Protein	CCL5,99,103,Protein	CCR5,165,169,Protein	"[{""token"": ""CCR5"", ""start_span"": 57, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""CCL5"", ""start_span"": 64, ""end_span"": 68, ""type"": ""Protein""}, {""token"": ""CCL5"", ""start_span"": 99, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""CCR5"", ""start_span"": 165, ""end_span"": 169, ""type"": ""Protein""}]"	test
The CCR5 wild type ( CCR5 + / +) and CCR5 knockout ( CCR5 - / -) mice were purchased from The Jackson Laboratory ( Bar Harbor, Maine 04609 USA).	CCR5,4,8,Protein	CCR5,21,25,Protein	CCR5,37,41,Protein	CCR5,53,57,Protein	"[{""token"": ""CCR5"", ""start_span"": 4, ""end_span"": 8, ""type"": ""Protein""}, {""token"": ""CCR5"", ""start_span"": 21, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""CCR5"", ""start_span"": 37, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""CCR5"", ""start_span"": 53, ""end_span"": 57, ""type"": ""Protein""}]"	test
These data are reminiscent of the observations in L929 cells where the loss of caspase activity in healthy cells is sufficient to trigger necroptosis and prompted us to explore the extrinsic or intrinsic cellular factors that promote necroptosis once caspase - 8 activity, which cleaves and inactivates RIP1 kinase and the RIP1 deubiquitinase CYLD [ 21], [ 22], is removed in L929 cells.	caspase - 8,251,262,Protein	RIP1,303,307,Protein	RIP1 deubiquitinase,323,342,Protein	CYLD,343,347,Protein	"[{""token"": ""caspase - 8"", ""start_span"": 251, ""end_span"": 262, ""type"": ""Protein""}, {""token"": ""RIP1"", ""start_span"": 303, ""end_span"": 307, ""type"": ""Protein""}, {""token"": ""RIP1 deubiquitinase"", ""start_span"": 323, ""end_span"": 342, ""type"": ""Protein""}, {""token"": ""CYLD"", ""start_span"": 343, ""end_span"": 347, ""type"": ""Protein""}]"	test
Consistent with a RIP1 - dependent increase in TNFalpha protein ( Fig. S6A, B), we found that TNFalpha mRNA levels increased during necroptosis in L929 cells in a RIP1 ( Fig.	RIP1,18,22,Protein	TNFalpha,47,55,Protein	TNFalpha,94,102,Protein	RIP1,163,167,Protein	"[{""token"": ""RIP1"", ""start_span"": 18, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 47, ""end_span"": 55, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 94, ""end_span"": 102, ""type"": ""Protein""}, {""token"": ""RIP1"", ""start_span"": 163, ""end_span"": 167, ""type"": ""Protein""}]"	test
Notably, RIP1 and Akt inhibitors had no effect on the levels of TNFalpha mRNA in control cells or in the cells stimulated with bFGF alone ( Fig. 6A, B, Fig. S6C), suggesting that these kinases specifically mediate necroptosis - dependent increase in TNFalpha synthesis.	RIP1,9,13,Protein	TNFalpha,64,72,Protein	bFGF,127,131,Protein	TNFalpha,250,258,Protein	"[{""token"": ""RIP1"", ""start_span"": 9, ""end_span"": 13, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 64, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""bFGF"", ""start_span"": 127, ""end_span"": 131, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 250, ""end_span"": 258, ""type"": ""Protein""}]"	test
Knockdown of Akt isoforms Akt1 and Akt2 or inhibition of Akt prominently suppressed the necroptosis dependent increase in JNK and c - Jun phosphorylation ( Fig. 6E, S6D, E) suggesting that Akt may provide a link between RIP1 and JNK activation.	Akt1,26,30,Protein	Akt2,35,39,Protein	c - Jun,130,137,Protein	RIP1,220,224,Protein	"[{""token"": ""Akt1"", ""start_span"": 26, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""Akt2"", ""start_span"": 35, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""c - Jun"", ""start_span"": 130, ""end_span"": 137, ""type"": ""Protein""}, {""token"": ""RIP1"", ""start_span"": 220, ""end_span"": 224, ""type"": ""Protein""}]"	test
We used L929 cells stably expressing constitutively active wild type Akt1 ( Myr - Akt) or the catalytically inactive mutant K179M in order to further understand the contribution of growth factors and RIP1 kinase to Akt activation during necroptosis.	Akt1,69,73,Protein	Myr - Akt,76,85,Protein	K179M,124,129,Protein	RIP1,200,204,Protein	"[{""token"": ""Akt1"", ""start_span"": 69, ""end_span"": 73, ""type"": ""Protein""}, {""token"": ""Myr - Akt"", ""start_span"": 76, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""K179M"", ""start_span"": 124, ""end_span"": 129, ""type"": ""Protein""}, {""token"": ""RIP1"", ""start_span"": 200, ""end_span"": 204, ""type"": ""Protein""}]"	test
Human and mouse TNFalpha ( 10 ng / ml), human bFGF ( 25 ng / ml), EGF ( 50 ng / ml), PDGF - BB ( 20 ng / ml), and IGF - 1 ( 50 ng / ml) were from Cell Sciences or Peprotech.	TNFalpha,16,24,Protein	bFGF,46,50,Protein	EGF,66,69,Protein	IGF - 1,114,121,Protein	"[{""token"": ""TNFalpha"", ""start_span"": 16, ""end_span"": 24, ""type"": ""Protein""}, {""token"": ""bFGF"", ""start_span"": 46, ""end_span"": 50, ""type"": ""Protein""}, {""token"": ""EGF"", ""start_span"": 66, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""IGF - 1"", ""start_span"": 114, ""end_span"": 121, ""type"": ""Protein""}]"	test
( C) L929 cells transfected with Akt1, Akt2, and Akt3 siRNAs for 72 hrs were treated with zVAD. fmk or TNFalpha for 9 hrs.	Akt1,33,37,Protein	Akt2,39,43,Protein	Akt3 siRNAs,49,60,Protein	TNFalpha,103,111,Protein	"[{""token"": ""Akt1"", ""start_span"": 33, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""Akt2"", ""start_span"": 39, ""end_span"": 43, ""type"": ""Protein""}, {""token"": ""Akt3 siRNAs"", ""start_span"": 49, ""end_span"": 60, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 103, ""end_span"": 111, ""type"": ""Protein""}]"	test
FADD deficient Jurkat cells were treated with TNFalpha followed by measurement of ( A) human TNFalpha mRNA levels by qRT - PCR and normalized using human 18S RNA or ( B) western blot at 9 hr.	FADD,0,4,Protein	TNFalpha,46,54,Protein	TNFalpha,93,101,Protein	18S,154,157,Protein	"[{""token"": ""FADD"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 46, ""end_span"": 54, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 93, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""18S"", ""start_span"": 154, ""end_span"": 157, ""type"": ""Protein""}]"	test
( H) Mouse lung fibroblasts expressing only endogenous Akt1 or Akt2 were treated with zVAD. fmk and TNFalpha followed by measurement of TNFalpha mRNA levels by qRT - PCR at 9 hr.	Akt1,55,59,Protein	Akt2,63,67,Protein	TNFalpha,100,108,Protein	TNFalpha,136,144,Protein	"[{""token"": ""Akt1"", ""start_span"": 55, ""end_span"": 59, ""type"": ""Protein""}, {""token"": ""Akt2"", ""start_span"": 63, ""end_span"": 67, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 100, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 136, ""end_span"": 144, ""type"": ""Protein""}]"	test
WW domain - containing oxidoreductase WWOX ( FOR or WOX1) is a proapoptotic protein and is considered as a tumor suppressor.	WW domain - containing oxidoreductase,0,37,Protein	WWOX,38,42,Protein	FOR,45,48,Protein	WOX1,52,56,Protein	"[{""token"": ""WW domain - containing oxidoreductase"", ""start_span"": 0, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""WWOX"", ""start_span"": 38, ""end_span"": 42, ""type"": ""Protein""}, {""token"": ""FOR"", ""start_span"": 45, ""end_span"": 48, ""type"": ""Protein""}, {""token"": ""WOX1"", ""start_span"": 52, ""end_span"": 56, ""type"": ""Protein""}]"	test
Here, we provide an overview for the updated knowledge in p53 and WWOX, and postulate potential scenarios that wild type and mutant p53, or isoforms, modulate the apoptotic function of WWOX.	p53,58,61,Protein	WWOX,66,70,Protein	p53,132,135,Protein	WWOX,185,189,Protein	"[{""token"": ""p53"", ""start_span"": 58, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""WWOX"", ""start_span"": 66, ""end_span"": 70, ""type"": ""Protein""}, {""token"": ""p53"", ""start_span"": 132, ""end_span"": 135, ""type"": ""Protein""}, {""token"": ""WWOX"", ""start_span"": 185, ""end_span"": 189, ""type"": ""Protein""}]"	test
Intriguingly, overexpressed microRNA - 21 reduces Bax / Bcl - 2 ratio and caspase - 3 activity, thereby blocking TMZ - induced apoptosis ( Shi et al., 2010).	microRNA - 21,28,41,Protein	Bax,50,53,Protein	Bcl - 2,56,63,Protein	caspase - 3,74,85,Protein	"[{""token"": ""microRNA - 21"", ""start_span"": 28, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""Bax"", ""start_span"": 50, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""Bcl - 2"", ""start_span"": 56, ""end_span"": 63, ""type"": ""Protein""}, {""token"": ""caspase - 3"", ""start_span"": 74, ""end_span"": 85, ""type"": ""Protein""}]"	test
Transiently overexpressed WWOX binds transcription factors AP - 2, p73, and c - Jun and block their nuclear relocation in vitro, which suppresses cancer cell survival ( Salah et al., 2012).	WWOX,26,30,Protein	AP - 2,59,65,Protein	p73,67,70,Protein	c - Jun,76,83,Protein	"[{""token"": ""WWOX"", ""start_span"": 26, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""AP - 2"", ""start_span"": 59, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""p73"", ""start_span"": 67, ""end_span"": 70, ""type"": ""Protein""}, {""token"": ""c - Jun"", ""start_span"": 76, ""end_span"": 83, ""type"": ""Protein""}]"	test
Also, p53 plays a role in controlling cell motility via regulating the expression of smooth muscle alpha - actin ( Comer et al., 1998), collagens IIalpha1 and VIalpha1 ( Sun et al., 1999), and many others.	p53,6,9,Protein	smooth muscle alpha - actin,85,112,Protein	collagens IIalpha1,136,154,Protein	VIalpha1,159,167,Protein	"[{""token"": ""p53"", ""start_span"": 6, ""end_span"": 9, ""type"": ""Protein""}, {""token"": ""smooth muscle alpha - actin"", ""start_span"": 85, ""end_span"": 112, ""type"": ""Protein""}, {""token"": ""collagens IIalpha1"", ""start_span"": 136, ""end_span"": 154, ""type"": ""Protein""}, {""token"": ""VIalpha1"", ""start_span"": 159, ""end_span"": 167, ""type"": ""Protein""}]"	test
However, it is not surprising to find that many tumor suppressor proteins, e. g., p53, WWOX, Smad4, PTEN, PP2A, and etc., are significantly upregulated during the early stage of cancer progression ( Lai et al., 2005; Chang et al., unpublished).	p53,82,85,Protein	WWOX,87,91,Protein	Smad4,93,98,Protein	PTEN,100,104,Protein	"[{""token"": ""p53"", ""start_span"": 82, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""WWOX"", ""start_span"": 87, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""Smad4"", ""start_span"": 93, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""PTEN"", ""start_span"": 100, ""end_span"": 104, ""type"": ""Protein""}]"	test
WWOX also binds PPxY motif - containing transcription factors, such as RUNX2, c - Jun, and ERBB4, via its first WW domain, and the binding blocks the activity of these proteins by retaining them in the cytoplasm.	WWOX,0,4,Protein	RUNX2,71,76,Protein	c - Jun,78,85,Protein	ERBB4,91,96,Protein	"[{""token"": ""WWOX"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""RUNX2"", ""start_span"": 71, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""c - Jun"", ""start_span"": 78, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""ERBB4"", ""start_span"": 91, ""end_span"": 96, ""type"": ""Protein""}]"	test
Ack1, activated Cdc42 - associated kinase 1; Hyal - 2, hyaluronoglucosaminidase 2; CKI, casein kinase; GSK, glycogen synthase kinase; PKA, protein kinase A.	Ack1,0,4,Protein	activated Cdc42 - associated kinase 1,6,43,Protein	Hyal - 2,45,53,Protein	hyaluronoglucosaminidase 2,55,81,Protein	"[{""token"": ""Ack1"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""activated Cdc42 - associated kinase 1"", ""start_span"": 6, ""end_span"": 43, ""type"": ""Protein""}, {""token"": ""Hyal - 2"", ""start_span"": 45, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""hyaluronoglucosaminidase 2"", ""start_span"": 55, ""end_span"": 81, ""type"": ""Protein""}]"	test
SerpinB2 was first identified as an inhibitor of urokinase - type plasminogen activator ( uPA) [ 6] - [ 8], a serine protease involved in the degradation and turnover of the extracellular matrix through the activation of plasminogen [ 7]; [ 9].	SerpinB2,0,8,Protein	urokinase - type plasminogen activator,49,87,Protein	uPA,90,93,Protein	plasminogen,221,232,Protein	"[{""token"": ""SerpinB2"", ""start_span"": 0, ""end_span"": 8, ""type"": ""Protein""}, {""token"": ""urokinase - type plasminogen activator"", ""start_span"": 49, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""uPA"", ""start_span"": 90, ""end_span"": 93, ""type"": ""Protein""}, {""token"": ""plasminogen"", ""start_span"": 221, ""end_span"": 232, ""type"": ""Protein""}]"	test
Our previously published data indicated that SerpinB2 is distinctly regulated from other LPS - inducible genes in terms of kinetics, LPS dose response and sensitivity to IFN - gamma co - stimulation [ 4]; however, the cis - acting elements in the SerpinB2 promoter responsible for LPS - dependent transcription in macrophages and the specific LPS - responsive transcription factors that bind the SerpinB2 promoter were not defined.	SerpinB2,45,53,Protein	IFN - gamma,170,181,Protein	SerpinB2,247,255,Protein	SerpinB2,396,404,Protein	"[{""token"": ""SerpinB2"", ""start_span"": 45, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 170, ""end_span"": 181, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 247, ""end_span"": 255, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 396, ""end_span"": 404, ""type"": ""Protein""}]"	test
qPCR was performed using TaqMan ( R) Gene Expression 20X primers for Serpinb2 / SerpinB2 ( Mm00440905 _ m1), Cebpb ( Mm00843434 _ s1) and beta - actin ( Mm00607939 _ s1) ( Applied Biosystems).	Serpinb2,69,77,Protein	SerpinB2,80,88,Protein	Cebpb,109,114,Protein	beta - actin,138,150,Protein	"[{""token"": ""Serpinb2"", ""start_span"": 69, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 80, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""Cebpb"", ""start_span"": 109, ""end_span"": 114, ""type"": ""Protein""}, {""token"": ""beta - actin"", ""start_span"": 138, ""end_span"": 150, ""type"": ""Protein""}]"	test
Cebpb - / - MEFs ( 1x105) [ 34] were transfected with the indicated luciferase reporter plasmid ( 400 ng) along with a beta - actin - beta - galactosidase reporter plasmid ( 200 ng) by electroporation using the Invitrogen Neon ( TM) system ( 1 pulse, 1350 V, 30 msec).	Cebpb,0,5,Protein	luciferase,68,78,Protein	beta - actin,119,131,Protein	beta - galactosidase,134,154,Protein	"[{""token"": ""Cebpb"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""luciferase"", ""start_span"": 68, ""end_span"": 78, ""type"": ""Protein""}, {""token"": ""beta - actin"", ""start_span"": 119, ""end_span"": 131, ""type"": ""Protein""}, {""token"": ""beta - galactosidase"", ""start_span"": 134, ""end_span"": 154, ""type"": ""Protein""}]"	test
Luciferase activity was determined and normalized to that of beta - galactosidase [ 38] using the Luciferase Assay System and beta - Galactosidase Enzyme Assay System Kits, respectively ( Promega).	Luciferase,0,10,Protein	beta - galactosidase,61,81,Protein	Luciferase,98,108,Protein	beta - Galactosidase,126,146,Protein	"[{""token"": ""Luciferase"", ""start_span"": 0, ""end_span"": 10, ""type"": ""Protein""}, {""token"": ""beta - galactosidase"", ""start_span"": 61, ""end_span"": 81, ""type"": ""Protein""}, {""token"": ""Luciferase"", ""start_span"": 98, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""beta - Galactosidase"", ""start_span"": 126, ""end_span"": 146, ""type"": ""Protein""}]"	test
Four family members, C / EBP - alpha, C / EBP - beta, C / EBP - delta and C / EBP - epsilon, are present in myeloid cells and play different roles in differentiating myeloid cells depending on the extracellular environment [ 61].	C / EBP - alpha,21,36,Protein	C / EBP - beta,38,52,Protein	C / EBP - delta,54,69,Protein	C / EBP - epsilon,74,91,Protein	"[{""token"": ""C / EBP - alpha"", ""start_span"": 21, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 38, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""C / EBP - delta"", ""start_span"": 54, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""C / EBP - epsilon"", ""start_span"": 74, ""end_span"": 91, ""type"": ""Protein""}]"	test
To determine which C / EBP proteins were involved in the formation of the different nucleo - protein complexes, and particularly of the LPS - inducible complex, EMSA was performed after incubating the nucleo - protein complexes with antibodies specific for C / EBP - alpha, C / EBP - beta, C / EBP - delta and C / EBP - epsilon.	C / EBP - alpha,257,272,Protein	C / EBP - beta,274,288,Protein	C / EBP - delta,290,305,Protein	C / EBP - epsilon,310,327,Protein	"[{""token"": ""C / EBP - alpha"", ""start_span"": 257, ""end_span"": 272, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 274, ""end_span"": 288, ""type"": ""Protein""}, {""token"": ""C / EBP - delta"", ""start_span"": 290, ""end_span"": 305, ""type"": ""Protein""}, {""token"": ""C / EBP - epsilon"", ""start_span"": 310, ""end_span"": 327, ""type"": ""Protein""}]"	test
These data show an inverse relationship between C / EBP - beta and p - C / EBP - betaT217 recruitment, and indicate that T217 - phosphorylated C / EBP - beta may not be responsible for increased transcription from the SerpinB2 promoter in response to LPS.	C / EBP - beta,48,62,Protein	p - C / EBP - betaT217,67,89,Protein	C / EBP - beta,143,157,Protein	SerpinB2,218,226,Protein	"[{""token"": ""C / EBP - beta"", ""start_span"": 48, ""end_span"": 62, ""type"": ""Protein""}, {""token"": ""p - C / EBP - betaT217"", ""start_span"": 67, ""end_span"": 89, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 143, ""end_span"": 157, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 218, ""end_span"": 226, ""type"": ""Protein""}]"	test
Since C / EBP - beta binds to the SerpinB2 proximal promoter in an LPS - inducible manner both in vitro and in vivo, we wanted to address the question of whether C / EBP - beta was an essential factor for driving transcription from the SerpinB2 promoter in cells in response to LPS.	C / EBP - beta,6,20,Protein	SerpinB2,34,42,Protein	C / EBP - beta,162,176,Protein	SerpinB2,236,244,Protein	"[{""token"": ""C / EBP - beta"", ""start_span"": 6, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 34, ""end_span"": 42, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 162, ""end_span"": 176, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 236, ""end_span"": 244, ""type"": ""Protein""}]"	test
C / EBP - betaT188 is implicated in regulating DAPK1, an IFNgamma - inducible gene involved in the regulation of cell cycle and apoptosis [ 38], processes with which SerpinB2 has also been associated [ 17].	DAPK1,47,52,Protein	IFNgamma,57,65,Protein	gene,78,82,Protein	SerpinB2,166,174,Protein	"[{""token"": ""DAPK1"", ""start_span"": 47, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 57, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""gene"", ""start_span"": 78, ""end_span"": 82, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 166, ""end_span"": 174, ""type"": ""Protein""}]"	test
LPS - induced C / EBP - beta was shown to specifically bind the C / EBP response element in the SerpinB2 proximal promoter in vitro and in vivo, and loss of C / EBP - beta abrogates constitutive SerpinB2 gene transcription and the response to LPS.	C / EBP - beta,14,28,Protein	SerpinB2,96,104,Protein	C / EBP - beta,157,171,Protein	SerpinB2,195,203,Protein	"[{""token"": ""C / EBP - beta"", ""start_span"": 14, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 96, ""end_span"": 104, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 157, ""end_span"": 171, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 195, ""end_span"": 203, ""type"": ""Protein""}]"	test
In a previous microarray expression profiling study, SerpinB2 was identified as gene whose induction in C / EBP - beta - deficient peritoneal macrophages by LPS and IFNgamma was severely impaired compared to wild - type macrophages [ 68].	SerpinB2,53,61,Protein	gene,80,84,Protein	C / EBP - beta,104,118,Protein	IFNgamma,165,173,Protein	"[{""token"": ""SerpinB2"", ""start_span"": 53, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""gene"", ""start_span"": 80, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 104, ""end_span"": 118, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 165, ""end_span"": 173, ""type"": ""Protein""}]"	test
While C / EBP proteins can act as either homodimers or heterodimers [ 63], we identified C / EBP - beta as the only LPS - inducible C / EBP isoform to bind the SerpinB2 C / EBP response element, suggesting a predominant role for C / EBP - beta in LPS - induced SerpinB2 gene expression.	C / EBP - beta,89,103,Protein	SerpinB2,160,168,Protein	C / EBP - beta,229,243,Protein	SerpinB2,261,269,Protein	"[{""token"": ""C / EBP - beta"", ""start_span"": 89, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 160, ""end_span"": 168, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 229, ""end_span"": 243, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 261, ""end_span"": 269, ""type"": ""Protein""}]"	test
In contrast, expression of C / EBP - betaS64A significantly enhanced LPS - induced SerpinB2 promoter activity, indicating that phosphorylation of C / EBP - beta at S64 negatively regulates LPS - induced SerpinB2 promoter activity.	C / EBP - betaS64A,27,45,Protein	SerpinB2,83,91,Protein	C / EBP - beta,146,160,Protein	SerpinB2,203,211,Protein	"[{""token"": ""C / EBP - betaS64A"", ""start_span"": 27, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 83, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 146, ""end_span"": 160, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 203, ""end_span"": 211, ""type"": ""Protein""}]"	test
Roy and colleagues demonstrated that Mixed lineage kinase - 3 ( MLK3) - driven dephosphorylation of C / EBP - beta S64 was important for IFNgamma - regulated signaling pathways [ 73].	Mixed lineage kinase - 3,37,61,Protein	MLK3,64,68,Protein	C / EBP - beta,100,114,Protein	IFNgamma,137,145,Protein	"[{""token"": ""Mixed lineage kinase - 3"", ""start_span"": 37, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""MLK3"", ""start_span"": 64, ""end_span"": 68, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 100, ""end_span"": 114, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 137, ""end_span"": 145, ""type"": ""Protein""}]"	test
AP - 1 = activator protein 1; C / EBP = CCAAT enhancer binding protein; CRE = cAMP response element; Oct1 = octamer transcription factor 1 / POU2F1; PU. 1 = purine box binding protein 1.	Oct1,101,105,Protein	octamer transcription factor 1,108,138,Protein	POU2F1,141,147,Protein	purine box binding protein 1,157,185,Protein	"[{""token"": ""Oct1"", ""start_span"": 101, ""end_span"": 105, ""type"": ""Protein""}, {""token"": ""octamer transcription factor 1"", ""start_span"": 108, ""end_span"": 138, ""type"": ""Protein""}, {""token"": ""POU2F1"", ""start_span"": 141, ""end_span"": 147, ""type"": ""Protein""}, {""token"": ""purine box binding protein 1"", ""start_span"": 157, ""end_span"": 185, ""type"": ""Protein""}]"	test
( A) EMSA with nuclear extracts from untreated ( UN) and 10 hr LPS treated ( LPS) RAW 264. 7 cells incubated with either the murine SerpinB2 promoter - 212 / - 185 probe containing an intact ( SerpinB2 C / EBP) or mutated ( mutant C / EBP) C / EBP site or with the rat albumin promoter DEI region C / EBP ( rat albumin C / EBP) probe.	SerpinB2,132,140,Protein	SerpinB2,193,201,Protein	albumin,269,276,Protein	albumin,311,318,Protein	"[{""token"": ""SerpinB2"", ""start_span"": 132, ""end_span"": 140, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 193, ""end_span"": 201, ""type"": ""Protein""}, {""token"": ""albumin"", ""start_span"": 269, ""end_span"": 276, ""type"": ""Protein""}, {""token"": ""albumin"", ""start_span"": 311, ""end_span"": 318, ""type"": ""Protein""}]"	test
Murine SerpinB2 gene promoter activity measured in Cebpb + / + and Cebpb - / - MEFs expressing the pGLmP - 539 SerpinB2 promoter - luciferase reporter in the presence or absence of LPS ( 100 ng / mL).	SerpinB2,7,15,Protein	Cebpb,51,56,Protein	Cebpb,67,72,Protein	SerpinB2 promoter - luciferase reporter,111,150,Protein	"[{""token"": ""SerpinB2"", ""start_span"": 7, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""Cebpb"", ""start_span"": 51, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""Cebpb"", ""start_span"": 67, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""SerpinB2 promoter - luciferase reporter"", ""start_span"": 111, ""end_span"": 150, ""type"": ""Protein""}]"	test
Cells were co - transfected with the pGLmP - 539 SerpinB2 promoter - luciferase reporter and beta - galactosidase reporter plasmids, and luciferase units normalized to beta - galactosidase activity.	SerpinB2 promoter - luciferase reporter,49,88,Protein	beta - galactosidase reporter,93,122,Protein	luciferase,137,147,Protein	beta - galactosidase,168,188,Protein	"[{""token"": ""SerpinB2 promoter - luciferase reporter"", ""start_span"": 49, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""beta - galactosidase reporter"", ""start_span"": 93, ""end_span"": 122, ""type"": ""Protein""}, {""token"": ""luciferase"", ""start_span"": 137, ""end_span"": 147, ""type"": ""Protein""}, {""token"": ""beta - galactosidase"", ""start_span"": 168, ""end_span"": 188, ""type"": ""Protein""}]"	test
